Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis by Tramacere, Irene et al.
Cochrane Database of Systematic Reviews
Immunomodulators and immunosuppressants for relapsing-
remittingmultiple sclerosis: a networkmeta-analysis
(Review)
Tramacere I, Del Giovane C, Salanti G, D’Amico R, Filippini G
Tramacere I, Del Giovane C, Salanti G, D’Amico R, Filippini G.
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a networkmeta-analysis.
Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No.: CD011381.
DOI: 10.1002/14651858.CD011381.pub2.
www.cochranelibrary.com
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a networkmeta-analysis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
21BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
23OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
23METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
28RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Figure 7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Figure 8. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Figure 9. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
Figure 10. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
Figure 11. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Figure 12. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Figure 13. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Figure 14. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Figure 15. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
Figure 16. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
Figure 17. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
52DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
55AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
55ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
55REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
63CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
114DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Treatment benefit within pairwise comparisons, Outcome 1 Comparisons for relapses over 12
months. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
Analysis 1.2. Comparison 1 Treatment benefit within pairwise comparisons, Outcome 2 Comparisons for relapses over 24
months. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
Analysis 1.3. Comparison 1 Treatment benefit within pairwise comparisons, Outcome 3 Comparisons for disability
worsening over 24 months. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
Analysis 2.1. Comparison 2 Treatment acceptability within pairwise comparisons, Outcome 1 Comparisons for treatment
discontinuation due to AEs over 12 months. . . . . . . . . . . . . . . . . . . . . . . . 132
Analysis 2.2. Comparison 2 Treatment acceptability within pairwise comparisons, Outcome 2 Comparisons for treatment
discontinuation due to AEs over 24 months. . . . . . . . . . . . . . . . . . . . . . . . 135
Analysis 3.1. Comparison 3 Treatment safety against placebo within pairwise comparisons, Outcome 1 Serious adverse
events. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
142ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
150APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
151CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
151DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
152SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
152DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
152INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Immunomodulators and immunosuppressants for relapsing-
remitting multiple sclerosis: a network meta-analysis
Irene Tramacere1, Cinzia Del Giovane2, Georgia Salanti3, Roberto D’Amico2, Graziella Filippini4
1Neuroepidemiology Unit, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milano, Italy. 2Italian Cochrane Centre, Depart-
ment of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy. 3Department of
Hygiene and Epidemiology, University of Ioannina School ofMedicine, Ioannina, Greece. 4Scientific Direction, Fondazione I.R.C.C.S.
Istituto Neurologico Carlo Besta, Milano, Italy
Contact address: Graziella Filippini, Scientific Direction, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, via Celoria, 11,
Milano, 20133, Italy. gfilippini@istituto-besta.it.
Editorial group: Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group.
Publication status and date: New, published in Issue 9, 2015.
Review content assessed as up-to-date: 30 September 2014.
Citation: Tramacere I, Del Giovane C, Salanti G, D’Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-
remitting multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No.: CD011381.
DOI: 10.1002/14651858.CD011381.pub2.
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Different therapeutic strategies are available for the treatment of people with relapsing-remitting multiple sclerosis (RRMS), including
immunomodulators, immunosuppressants and biologics. Although there is consensus that these therapies reduce the frequency of
relapses, their relative benefit in delaying new relapses or disability worsening remains unclear due to the limited number of direct
comparison trials.
Objectives
To compare the benefit and acceptability of interferon beta-1b, interferon beta-1a (Avonex, Rebif ), glatiramer acetate, natalizumab,
mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, pegylated interferon beta-1a, daclizumab, laquinimod,
azathioprine and immunoglobulins for the treatment of people with RRMS and to provide a ranking of these treatments according to
their benefit and acceptability, defined as the proportion of participants who withdrew due to any adverse event.
Search methods
We searched the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group Trials Register, which contains trials from CEN-
TRAL (2014, Issue 9), MEDLINE (1966 to 2014), EMBASE (1974 to 2014), CINAHL (1981 to 2014), LILACS (1982 to 2014),
clinicaltrials.gov and the WHO trials registry, and US Food and Drug Administration (FDA) reports. We ran the most recent search
in September 2014.
Selection criteria
Randomised controlled trials (RCTs) that studied one or more of the 15 treatments as monotherapy, compared to placebo or to another
active agent, for use in adults with RRMS.
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Data collection and analysis
Two authors independently identified studies from the search results and performed data extraction. We performed data synthesis by
pairwise meta-analysis and network meta-analysis. We assessed the quality of the body of evidence for outcomes within the network
meta-analysis according to GRADE, as very low, low, moderate or high.
Main results
We included 39 studies in this review, in which 25,113 participants were randomised. The majority of the included trials were short-
term studies, with a median duration of 24 months. Twenty-four (60%) were placebo-controlled and 15 (40%) were head-to-head
studies.
Network meta-analysis showed that, in terms of a protective effect against the recurrence of relapses in RRMS during the first 24
months of treatment, alemtuzumab, mitoxantrone, natalizumab, and fingolimod outperformed other drugs. The most effective drug
was alemtuzumab (risk ratio (RR) versus placebo 0.46, 95% confidence interval (CI) 0.38 to 0.55; surface under the cumulative ranking
curve (SUCRA) 96%; moderate quality evidence), followed by mitoxantrone (RR 0.47, 95% CI 0.27 to 0.81; SUCRA 92%; very low
quality evidence), natalizumab (RR 0.56, 95% CI 0.47 to 0.66; SUCRA 88%; high quality evidence), and fingolimod (RR 0.72, 95%
CI 0.64 to 0.81; SUCRA 71%; moderate quality evidence).
Disability worsening was based on a surrogate marker, defined as irreversible worsening confirmed at three-month follow-up, measured
during the first 24 months in the majority of included studies. Both direct and indirect comparisons revealed that the most effective
treatments were mitoxantrone (RR versus placebo 0.20, 95% CI 0.05 to 0.84; SUCRA 96%; low quality evidence), alemtuzumab (RR
0.35, 95% CI 0.26 to 0.48; SUCRA 94%; low quality evidence), and natalizumab (RR 0.64, 95% CI 0.49 to 0.85; SUCRA 74%;
moderate quality evidence).
Almost all of the agents included in this review were associated with a higher proportion of participants who withdrew due to any
adverse event compared to placebo. Based on the network meta-analysis methodology, the corresponding RR estimates versus placebo
over the first 24 months of follow-up were: mitoxantrone 9.92 (95% CI 0.54 to 168.84), fingolimod 1.69 (95% CI 1.32 to 2.17),
natalizumab 1.53 (95% CI 0.93 to 2.53), and alemtuzumab 0.72 (95% CI 0.32 to 1.61).
Information on serious adverse events (SAEs) was scanty, characterised by heterogeneous results and based on a very low number of
events observed during the short-term duration of the trials included in this review.
Authors’ conclusions
Conservative interpretation of these results is warranted, since most of the included treatments have been evaluated in few trials. The
GRADE approach recommends providing implications for practice based on moderate to high quality evidence. Our review shows
that alemtuzumab, natalizumab, and fingolimod are the best choices for preventing clinical relapses in people with RRMS, but this
evidence is limited to the first 24 months of follow-up. For the prevention of disability worsening in the short term (24 months), only
natalizumab shows a beneficial effect on the basis of moderate quality evidence (all of the other estimates were based on low to very
low quality evidence). Currently, therefore, insufficient evidence is available to evaluate treatments for the prevention of irreversible
disability worsening.
There are two additional major concerns that have to be considered. First, the benefit of all of these treatments beyond two years is
uncertain and this is a relevant issue for a disease with a duration of 30 to 40 years. Second, short-term trials provide scanty and poorly
reported safety data and do not provide useful evidence in order to obtain a reliable risk profile of treatments. In order to provide long-
term information on the safety of the treatments included in this review, it will be necessary also to evaluate non-randomised studies
and post-marketing reports released from the regulatory agencies. Finally, more than 70% of the studies included in this review were
sponsored by pharmaceutical companies and this may have influenced the results.
There are three needs that the research agenda should address. First, randomised trials of direct comparisons between active agents
would be useful, avoiding further placebo-controlled studies. Second, follow-up of the original trial cohorts should be mandatory.
Third, more studies are needed to assess the medium and long-term benefit and safety of immunotherapies and the comparative safety
of different agents.
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Background
Different therapeutic strategies are available for the treatment of people with relapsing-remitting multiple sclerosis (RRMS), including
immunomodulators, immunosuppressants, and biologics. Although there is consensus that these therapies may reduce the frequency
of relapses, their relative benefit (effectiveness compared to each other) in delaying new relapses or disability worsening remains unclear
due to the limited number of direct comparison studies (i.e. studies comparing two or more active agents with each other).
Objectives
We aimed to assess and rank the benefit from and the extent of adverse events associated with 15 drugs, i.e. interferon beta-1b, interferon
beta-1a (Avonex, Rebif ), glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab,
pegylated interferon beta-1a, daclizumab, laquinimod, azathioprine, and immunoglobulins.
Study characteristics
We included 39 studies up to September 2014 in this review, comprising a total of 25,113 participants suffering from RRMS. The
majority of the included studies were short-term, with a median duration of 24 months.
Key results and quality of the evidence
For preventing relapses, alemtuzumab, natalizumab, and fingolimod are more effective than the other drugs, based on moderate to high
quality evidence.
For preventing irreversible disability worsening, insufficient evidence is currently available.
Almost all of the agents included in this review were associated with a higher proportion of participants who withdrew due to any
adverse event compared to placebo.
It is worth noting the following:
- The benefit of all of these treatments beyond two years is uncertain and this is a very relevant issue for people with a lifelong disease
such as multiple sclerosis, who will possibly need long-term treatments.
- Safety data from these short-term studies are scanty, poorly reported and cannot provide enough evidence for us to obtain a reliable
risk profile of the treatments included in this review.
- Most of the included studies were sponsored by pharmaceutical companies and this is a known potential source of bias.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Patient or population: pat ients with relapsing-remit t ing mult iple sclerosis (RRMS)
Settings: secondary healthcare centres
Intervention: any immunomodulators or immunosuppressants used for RRMS
Comparison: placebo
Intervention Illustrative comparative risks* Relative effect
(95% CI)
SUCRA No of participants
(studies)#
Confidence in the evi-
dence
(GRADE)
Reasons for downgrad-
ing
our confidence in the
evidence°Assumed risk with
placebo
Corresponding risk
with intervention
(95% CI)
CHANCE OF EXPERIENCING ONE OR M ORE RELAPSES OVER 12 M ONTHS
Alemtuzumab Low RR 0.40
(0.31 to 0.51)
97% - Moderate Downgraded one level
due to risk of bias -
the majority of studies
at high or unclear risk
of bias in allocat ion con-
cealment and/ or blind-
ing of outcome assessor
domains
41 per 100 16 per 100
(13 to 21)
High
89 per 100 36 per 100
(28 to 45)
M itoxantrone Low RR 0.40
(0.20 to 0.76)
93% 51
(1 study)
Low Downgraded two levels
due to risk of bias - the
singular study contribut-
ing to this est imate at
high risk of bias in blind-
ing of outcome assessor
domain
41 per 100 16 per 100
(8 to 31)
High
89 per 100 36 per 100
(18 to 68)
Natalizumab Low RR 0.56
(0.43 to 0.73)
85% 942
(1 study)
High -
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41 per 100 23 per 100
(18 to 30)
High
89 per 100 50 per 100
(38 to 65)
Fingolimod Low RR 0.63
(0.53 to 0.74)
80% 2355
(2 studies)
Low Downgraded one level
due to risk of bias and
one level due to in-
consistency - the ma-
jority of studies at high
or unclear risk of bias
in allocat ion conceal-
ment and/ or blinding of
outcome assessor do-
mains; I2 = 82% (P value
= 0.02)
41 per 100 26 per 100
(22 to 30)
High
89 per 100 56 per 100
(47 to 66)
Dimethyl fumarate Low RR 0.78
(0.65 to 0.93)
55% 2307
(2 studies)
Moderate Downgraded one level
due to inconsistency -
wide predict ive interval41 per 100 32 per 100
(27 to 38)
High
89 per 100 69 per 100
(58 to 83)
Immunoglobulins Low RR 0.78
(0.61 to 1.00)
53% 219
(3 studies)
Very low Downgraded one level
due to risk of bias,
two levels due to in-
consistency, and one
level due to imprecision
- the majority of stud-
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ies at unclear risk of
bias in allocat ion con-
cealment and/ or blind-
ing of outcome asses-
sor domains; I2 = 83% (P
value = 0.003) and dif -
ferences between pair-
wise and common τ 2 (0.
18 versus 0.01); wide CIs
41 per 100 32 per 100
(25 to 41)
High
89 per 100 69 per 100
(54 to 89)
Glatiramer acetate Low RR 0.80
(0.68 to 0.93)
52% 2416
(4 studies)
Moderate Downgraded one level
due to inconsistency -
wide predict ive interval41 per 100 33 per 100
(28 to 38)
High
89 per 100 71 per 100
(61 to 83)
Daclizumab Low RR 0.79
(0.61 to 1.02)
52% 621
(1 study)
Moderate Downgraded one level
due to imprecision -wide
CIs41 per 100 32 per 100
(25 to 42)
High
89 per 100 70 per 100
(54 to 91)
Teriflunomide Low RR 0.84
(0.72 to 0.99)
42% 2257
(2 studies)
Low Downgraded one level
due to risk of bias and
one level due to incon-
sistency - the majority
of studies at unclear risk
of bias in allocat ion con-
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cealment and/ or blind-
ing of outcome asses-
sor domains; wide pre-
dict ive interval
41 per 100 34 per 100
(30 to 41)
High
89 per 100 75 per 100
(64 to 88)
Azathioprine Low RR 0.87
(0.58 to 1.31)
39% 59
(1 study)
Very low Downgraded one level
due to risk of bias,
one level due to indi-
rectness, and two levels
due to imprecision - the
singular study contribut-
ing to this est imate at
unclear risk of bias in
allocat ion concealment
domain; indirectness of
populat ion (one mono-
centric study); wide CIs
41 per 100 36 per 100
(24 to 54)
High
89 per 100 77 per 100
(52 to 100)
Interferon beta-1a
(Rebif)
Low RR 0.87
(0.76 to 1.01)
36% 853
(2 studies)
Low Downgraded one level
due to risk of bias and
one level due to in-
consistency - the ma-
jority of studies at high
or unclear risk of bias
in allocat ion conceal-
ment and/ or blinding of
outcome assessor do-
mains; I2 = 88% (P value
= 0.004)
7
Im
m
u
n
o
m
o
d
u
la
to
rs
a
n
d
im
m
u
n
o
su
p
p
re
ssa
n
ts
fo
r
re
la
p
sin
g
-re
m
ittin
g
m
u
ltip
le
sc
le
ro
sis:
a
n
e
tw
o
rk
m
e
ta
-a
n
a
ly
sis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
41 per 100 36 per 100
(31 to 41)
High
89 per 100 77 per 100
(68 to 90)
Pegylated
interferon beta-1a
Low RR 0.89
(0.70 to 1.13)
33% 1512
(1 study)
Low Downgraded one level
due to risk of bias and
one level due to impreci-
sion - the singular study
contribut ing to this est i-
mate at unclear risk of
bias in blinding of out-
come assessor domain;
wide CIs
41 per 100 36 per 100
(29 to 46)
High
89 per 100 79 per 100
(62 to 100)
Interferon beta-1b
(Betaseron)
Low RR 0.98
(0.54 to 1.75)
27% - Very low Downgraded one level
due to risk of bias and
two levels due to impre-
cision - the majority of
studies at unclear risk
of bias in allocat ion con-
cealment and/ or blind-
ing of outcome assessor
domains; wide CIs
41 per 100 40 per 100
(22 to 72)
High
89 per 100 87 per 100
(48 to 100)
Interferon beta-1a
(Avonex)
Low RR 0.93
(0.78 to 1.10)
25% 301
(1 study)
Moderate Downgraded one level
due to risk of bias -
the majority of studies
at high or unclear risk
of bias in allocat ion con-
cealment and/ or blind-
ing of outcome assessor
domains
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41 per 100 38 per 100
(32 to 45)
High
89 per 100 83 per 100
(69 to 98)
Interferons
beta (Avonex, Rebif
or Betaseron)
Low RR 1.05
(0.61 to 1.79)
20% - Very low Downgraded one level
due to risk of bias,
one level due to indi-
rectness, and two lev-
els due to imprecision -
the majority of studies
at high or unclear risk
of bias in allocat ion con-
cealment and/ or blind-
ing of outcome assessor
domains; indirectness of
populat ion (one mono-
centric study contribut-
ing 50% to this est imate)
; wide CIs
41 per 100 43 per 100
(25 to 73)
High
89 per 100 93 per 100
(54 to 100)
CHANCE OF EXPERIENCING ONE OR M ORE RELAPSES OVER 24 M ONTHS
Alemtuzumab Low RR 0.46
(0.38 to 0.55)
96% - Moderate Downgraded one level
due to risk of bias -
the majority of studies
at high or unclear risk
of bias in allocat ion con-
cealment and/ or blind-
ing of outcome assessor
domains
57 per 100 26 per 100
(22 to 31)
High
85 per 100 39 per 100
(32 to 47)
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M itoxantrone Low RR 0.47
(0.27 to 0.81)
92% 51
(1 study)
Very low Downgraded two levels
due to risk of bias and
one level due to incon-
sistency - the singular
study contribut ing to this
est imate at high risk of
bias in blinding of out-
come assessor domain;
wide predict ive interval
57 per 100 27 per 100
(15 to 46)
High
85 per 100 40 per 100
(23 to 69)
Natalizumab Low RR 0.56
(0.47 to 0.66)
88% 942
(1 study)
High -
57 per 100 32 per 100
(27 to 38)
High
85 per 100 48 per 100
(40 to 56)
Fingolimod Low RR 0.72
(0.64 to 0.81)
71% 2355
(2 studies)
Moderate Downgraded one level
due to risk of bias -
studies at unclear risk
of bias in allocat ion con-
cealment domain
57 per 100 41 per 100
(36 to 46)
High
85 per 100 61 per 100
(54 to 69)
Immunoglobulins Low RR 0.74
(0.60 to 0.91)
66% 190
(2 studies)
Moderate Downgraded one level
due to inconsistency -
wide predict ive interval57 per 100 42 per 100
(34 to 52)
High
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85 per 100 63 per 100
(51 to 77)
Azathioprine Low RR 0.77
(0.55 to 1.07)
57% 59
(1 study)
Very low Downgraded one level
due to risk of bias,
one level due to indi-
rectness, and one level
due to imprecision - the
singular study contribut-
ing to this est imate at
unclear risk of bias in
allocat ion concealment
domain; indirectness of
populat ion (one mono-
centric study); wide CIs
57 per 100 44 per 100
(31 to 61)
High
85 per 100 65 per 100
(47 to 91)
Glatiramer acetate Low RR 0.83
(0.75 to 0.91)
48% 1024
(3 studies)
Moderate Downgraded one level
due to inconsistency -
wide predict ive interval57 per 100 47 per 100
(43 to 52)
High
85 per 100 71 per 100
(64 to 77)
Interferon beta-1b
(Betaseron)
Low RR 0.85
(0.77 to 0.94)
42% 372
(1 study)
Very low Downgraded one level
due to risk of bias and
two levels due to in-
consistency - the ma-
jority of studies at high
or unclear risk of bias
in allocat ion conceal-
ment and/ or blinding of
outcome assessor do-
mains; wide predict ive
1
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interval and inconsistent
loops of evidence
57 per 100 48 per 100
(44 to 54)
High
85 per 100 72 per 100
(65 to 80)
Interferon beta-1a
(Rebif)
Low RR 0.86
(0.77 to 0.95)
39% 560
(1 study)
Low Downgraded one level
due to risk of bias and
one level due to in-
consistency - the ma-
jority of studies at high
or unclear risk of bias
in allocat ion conceal-
ment and/ or blinding of
outcome assessor do-
mains; wide predict ive
interval
57 per 100 49 per 100
(44 to 54)
High
85 per 100 73 per 100
(65 to 81)
Interferons
beta (Avonex, Rebif
or Betaseron)
Low RR 0.89
(0.56 to 1.42)
33% - Very low Downgraded one level
due to risk of bias,
one level due to indi-
rectness, and one level
due to imprecision - the
majority of studies at
high or unclear risk of
bias in allocat ion con-
cealment and/ or blind-
ing of outcome assessor
domains; indirectness of
populat ion (one mono-
centric study contribut-
1
2
Im
m
u
n
o
m
o
d
u
la
to
rs
a
n
d
im
m
u
n
o
su
p
p
re
ssa
n
ts
fo
r
re
la
p
sin
g
-re
m
ittin
g
m
u
ltip
le
sc
le
ro
sis:
a
n
e
tw
o
rk
m
e
ta
-a
n
a
ly
sis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
ing for 50% to this est i-
mate); wide CIs
57 per 100 51 per 100
(32 to 81)
High
85 per 100 76 per 100
(48 to 100)
Teriflunomide Low RR 0.88
(0.75 to 1.03)
32% 1088
(1 study)
Very low Downgraded two levels
due to risk of bias and
one level due to impreci-
sion - the singular study
contribut ing to this est i-
mate at high risk of bias
in blinding of outcome
assessor domain; wide
CIs
57 per 100 50 per 100
(43 to 59)
High
85 per 100 75 per 100
(64 to 88)
Laquinimod Low RR 0.88
(0.79 to 0.99)
31% 1990
(2 studies)
Very low Downgraded one level
due to risk of bias and
two levels due to in-
consistency - the ma-
jority of studies at high
or unclear risk of bias
in allocat ion conceal-
ment and/ or blinding of
outcome assessor do-
mains; I2 = 66% (P value
= 0.09), wide predict ive
interval and inconsistent
loops of evidence
57 per 100 50 per 100
(45 to 56)
High
85 per 100 75 per 100
(67 to 84)
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Dimethyl fumarate Low RR 0.89
(0.81 to 0.98)
30% 2307
(2 studies)
Moderate Downgraded one level
due to inconsistency -
wide predict ive interval57 per 100 51 per 100
(46 to 56)
High
85 per 100 76 per 100
(69 to 83)
Interferon beta-1a
(Avonex)
Low RR 0.91
(0.82 to 1.02)
22% 1198
(2 studies)
Low Downgraded one level
due to risk of bias and
one level due to in-
consistency - the ma-
jority of studies at
high or unclear risk of
bias in allocat ion con-
cealment and/ or blind-
ing of outcome asses-
sor domains; inconsis-
tent loops of evidence
57 per 100 52 per 100
(47 to 58)
High
85 per 100 77 per 100
(70 to 87)
CHANCE OF DISABILITY GETTING WORSE OVER 24 M ONTHS
M itoxantrone Low RR 0.20
(0.05 to 0.84)
96% 51
(1 study)
Low Downgraded one level
due to indirectness and
one level due to incon-
sistency - surrogate out-
come unclear; wide pre-
dict ive interval
25 per 100 5 per 100
(1 to 21)
High
52 per 100 10 per 100
(3 to 44)
1
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Alemtuzumab Low RR 0.35
(0.26 to 0.48)
94% - Low Downgraded one level
due to risk of bias and
one level due to indi-
rectness - the major-
ity of studies at high
or unclear risk of bias
in allocat ion conceal-
ment and/ or blinding of
outcome assessor do-
mains; surrogate out-
come in the majority of
studies contribut ing to
this est imate
25 per 100 9 per 100
(6 to 12)
High
52 per 100 18 per 100
(14 to 25)
Natalizumab Low RR 0.64
(0.49 to 0.85)
74% 942
(1 study)
Moderate Downgraded one level
due to indirectness - sur-
rogate outcome25 per 100 16 per 100
(12 to 21)
High
52 per 100 33 per 100
(25 to 44)
Azathioprine Low RR 0.64
(0.30 to 1.37)
64% 59
(1 study)
Very low Downgraded one level
due to risk of bias, two
levels due to indirect-
ness, and two levels due
to imprecision - the sin-
gular study contribut ing
to this est imate at un-
clear risk of bias in
allocat ion concealment
domain; indirectness of
populat ion (one mono-
centric study) and sur-
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rogate outcome unclear;
wide CIs
25 per 100 16 per 100
(8 to 34)
High
52 per 100 33 per 100
(16 to 71)
Glatiramer acetate Low RR 0.77
(0.64 to 0.92)
58% 1024
(3 studies)
Very low Downgraded one level
due to indirectness and
two levels due to incon-
sistency - surrogate out-
come in the majority of
studies contribut ing to
this est imate; wide pre-
dict ive interval and in-
consistent loops of evi-
dence
25 per 100 19 per 100
(16 to 23)
High
52 per 100 40 per 100
(33 to 48)
Immunoglobulins Low RR 0.70
(0.39 to 1.27)
56% 190
(2 studies)
Very low Downgraded one level
due to indirectness, one
level due to inconsis-
tency, and two levels
due to imprecision - sur-
rogate outcome in the
majority of studies con-
tribut ing to this est i-
mate; wide predict ive in-
terval; wide CIs
25 per 100 18 per 100
(10 to 32)
High
52 per 100 36 per 100
(20 to 66)
Interferon beta-1b
(Betaseron)
Low RR 0.79
(0.65 to 0.97)
51% 372
(1 study)
Very low Downgraded one level
due to risk of bias, one
level due to indirect-
ness, and two levels due
1
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to inconsistency - the
majority of studies at
high or unclear risk of
bias in allocat ion con-
cealment and/ or blind-
ing of outcome assessor
domains; surrogate out-
come in the majority of
studies contribut ing to
this est imate; wide pre-
dict ive interval and in-
consistent loops of evi-
dence
25 per 100 20 per 100
(16 to 24)
High
52 per 100 41 per 100
(34 to 50)
Dimethyl fumarate Low RR 0.80
(0.67 to 0.94)
50% 2307
(2 studies)
Low Downgraded one level
due to indirectness and
one level due to incon-
sistency - surrogate out-
come in the majority of
studies contribut ing to
this est imate; wide pre-
dict ive interval
25 per 100 20 per 100
(17 to 23)
High
52 per 100 42 per 100
(35 to 49)
Interferons
beta (Avonex, Rebif
or Betaseron)
Low RR 0.83
(0.34 to 2.07)
40% - Very low Downgraded one level
due to indirectness, one
level due to inconsis-
tency, and two levels
due to imprecision - in-
directness of populat ion
and surrogate outcome
unclear (one study con-
tribut ing for 50% to this
est imate); wide predic-
t ive interval; wide CIs
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25 per 100 21 per 100
(9 to 52)
High
52 per 100 43 per 100
(18 to 100)
Interferon beta-1a
(Rebif)
Low RR 0.86
(0.69 to 1.06)
36% 560
(1 study)
Very low Downgraded one level
due to risk of bias, one
level due to indirect-
ness, one level due to
inconsistency, and one
level due to imprecision
- the majority of studies
at high or unclear risk
of bias in allocat ion con-
cealment and/ or blind-
ing of outcome assessor
domains; surrogate out-
come in the majority of
studies contribut ing to
this est imate; inconsis-
tent loops of evidence;
wide CIs
25 per 100 22 per 100
(17 to 26)
High
52 per 100 45 per 100
(36 to 55)
Fingolimod Low RR 0.86
(0.73 to 1.03)
34% 2355
(2 studies)
Very low Downgraded one level
due to risk of bias, one
level due to indirect-
ness, and one level due
to imprecision - studies
at unclear risk of bias in
allocat ion concealment
domain; surrogate out-
come; wide CIs
1
8
Im
m
u
n
o
m
o
d
u
la
to
rs
a
n
d
im
m
u
n
o
su
p
p
re
ssa
n
ts
fo
r
re
la
p
sin
g
-re
m
ittin
g
m
u
ltip
le
sc
le
ro
sis:
a
n
e
tw
o
rk
m
e
ta
-a
n
a
ly
sis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
25 per 100 22 per 100
(18 to 26)
High
52 per 100 45 per 100
(38 to 54)
Laquinimod Low RR 0.87
(0.72 to 1.04)
34% 1990
(2 studies)
Low Downgraded one level
due to indirectness and
one level due to impre-
cision - surrogate out-
come in the majority of
studies contribut ing to
this est imate; wide CIs
25 per 100 22 per 100
(18 to 26)
High
52 per 100 45 per 100
(37 to 54)
Teriflunomide Low RR 0.87
(0.69 to 1.10)
34% 1088
(1 study)
Low Downgraded one level
due to indirectness and
one level due to impre-
cision - surrogate out-
come; wide CIs
25 per 100 22 per 100
(17 to 28)
High
52 per 100 45 per 100
(36 to 57)
Interferon beta-1a
(Avonex)
Low RR 0.93
(0.77 to 1.13)
21% 1198
(2 studies)
Very low Downgraded one level
due to risk of bias, one
level due to indirect-
ness, and two levels due
to inconsistency - the
majority of studies at
high or unclear risk of
bias in allocat ion con-
1
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cealment and/ or blind-
ing of outcome assessor
domains; surrogate out-
come in the majority of
studies contribut ing to
this est imate; I2 = 57%
(P value = 0.13), and in-
consistent loops of evi-
dence
25 per 100 23 per 100
(19 to 28)
High
52 per 100 48 per 100
(40 to 59)
* The corresponding risk with intervention (and its 95% conf idence interval) is based on the assumed risk with placebo and the relative effect of the intervent ion (and its 95%
CI). Two values were chosen for the assumed risk with placebo, i.e. the second highest and second lowest placebo group risks in the included studies, def ined as low and
high assumed risk.
# No of Part icipants (studies) is not available when the nature of the evidence is indirect
°We did not downgrade for reasons of report ing bias as insuf f icient studies contributed to network treatment est imates to draw meaningful conclusions.
CI: conf idence interval; RR: risk rat io; SUCRA: surface under the cumulat ive ranking curve
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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B A C K G R O U N D
Description of the condition
Multiple sclerosis (MS) is an inflammatory disease of the brain
and spinal cord resulting from interaction between unidentified
environmental factors and susceptibility genes. Several patholog-
ical processes occur in MS, involving the immune system, T-
cell-mediated and B-cell-mediated mechanisms, demyelination,
remyelination, microglial activation, and chronic neurodegener-
ation (Bennett 2009; Compston 2008). The sequential involve-
ment of these processes influences the clinical course, which is
characterised by attacks of neurological dysfunction with recovery,
attacks leaving persistent deficits, and progression that causes per-
manent physical and cognitive disability. MS is among the most
common causes of neurological disability in young people, with an
annual incidence ranging from 2 to 10 cases per 100,000 persons
per year and a north-south gradient, with lower incidence closer
to the equator. Its clinical manifestations typically occur between
20 and 40 years of age, with symptoms and signs involving differ-
ent regions of the central nervous system: optic nerve, brainstem,
cerebellum, cerebral hemispheres, and spinal cord.
MS has a chronic course that evolves over 30 to 40 years.
The clinical phenotypes include relapsing-remitting MS (RRMS),
secondary-progressive MS (SPMS), primary-progressive MS
(PPMS), and progressive-relapsing MS (PRMS) (Lublin 1996).
The development of progression after a relapsing-remitting course
is responsible for permanent long-term disability; it supervenes in
about 80% of RRMS people by 20 to 25 years from disease on-
set (Kremenchutzky 2006). Times to need assistance to walk, be
confined to bed, or have died were 14, 24, and 45 median years
from disease onset and 3, 12, and 30 median years from onset of
secondary progression, respectively (Scalfari 2014).
Male sex, older age at onset, and high early relapse frequency (more
than three attacks during the first three years) predict higher risk of
unremitting disability worsening (Scalfari 2014). In people with
RRMS, the onset of secondary progression is the determinant of
long-termprognosis, and its prevention is the key therapeutic goal.
According to the older Poser criteria (Poser 1983), MS can be
clinically diagnosed by demonstrating two separate clinical attacks
(dissemination in time) involving at least two different areas of
the central nervous system (dissemination in space). The 2001
McDonald criteria and their 2005 and 2010 revisions incorporate
magnetic resonance imaging (MRI) criteria for dissemination in
space and time, allowing a MS diagnosis at the time of first symp-
toms (McDonald 2001; Polman 2005; Polman 2011). Dissemina-
tion in space is demonstrated by greater than or equal to one MRI
lesion in at least two MS typical central nervous system regions
(periventricular, juxtacortical, infratentorial, spinal cord).Dissem-
ination in time is demonstrated by: (i) simultaneous asymptomatic
contrast-enhancing and non-enhancing MRI lesions at any time;
or (ii) a new lesion and/or contrast-enhancing lesions(s) on follow-
up MRI, irrespective of its timing. The diagnostic criteria include
exclusion of other possible diagnoses.
A declining trend in on-study relapse rate (one of the most com-
monly used primary outcomes in MS trials) of placebo partici-
pants in trials has been observed (Inusah 2010; Nicholas 2012;
Steinvorth 2013; Stellmann 2012). This decline is thought to re-
sult from decreasing pretrial relapse rates and a shorter time pe-
riod over which pretrial relapse rates were calculated in recent tri-
als (Steinvorth 2013; Stellmann 2012). Pre-study relapse rate was
found to be the best predictor for on-study relapse rate. Other par-
ticipant characteristics have changed in newer trials. Participants
were older and had a longer disease duration, whereas their base-
line Expanded Disability Status Scale (EDSS) scores were similar
to those reported in the older trials. In newer trials the introduc-
tion of the new McDonald diagnostic criteria led to inclusion of
participants who had had earlier diagnosis and were later in their
disease course, which was less severe compared to people in older
studies (Steinvorth 2013). These changes may explain the decrease
in pretrial relapse rate and the associated decrease in on-trial relapse
rate. Unwelcome consequences of the expected decreased relapse
rate were that the sample size of newer trials has been inflated and
follow-up periods shortened.
Another difference between older and newer studies is that the
latter may have included participants who had made prior use of
immunomodulators or immunosuppressants.
Description of the intervention
Several treatments are available for people with RRMS. For this re-
view we considered all immunomodulators and immunosuppres-
sants that, since 1966 up to September 2014, have been studied
in people with RRMS in randomised clinical trials (RCTs) with
more than six months’ follow-up.
Interferon beta-1b (EMEA 2002; FDA 1993), interferon beta-1a
(Rebif ) (EMEA 1998; FDA 2002), interferon beta-1a (Avonex)
(EMEA 1997; FDA 2003), and glatiramer acetate (FDA 1996)
were the first agents approved by national regulatory agencies. In-
terferon beta-1b, interferon beta-1a (Rebif ), and glatiramer ac-
etate are administered by subcutaneous injection, interferon beta-
1a (Avonex) by intramuscular injection. The main adverse effects
of interferons beta are local injection site reactions and flu-like
symptoms with hyperthermia.
Natalizumab was initially approved by the US Food and Drug
Administration (FDA) in November 2004 (FDA 2004), but was
withdrawn by the manufacturer in February 2005, after three par-
ticipants in the drug’s clinical trials developed progressive multi-
focal leukoencephalopathy (PML), a rare and serious viral infec-
tion of the brain. Two of the participants died. Following a re-
examination of the participants in the previous clinical trials, the
FDA allowed a clinical trial of natalizumab to proceed in February
2006. No additional cases of PML were reported and marketing
of the drug for severe RRMS resumed (EMA 2006; FDA 2006;
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Yousry 2006). Natalizumab is administered by intravenous infu-
sion, as a dose of 300 mg every four weeks.
Mitoxantrone was approved in 2000 under the indication “for re-
ducing neurological disability and/or the frequency of clinical re-
lapses in people with worsening RRMS, SPMS or PRMS” (FDA
2000). Safety issues of concern for people treated with mitox-
antrone are cardiotoxicity and acute leukaemia.
Fingolimod was the first oral treatment approved for people with
RRMS to reduce the frequency of relapses and delay the accumu-
lation of physical disability (EMA 2011; FDA 2010). Even at the
recommended low dose of 0.5 mg once daily, the FDA and Eu-
ropean Medicines Agency (EMA) warned about decrease in heart
rate following initiation of fingolimod treatment, recommending
that all patients be monitored for at least six hours for signs and
symptoms of bradycardia, considering that in some patients the
nadir of heart frequency can be observed up to 24 hours after the
first dose.
Teriflunomide was the second oral agent approved for people with
RRMS (EMA 2013a; FDA 2012). It is taken orally as a 7 mg
or 14 mg tablet once daily. Warnings issued with this drug were
hepatotoxicity and risk of teratogenicity.
Dimethyl fumarate has been approved as a first-line oral treatment
for people with RRMS (EMA 2014a; FDA 2013). The recom-
mended dose is 240 mg twice a day. Themost commonly reported
adverse events leading to discontinuation in clinical trials were
flushing and gastrointestinal events.
Alemtuzumab has been approved for treatment of people with
RRMS who have had an inadequate response to two or more
drugs indicated for the treatment of MS (EMA 2013b; FDA
2014a). The drug is administered by intravenous infusion, as a
dose of 12 mg/day for five consecutive days (60 mg total dose)
followed by 12 mg/day for three consecutive days (36 mg total
dose) administered 12 months after the initial treatment course.
Particular warnings and precautions have to be taken into account
for the treatment with alemtuzumab, since serious and sometimes
fatal autoimmune conditions, life-threatening infusion reactions,
and increased risk of malignancies were observed in people treated
with alemtuzumab.
Peg-interferon beta-1a, which has been designed to maintain the
effects of interferon beta in the body for a longer period of time,
was approved by the FDA and EMA for people with RRMS (EMA
2014b; FDA 2014b). It is administered by subcutaneous injection
at a dose of 125 µg every 14 days. The most common adverse
reactions are injection site erythema, influenza-like illness, pyrexia,
headache, myalgia, chills, injection site pain, asthenia, injection
site pruritus, and arthralgia.
Daclizumab is currently being investigated in clinical trials for
RRMS, but it has not yet been approved for MS by regulatory
agencies. It is administered by subcutaneous or intravenous in-
jections. Risks of serious infections and autoimmune diseases are
increased with daclizumab.
Ocrelizumab is in development for the treatment of RRMS, with
two active phase clinical trials ongoing. It is administered by in-
travenous injections.
Laquinimod is an immunomodulator that is currently under eval-
uation for the treatment of RRMS. It is taken orally as a 0.6 mg
tablet once daily. The EMA recommended refusal of the market-
ing authorisation for laquinimod as a treatment for RRMS due
to concerns about potentially increased risks of cancer and terato-
genicity in humans, especially given that the drug’s mechanism of
action is unclear (EMA 2014c). Further studies of laquinimod as
a monotherapy and an add-on therapy in people with RRMS are
ongoing.
Azathioprine has been used for the treatment of MS in many
countries on the basis of placebo-controlled RCTs published more
than two decades ago. However, since the approval of interferons
beta, azathioprine is no longer recommended as first-line ther-
apy (Goodin 2002). It is taken orally as a 2 mg/kg or 3 mg/kg
tablet daily. It was reported that chronic immunosuppression with
azathioprine increases the risk of malignancy in humans (FDA
2014c).
Intravenous immunoglobulins may have a role for people with
severe and frequent relapses for whom other treatments are con-
traindicated (Association of British Neurologists 2005). Severe ad-
verse events, including thrombosis of the jugular vein and allergic
reaction leading to treatment discontinuation, were noted in 4%
of 84 treatment courses with a total 341 infusions under routine
clinical conditions (Elovaara 2008).
How the intervention might work
Immunosuppressive or immunomodulatory effects are common
to all treatments included in the review.
Themechanism of action of interferons beta inMS is incompletely
understood. Interferons beta are naturally occurring cytokines pos-
sessing antiviral activity and a wide range of anti-inflammatory
properties. Recombinant forms of interferons beta are believed to
directly increase expression and concentration of anti-inflamma-
tory agents, while down-regulating the expression of pro-inflam-
matory cytokines (Kieseier 2011).
Glatiramer acetate has an immunomodulatory action by induc-
ing tolerance or anergy of myelin-reactive lymphocytes (Schmied
2003). It is furthermore believed to promote neuroprotective re-
pair processes (Aharoni 2014).
Natalizumab is a monoclonal antibody against the alfa4 integrin
on the surface of lymphocytes. This integrin is essential in the
process by which lymphocytes gain access to the brain by allowing
the cells to penetrate the blood brain barrier. Natalizumab blocks
the action of the alfa4 integrin so that lymphocytes are unable to
enter the brain and attack myelin protein (Yednock 1992).
Mitoxantrone is a cytotoxic drug that intercalates with DNA and
inhibits both DNA and RNA synthesis, thus reducing the number
of lymphocytes (Fox 2004).
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Fingolimod acts as a functional antagonist of sphingosine-1-phos-
phate(S1P) receptor on lymphocytes, resulting in a reduced egress
of lymphocytes from the lymph nodes. In particular, auto-aggres-
sive T-cells are prevented from recirculating to the central nervous
system (Mandala 2002).
Teriflunomide is an inhibitor of dihydroorotate dehydrogenase
(DHODH), a mitochondrial enzyme involved in new pyrimidine
synthesis for DNA replication. Consequently, the drug reduces
T- and B-lymphocytes activation, proliferation, and function in
response to autoantigens. The exact mechanism of action in MS is
not fully understood. The drug is thought to reduce the number
of activated lymphocytes, which would cause inflammation and
damage myelin in the central nervous system (Claussen 2012).
Dimethyl fumarate is a derivative of fumaric acid. It acts primarily
by triggering the activation of a nuclear factor (Nrf2) transcrip-
tional pathway, the primary cellular defence against the cytotoxic
effects of oxidative stress. It promotes anti-inflammatory activity
and can inhibit expression of pro-inflammatory cytokines and ad-
hesion molecules (Wilms 2010).
Alemtuzumab is amonoclonal antibody against theCD52 antigen
expressed on lymphocytes and monocytes. Its effects in MS are
thought to be mediated by an extended lymphocyte depletion
and change in the composition of lymphocytes that accompanies
lymphocyte reconstitution (Hill-Cawthorne 2012).
Pegylated interferon beta-1a has a polyethylene glycol group at-
tached to the α-amino group of the N terminus of interferon
beta-1a (Avonex). Pegylation of interferon beta-1a may improve
its pharmacokinetic and pharmacodynamic properties, allowing
for reduced dosing frequency while maintaining the clinical ef-
fectiveness and safety of the intramuscular interferon beta-1a (Hu
2012).
Daclizumab is a monoclonal antibody against the CD25 antigen
(interleukin 2 receptor) expressed on immune cells. The mecha-
nisms by which the drug exerts effects in MS are not clear. Da-
clizumab leads to expansion of regulatory CD56 natural killer T
lymphocytes, which may be an important mechanism of action
in MS. Furthermore, daclizumab modulates the function of den-
dritic cells, resulting in decreased T-cell activation (Wuest 2011).
Ocrelizumab is a monoclonal antibody against the CD20 antigen
expressed on B-lymphocytes. The antibody depletes circulating B-
lymphocytes predominately through antibody-mediated cytotox-
icity (Oh 2013).
Exactly how laquinimod works is unknown, but it is believed to
have an immunomodulatory effect on the peripheral and central
nervous systems. Data from animal studies indicate that laquini-
mod has a primary effect on innate immunity. The drug modu-
lates the function of various myeloid antigen-presenting cell pop-
ulations, which then down regulate pro-inflammatory T-cell re-
sponses. Furthermore, data indicate that laquinimod acts directly
on resident cells within the central nervous system to reduce de-
myelination and axonal damage (Varrin-Doyer 2014).
Azathioprine is a classical cytotoxic immunosuppressive drug that
acts as a prodrug for mercaptopurine, inhibiting an enzyme that is
required for DNA synthesis. Thus it most strongly affects prolif-
erating cells, such as the T-cells and B-cells of the immune system
(Tiede 2003).
The mechanism of action of intravenous immunoglobulins inMS
remains unclear, although remyelination of demyelinated axons
may occur through the mediation of the effects of cytokines (
Stangel 1999).
Why it is important to do this review
Although there is consensus that immunotherapies reduce the fre-
quency of relapses in MS, their relative benefit in delaying new
relapses or disability worsening remains unclear. This uncertainty
is due to the limited number of direct comparison trials, which
provide the most rigorous and valid research evidence on the rela-
tive benefit and safety of different, competing treatments. A sum-
mary of the results, including both direct and indirect compar-
isons, may help to clarify the stated uncertainty (Caldwell 2005;
Glenny 2005).
O B J E C T I V E S
To compare the benefit and acceptability of interferon beta-
1b, interferon beta-1a (Avonex, Rebif ), glatiramer acetate, natal-
izumab, mitoxantrone, fingolimod, teriflunomide, dimethyl fu-
marate, alemtuzumab, pegylated interferon beta-1a, daclizumab,
laquinimod, azathioprine and immunoglobulins for the treatment
of people with RRMS and to provide a ranking of these treatments
according to their benefit and acceptability, defined as the propor-
tion of participants who withdrew due to any adverse event.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all RCTs that studied one or more of the agents for
use in RRMS and compared them to placebo or to another active
agent. We also included trials for which it was unclear whether the
method of randomisation provided adequate allocation conceal-
ment or open-label studies, but we took the quality of these studies
into account. We excluded RCTs with follow-up of less than or
equal to six months because these trials measured too short-term
outcomes that are not clinically relevant to patients with MS. We
excluded non-randomised studies.
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Types of participants
We included participants 18 years of age or older with a diag-
nosis of RRMS according to Poser (Poser 1983) or McDonald
(McDonald 2001; Polman 2005; Polman 2011) diagnostic crite-
ria. We included all participants regardless of sex, degree of dis-
ability, and disease duration.
Types of interventions
We included all immunomodulators or immunosuppressants
(even if they were not licensed in any country). We excluded: (i)
combination treatments; (ii) trials in which a drug regimen was
compared with a different regimen of the same drug without an-
other active agent or placebo as a control arm; (iii) all non-pharma-
cological treatments; and (iv) interventions with over-the-counter
drugs.
We included RCTs that evaluated one or more of the follow-
ing pharmacological interventions as monotherapy, compared to
placebo or to another active agent:
• interferon beta-1b
• interferon beta-1a (Avonex, Rebif )
• glatiramer acetate
• natalizumab
• mitoxantrone
• fingolimod
• teriflunomide
• dimethyl fumarate
• alemtuzumab
• pegylated interferon beta-1a
• daclizumab
• ocrelizumab
• laquinimod
• azathioprine
• immunoglobulins
We included regimens as defined in primary studies irrespective
of their dose.
We assumed that any patient who met the inclusion criteria was,
in principle, equally likely to have been randomised to any of the
eligible interventions.
Types of outcome measures
Primary outcomes
We estimated the relative effects of the competing interventions
according to the following primary outcomes:
Benefit
• Relapses: proportion of participants who experienced new
relapses over 12, 24, or 36 months after randomisation or at the
end of the study. A relapse is defined as newly developed or
recently worsened symptoms of neurologic dysfunction that last
for at least 24 hours, occurring in the absence of fever or other
acute diseases and separated in time from any previous episode
by more than 30 days (McDonald 2001; Polman 2005). A more
stringent 48-hour criterion has been used in some RCTs. A
relapse can resolve either partially or completely.
• Disability worsening: proportion of participants who
experienced disability worsening over 24 or 36 months after
randomisation or at the end of the study. Worsening is defined as
at least a 1-point Expanded Disability Status Scale (EDSS)
increase or a 0.5-point increase if the baseline EDSS was greater
than or equal to 5.5, confirmed during two subsequent
neurological examinations separated by at least a six-month
interval free of attacks (Kurtzke 1983). Disability worsening
confirmed after only three months of follow-up is considered a
surrogate marker for unremitting disability. The EDSS is a
common measure of MS disability (where 0 is normal, 3 mild
disability, 6 care requirement, 7 wheelchair use, and 10 is death
from MS) and is used to measure disability worsening in clinical
trials for MS.
Acceptability
We used treatment discontinuation due to adverse events to assess
acceptability and we measured it by the number of participants
who withdrew due to any adverse event over 12, 24, or 36 months
after randomisation or at the end of the study out of the total
number of participants randomly assigned to each treatment arm.
Secondary outcomes
The total number of serious adverse events (SAEs). If not enough
studies reported the total number of SAEs and person-years, we
planned to use the number of participants with at least one SAE
as defined in the study.
Search methods for identification of studies
We searched for all possible comparisons formed by the interven-
tions of interest. We applied no language restrictions to the search.
Electronic searches
The Trials Search Co-ordinator searched the Cochrane Multiple
Sclerosis and Rare Diseases of the CNS Group Trials Register
(30 September 2014) which, among other sources, contains trials
from:
• Cochrane Central Register of Controlled Trials
(CENTRAL 2014, Issue 9);
• MEDLINE (PubMed) (1966 to 30 September 2014);
• EMBASE (EMBASE.com) (1974 to 30 September 2014);
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL) (EBSCOhost) (1981 to 30 September 2014);
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• Latin American and Caribbean Health Science Information
Database (LILACS) (Bireme) (1982 to 30 September 2014);
• Clinical trial registries:
◦ clinicaltrials.gov;
◦ World Health Organization (WHO) International
Clinical Trials Registry Portal (apps.who.int/trialsearch/).
Information on the Trials Register of the ReviewGroup and details
of the search strategies used to identify trials can be found in
the ’Specialised Register’ section within the Cochrane Multiple
Sclerosis and Rare Diseases of the CNS Group module.
The keywords used to search for trials for this review are listed in
Appendix 1.
Searching other resources
We extended the search to other resources, including:
• contact with principal authors of the included trials for
additional information;
• searching FDA reports on all of the treatments included in
this review (www.fda.gov).
Data collection and analysis
Selection of studies
We used the search strategy described above to obtain titles and
abstracts of studies that were relevant to the review. Two review
authors independently screened the titles and abstracts and dis-
carded studies that were not applicable; however, we initially re-
tained studies and reviews that might have included relevant data
or information on trials. Two review authors independently as-
sessed the retrieved abstracts and, when necessary, the full text of
these studies to determine which studies satisfied the inclusion cri-
teria. We compared multiple reports of the same study and used
the most comprehensive report. We linked together multiple pub-
lications as companion reports, but excluded true duplicates. We
resolved discrepancies in judgement by discussion with a third au-
thor.
Data extraction and management
Two authors (IP, IT) independently extracted data using a prede-
fined data extraction form in an Excel spreadsheet. We resolved
disagreements by discussion with a third author (GF).
Outcome data
We extracted from each included study the number of participants
who:
• had relapses or disability worsening at 12, 24, and 36
months;
• withdrew due to any adverse event at 12, 24, and 36
months;
• dropped out at each time point;
• had at least one SAE.
We extracted the authors’ definition of relapses and disability wors-
ening.We extracted arm-level datawhen possible.When arm-level
data were not available we extracted effect sizes.
When outcomes were not reported at the predefined time points,
we extracted data as close as possible to that time point. When
numbers of dropouts were not reported or unclear in the primary
studies, we consulted reports from the FDA or asked the trial
author to supply data.
Data on potential effect modifiers
We extracted from each included study data on the following po-
tential effect modifiers:
• population: diagnostic criteria (Poser or McDonald
criteria), baseline mean age, prior immunomodulator or
immunosuppressant treatments (yes, no), definition of relapse,
pre-trial relapse rate and number of years over which the pretrial
relapse rate was calculated;
• intervention: dose, frequency, or duration of treatment;
• risk of bias: allocation concealment, blinding of outcome
assessors, incomplete outcome data;
• funding source.
Other data
We extracted from each included study data on the following ad-
ditional information:
• study: first author or acronym, number of centres, year of
publication, years that the study was conducted (recruitment and
follow-up), publication (full-text publication, abstract
publication, unpublished data);
• study design: inclusion criteria, number of randomised
participants, duration of follow-up (12, 24, or 36 months),
sequence generation, blinding of participants, selective outcome
reporting, early termination of trial.
Assessment of risk of bias in included studies
We assessed the risk of bias of each included study using The
Cochrane Collaboration criteria (Higgins 2011). These include:
random sequence generation, allocation concealment, blinding of
participants, blinding of outcome assessor, incomplete outcome
data, and selective outcome reporting. Other potential risks of bias
included the role of the sponsor. We explicitly judged the risk of
bias of each study on each criterion and classified it as at ’low’,
’high’, or ’unclear’ risk of bias. We judged incomplete outcome
data at low risk of bias when numbers and causes of dropouts were
balanced (i.e. in the absence of a significant difference) between
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arms and appeared to be unrelated to the studied outcomes. Fur-
thermore, we stated for each included study and for each out-
come the accuracy of reporting dropouts, i.e. identifying studies
that provided (or did not provide) complete and clear reporting
of dropout data. We assessed selective outcome reporting bias by
comparing outcomes reported in the study protocol along with
published outcome results. When a study protocol was not avail-
able, we assigned low risk of bias if the study results included the
two primary outcomes relevant to the review, i.e. relapse and dis-
ability worsening.
To summarise the quality of the evidence we considered alloca-
tion concealment, blinding of outcome assessor, and incomplete
outcome data in order to classify each study as at: low risk of bias
when we judged all of the three criteria as at low risk of bias; high
risk of bias when we judged at least one criterion as at high risk of
bias; unclear risk of bias when we judged all of the three criteria as
at unclear risk of bias; and moderate risk of bias in the remaining
cases.
We assessed characteristics associated with the monitoring and
reporting of adverse events considering specific factors that may
have a large influence on adverse event data.We evaluatedmethods
of monitoring and detecting adverse events in each primary study:
Did the researchers actively monitor for adverse events, or did they
simply provide spontaneous reporting of adverse events that arose?
Did the authors define adverse events according to an accepted
international classification and report the number of SAEs? We
reported this information in an additional table called ’Assessment
of Adverse Events Monitoring’.
Three authors (IP, IT, GF) assessed the risk of bias of each study in-
dependently andresolved any disagreement by discussion to reach
consensus.
Measures of treatment effect
Relative treatment effects
We estimated, through pairwise meta-analysis, the treatment ef-
fects of the competing interventions using risk ratio (RR) with
95% confidence intervals (95%CI) for each outcome at each time
point. We presented results from network meta-analysis as sum-
mary relative effect sizes (RR) for each possible pair of treatments.
Relative treatment ranking
We estimated the ranking probabilities for all treatments of being
at each possible rank for each intervention. We then obtained a
treatment hierarchy using the surface under the cumulative rank-
ing curve (SUCRA) and mean ranks. SUCRA can also be ex-
pressed as the percentage of benefit/acceptability of a treatment
that would be ranked first without uncertainty (Salanti 2011).
Unit of analysis issues
Cluster and cross-over trials have not been carried out to evaluate
immunomodulator and immunosuppressant treatments for MS.
We performed separate analyses for participants who had relapses
at 12, 24, and 36 months and disability worsening at 24 and 36
months.
Studies with multiple treatment groups
For multi-arm trials, the intervention groups of relevance were all
those that could be included in a pairwise comparison of inter-
vention groups which, if investigated alone, would have met the
criteria for including studies in the review. For example, if we iden-
tified a study comparing ’interferon beta versus natalizumab ver-
sus interferon beta plus natalizumab’, only one comparison (’in-
terferon beta versus natalizumab’) addresses the review objective,
and no comparison involving combination therapy does. Thus,
the ’interferon beta plus natalizumab’ therapy group was not rele-
vant to the review. However, if the study had compared ’interferon
beta-1b versus interferon beta-1a (Rebif ) versus interferon beta-
1a (Avonex)’, all three pairwise comparisons of interventions are
relevant to the review. In this case we treated themulti-arm studies
as multiple independent two-arm studies in pairwise meta-analy-
sis; we accounted for the correlation between the effect sizes from
multi-arm studies in network meta-analysis. We converted multi-
arm trials involving the same agent at different doses compared
to a control treatment into a single arm by merging of doses and
summing the number of events and the sample size.
Dealing with missing data
In order to assess the effect of missing outcome data, we analysed
data according to a likely scenario, i.e. we assumed that treated
and control group participants who contributed to missing out-
come data both had an unfavourable outcome (relapse or disabil-
ity worsening).
Assessment of heterogeneity
Assessment of clinical heterogeneity within treatment
comparisons
To evaluate the presence of heterogeneity deriving from different
characteristics of study participants, we assessed differences in age,
disease duration, and baseline EDSS scores across the trials using
information reported in the table ’Characteristics of included
studies’.
Assessment of transitivity across treatment comparisons
We expected that the transitivity assumption held, assuming that
all pairwise comparisons did not differ with respect to the distri-
bution of effect modifiers. We evaluated the assumption of transi-
tivity by comparing potential effect modifiers, which are reported
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in the ’Data extraction and management’ section, across the dif-
ferent pairwise comparisons.
Assessment of reporting biases
Considering that it is not mandatory to publish results of clinical
trials, it is difficult to have an estimate of the number of unpub-
lished trials inMS.We evaluated the possibility of reporting bias by
means of contour-enhanced funnel plots (Peters 2008). Contour-
enhanced funnel plots show areas of statistical significance, and
they can help in distinguishing reporting bias from other possible
reasons for asymmetry. In a network of interventions, each study
estimates the relative effect of different interventions, so asymme-
try in the funnel plot cannot be judged. To account for this, we
used an adaptation of the funnel plot by subtracting from each
study-specific effect size the mean of meta-analysis of the study-
specific comparison and plotted it against the study’s standard er-
ror (Chaimani 2012; Chaimani 2013). We employed the com-
parison-adjusted funnel plot for all placebo-controlled trials. Note
that any asymmetry in the plot indicates the presence of small
study effects and not necessarily reporting bias.
Data synthesis
Methods for direct treatment comparisons
We performed conventional pairwise meta-analyses for each pri-
mary outcome using a random-effects model for each treatment
comparison with at least two studies (DerSimonian 1986).
Methods for indirect and mixed comparisons
We performed network meta-analysis for primary outcomes (re-
lapses, disability worsening, and acceptability), using a random-
effects model within a frequentist setting assuming equal hetero-
geneity across all comparisons, and we accounted for correlations
induced by multi-arm studies (Miladinovic 2014; Salanti 2012).
The models enabled us to estimate the probability for each in-
tervention to be at each possible rank for each outcome, given
the relative effect sizes as estimated in network meta-analysis. We
summarised the probabilities of a treatment being at each possi-
ble rank using SUCRAs. By using the cluster analysis technique,
we grouped the treatments according to the SUCRA values for
both benefit and acceptability outcomes and presented them in a
plot. We performed network meta-analysis in Stata 13 using the
’mvmeta’ command and self programmed Stata routines available
at http://www.mtm.uoi.gr (Chaimani 2013; White 2011; White
2012).
Assessment of statistical heterogeneity
Assumptions when estimating heterogeneity
As we expected to have few studies (around two to four) in each
direct comparison, in standard pairwise meta-analysis we assumed
a common heterogeneity variance for all direct comparisons. In
network meta-analysis we assumed a common estimate for the
heterogeneity variance across the different comparisons.
Measures and tests for heterogeneity
We statistically assessed the presence of heterogeneity for all direct
pairwise comparisons using the common τ 2 and I2 statistic.
The assessment of statistical heterogeneity in the entire network
was based on themagnitude of the heterogeneity variance parame-
ter (τ 2) estimated from the networkmeta-analysismodels (Jackson
2014).
Assessment of statistical inconsistency
Consistency in a network of treatments refers to the agreement
between direct and indirect estimates. Joint analysis of treatments
can be misleading if the network is substantially inconsistent. In-
consistency can be present if the trials in the network have different
protocols and their inclusion/exclusion criteria are not compara-
ble or may result as an uneven distribution of the effect modifiers
across groups of trials that compare different treatments.
Local approaches for evaluating inconsistency
To evaluate the presence of inconsistency locally we used the loop-
specific approach. This method evaluates the consistency assump-
tion in each closed loop of the network separately as the difference
between direct and indirect estimates for a specific comparison in
the loop (inconsistency factor) (Veroniki 2013). The magnitude
of the inconsistency factors and their 95% CIs can then be used
to infer the presence of inconsistency in each loop. We assumed a
common heterogeneity estimate within each loop. We presented
the results of this approach graphically in a forest plot using the
’ifplot’ command in Stata (Chaimani 2013).
Global approaches for evaluating inconsistency
We used the ’design-by-treatment’ model to evaluate the assump-
tion of consistency in the entire network (Higgins 2012). This
method accounts for different sources of inconsistency that can
occur when studies with different designs (two-arm trials versus
three-arm trials) give different results, as well as disagreement be-
tween direct and indirect evidence. Using this approach we in-
ferred the presence of inconsistency from any source in the entire
network based on a Chi2 test. We performed the design-by-treat-
ment model in Stata using the ’mvmeta’ command. Inconsistency
and heterogeneity are interwoven; to distinguish between these
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two sources of variability we employed the I2 for inconsistency,
which measures the percentage of variability that cannot be at-
tributed to random error or heterogeneity (Jackson 2014).
Subgroup analyses
We performed subgroup analyses for benefit at 12, 24, and 36
months’ follow-up by using the following effect modifiers as pos-
sible sources of inconsistency or heterogeneity, or both:
• diagnostic criteria (Poser or McDonald criteria);
• previous treatment with immunomodulators or
immunosuppressants (no or yes), i.e. first- or second-line
treatments;
• definition of relapse (24-hour definition or 48-hour
definition);
• pre-trial relapse rate and number of years over which the
pre-trial relapse rate was calculated (relapse rate of one or greater
than one during the year before randomisation, one or greater
than one during the two years before randomisation, two or
greater than two during the two/three years before
randomisation).
Sensitivity analysis
We performed the following sensitivity analyses:
• including only trials with low risk of bias;
• excluding studies that did not provide complete and clear
reporting of dropout data (see ’Assessment of risk of bias in
included studies’ section);
• excluding trials with a total sample size of fewer than 50
randomised participants to detect potential small study effects.
’Summary of findings’ table
We presented the main results of the review in a ’Summary of
findings’ (SoF) table, according to recommendations described in
Chapter 11 of the Cochrane Handbook for Systematic Reviews of In-
terventions (version 5.1.0) (Schünemann 2011).We provided esti-
mates from the network meta-analysis based on the methodology
developed from the GRADE Working Group (GRADE Working
Group 2004). For more details, see Salanti 2014. We included an
overall grading of the evidence for three patient-important out-
comes:
• proportion of people who experienced new relapses over 12
months;
• proportion of people who experienced new relapses over 24
months;
• proportion of people who experienced disability worsening
over 24 months.
For each outcome, we chose two values for the assumed risk with
placebo, i.e. the second highest and second lowest placebo group
risks in the included studies.
We graded the quality of evidence for each outcome considering
study limitations, indirectness, inconsistency, imprecision of ef-
fect estimates, and risk of reporting bias. Since we chose a likely
scenario, accounting for incomplete outcome data, for the overall
analyses, the grading of the evidence related to the study limita-
tions was based on allocation concealment and blinding of out-
come assessor only, and not on incomplete outcome data. Accord-
ing to the software GRADEpro 2008, we assigned four levels of
quality of evidence: high, moderate, low, and very low.
R E S U L T S
Description of studies
Results of the search
Figure 1 shows the results of the electronic search. We identified
415 articles through the search strategy (CENTRAL 10, MED-
LINE 131, EMBASE 254, CINAHL 2, clinical trials registries
18). We excluded 356 articles on the basis of abstracts that we
considered not pertinent.
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Figure 1. Study flow diagram.
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We provisionally selected a total of 56 articles and three ongoing
trials as potentially fulfilling the inclusion criteria. After full-text
review, we included 39 studies and three ongoing trials, and ex-
cluded 17 studies.
Included studies
We included 39 studies involving 25,113 participants and
published between 1987 and 2014 in this review (Achiron
1998; ADVANCE 2014; AFFIRM 2006; ALLEGRO 2012;
BECOME 2009; BEYOND 2009; Bornstein 1987; BRAVO
2014; CAMMS223 2008; CARE-MS I 2012; CARE-MS II
2012; CombiRx 2013; Comi 2001; CONFIRM 2012; DEFINE
2012; Etemadifar 2007; EVIDENCE2007; Fazekas 1997; Fazekas
2008; FREEDOMS 2010; FREEDOMS II 2014; GALA 2013;
Goodkin 1991; IFNB MS Group 1993; INCOMIN 2002;
Johnson 1995; Koch-Henriksen 2006; Lewanska 2002; MAIN
TRIAL; Millefiorini 1997; MSCRG 1996; OWIMS 1999;
PRISMS 1998; REGARD 2008; SELECT 2013; TEMSO 2011;
TENERE 2014; TOWER 2014; TRASFORMS 2010). The table
’Characteristics of included studies’ provides details of included
studies. Median follow-up was 24 months (12-month follow-up
from 12 studies, 24-month follow-up from 25 studies, and 36-
month follow-up from two studies). Twenty-four (60%) were
placebo-controlled and 15 (40%) were head-to-head studies.
We identified three ongoing trials (DECIDE; NCT01247324;
NCT01412333). We will include these studies in a future update
of this review. ’Characteristics of ongoing studies’ provides details
on the characteristics of these studies.
Excluded studies
After full-text review we excluded 17 studies (see ’Characteristics
of excluded studies’): seven studies for insufficient duration
(CHOICE 2010; Kappos 2006; Kappos 2008; Kappos 2011;
Knobler 1993; Saida 2012; Sorensen 2014), five studies evaluating
combination therapies (ACT 2009; Freedman 2012; Havrdova
2009; Khoury 2010; SENTINEL 2006), two studies evaluating
treatments that are not included in this review (Ashtari 2011;
ATAMS 2014), two studies that were non-randomised (Calabrese
2012; Etemadifar 2006), and one dose-finding study without a
control group (FORTE 2011).
Risk of bias in included studies
The risks of bias of the included studies are summarised in
Figure 2 and Figure 3. Considering our predefined criteria (al-
location concealment, blinding of outcome assessor, and in-
complete outcome data) to assess the overall risk of bias of a
study, we judged three out of 39 (8%) trials at low risk of
bias (AFFIRM 2006; Fazekas 1997; PRISMS 1998), we judged
16 (41%) at moderate risk of bias (Achiron 1998; BECOME
2009; BEYOND 2009; BRAVO 2014; Comi 2001; Etemadifar
2007; EVIDENCE 2007; Fazekas 2008; GALA 2013; Goodkin
1991; IFNB MS Group 1993; Johnson 1995; Lewanska 2002;
MSCRG 1996; REGARD 2008; SELECT 2013), and we judged
20 (51%) at high risk of bias (ADVANCE 2014; ALLEGRO
2012; Bornstein 1987; CAMMS223 2008; CARE-MS I 2012;
CARE-MS II 2012; CombiRx 2013; CONFIRM2012;DEFINE
2012; FREEDOMS 2010; FREEDOMS II 2014; INCOMIN
2002; Koch-Henriksen 2006; MAIN TRIAL; Millefiorini 1997;
OWIMS 1999; TEMSO 2011; TENERE 2014; TOWER 2014;
TRASFORMS 2010).
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Five trials (13%) did not provide enough information to assess se-
quence generation (unclear risk), and 34 (87%) reported adequate
methods (low risk).
Of 39 included studies, 21 (54%) reported adequate methods
of allocation concealment (low risk), 17 (44%) did not provide
sufficient information to enable a risk of bias judgment (unclear
risk), and one trial used an unconcealed procedure (high risk)
(Bornstein 1987).
Blinding
Twelve studies (31%) reported that participants and investigators
were blinded (low risk), 15 studies (38%) reported that they were
not blinded (high risk), and the remaining 12 studies (31%) did
not provide sufficient information to enable assessment (unclear
risk). We suspected that most participants and treating physicians
had become aware of the treatment they were receiving during
the course of the trial because most of the agents included in this
review have well-documented side effects, for example injection
site reactions and influenza-like symptoms after interferon beta
injection.
Nineteen studies (49%) were at low risk of detection bias (i.e.
they reported that outcome assessors were blinded), seven studies
(18%) were at high risk, and the remaining 13 studies (33%) did
not provide sufficient information to enable assessment (unclear
risk).
Incomplete outcome data
We judged 20 of 39 (51%) included studies to meet the criteria
for low risk of incomplete outcome data (balanced numbers across
intervention groups with similar reasons for loss to follow-up), 14
studies (36%) were at high risk, and the remaining five studies
(13%) did not provide sufficient information to assess risk of in-
complete outcome data (unclear risk). The percentage of people
who were lost-to follow-up among the 39 studies varied from 0%
to 43%, with an average of 13.5% (standard deviation 9.1%), and
a median of 11.9%.
Selective reporting
All the studies reported all pre-specified primary benefit outcomes,
with the exception of three trials (CONFIRM 2012; DEFINE
2012; TEMSO 2011), in which disability worsening confirmed
at six months was not reported in the published report, but was
reported in the FDA reports, and thus we considered them at high
risk of reporting bias.
Other potential sources of bias
Other bias
We judged 33 studies (85%) at high risk of other bias; this in-
cludes the role of the sponsor in authorship of the study report or
in data management or analysis (27/39), and incomplete or un-
clear reporting of data on outcomes and/or study discontinuation
(27/39), which make it impossible to understand how the cor-
responding analyses were performed (e.g. annualised relapse rate
estimation).
Method of adverse event monitoring
(See Table 1). In 28 trials (72%), adverse events were activelymon-
itored and we judged the risk of bias to be low. Eight trials (21%)
reported insufficient information about the method of adverse
event monitoring so that it was uncertain whether or not adverse
events were monitored appropriately. We judged the risk of bias
to be unclear in these studies. Spontaneous reporting of adverse
events as they occurred was reported in three studies and thus we
judged them at high risk of bias (Bornstein 1987; EVIDENCE
2007; Goodkin 1991).
Serious adverse event (SAE) definition and reporting
In nine trials (23%) SAEs were not reported and we judged the
risk of bias to be high. In 15 trials (38%) SAEs were reported
but insufficient information on their definition was given and we
judged the risk of bias to be unclear. Fifteen studies (38%)provided
a definition of SAEs and we judged the risk of bias to be low.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings for the main comparisons of treatment effects against
placebo
Summary of findings for the main comparison provides overall es-
timates of treatment effects comparedwith placebo and the quality
of the available evidence for the three benefit outcomes (chance
of experiencing one or more relapses over 12 months, chance of
experiencing one or more relapses over 24 months, chance of dis-
ability getting worse over 24 months), obtained through a net-
work meta-analysis. Figure 4 shows the networks of evidence for
the benefit and acceptability of immunomodulators and immuno-
suppressants included in the review. Each line links the treatments
that have been directly compared in studies. The thickness of the
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line is proportional to the number of participants included in the
comparison and the width of each circle is proportional to the
number of studies included in the comparison. Figure 5 and Figure
6 show, respectively, the estimates of benefit and acceptability of
each treatment against placebo within the networks. Analysis 3.1
provides the summary of treatment safety compared with placebo
within pairwise comparisons. Figure 7, Figure 8, Figure 9, Figure
10 and Figure 11 show the network meta-analysis estimates of
primary benefit and acceptability outcomes for each comparison.
Figure 4. Network plots of treatment comparisons for benefit and acceptability outcomes.
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Figure 5. Network meta-analysis (NMA) estimates of treatment benefit against placebo: relapses over 12
and 24 months, and disability worsening over 24 months.CI: confidence interval; RR: risk ratio.
34Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 6. Network meta-analysis (NMA) estimates of treatment acceptability against placebo: treatment
discontinuation due to AEs over 12 and 24 months.AEs: adverse events; CI: confidence interval; RR: risk ratio.
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Figure 7. Network meta-analysis (NMA) estimates of treatment benefit (lower triangle) and acceptability
(upper triangle) over 12 months for each comparison: relapses and treatment discontinuation due to adverse
events (AEs) over 12 months.Drugs are reported in order of primary benefit ranking. Comparisons should be
read from left to right. The estimate (risk ratio, RR) is located at the intersection of the column-defining
treatment and the row-defining treatment. A RR value below 1 favours the column-defining treatment for
lower triangle, and the row-defining treatment for upper triangle. To obtain RRs for comparisons in the
opposing direction, reciprocals should be taken. Significant results are bolded and underscored.Alemtuz:
alemtuzumab; Avonex: interferon beta-1a (Avonex); Aza: azathioprine; Betaseron: interferon beta-1b
(Betaseron); Dacliz: daclizumab; Dimethyl: dimethyl fumarate; Fingolim: fingolimod; Glatir: glatiramer
acetate; IFNß: interferons beta; Immunogl: immunoglobulins; Mitoxan: mitoxantrone; Nataliz: natalizumab;
PegIFNß: pegylated interferon beta-1a; Rebif: interferon beta-1a (Rebif); Terifl: teriflunomide.
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Figure 8. Network meta-analysis (NMA) estimates of treatment benefit (lower triangle) and acceptability
(upper triangle) over 24 months for each comparison: relapses and treatment discontinuation due to adverse
events (AEs) over 24 months. Drugs are reported in order of primary benefit ranking. Comparisons should be
read from left to right. The estimate (risk ratio, RR) is located at the intersection of the column-defining
treatment and the row-defining treatment. A RR value below 1 favours the column-defining treatment for
lower triangle, and the row-defining treatment for upper triangle. To obtain RRs for comparisons in the
opposing direction, reciprocals should be taken. Significant results are bolded and underscored.Alemtuz:
alemtuzumab; Avonex: interferon beta-1a (Avonex); Aza: azathioprine; Betaseron: interferon beta-1b
(Betaseron); Dimethyl: dimethyl fumarate; Fingolim: fingolimod; Glatir: glatiramer acetate; IFNß: interferons
beta; Immunogl: immunoglobulins; Laquin: laquinimod; Mitoxan: mitoxantrone; Nataliz: natalizumab; Rebif:
interferon beta-1a (Rebif); Terifl: teriflunomide.
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Figure 9. Clustered ranking plot based on cluster analysis of surface under the cumulative ranking curve
(SUCRA) values for benefit (relapses) and acceptability (treatment discontinuation due to AEs) over 24
months. Each colour represents a group of treatments that belong to the same cluster. Treatments lying in the
upper right corner are more effective and acceptable than the other treatments.
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Figure 10. Network meta-analysis (NMA) estimates of treatment benefit (lower triangle) and acceptability
(upper triangle) over 24 months for each comparison: disability worsening and treatment discontinuation due
to adverse events (AEs) over 24 months. Drugs are reported in order of primary benefit ranking. Comparisons
should be read from left to right. The estimate is located at the intersection of the column-defining treatment
and the row-defining treatment. A RR value below 1 favours the column-defining treatment for lower triangle,
and the row-defining treatment for upper triangle. To obtain RRs for comparisons in the opposing direction,
reciprocals should be taken. Significant results are bolded and underscored.Alemtuz: alemtuzumab; Avonex:
interferon beta-1a (Avonex); Aza: azathioprine; Betaseron: interferon beta-1b (Betaseron); Dimethyl:
dimethyl fumarate; Fingolim: fingolimod; Glatir: glatiramer acetate; IFNß: interferons beta; Immunogl:
immunoglobulins; Laquin: laquinimod; Mitoxan: mitoxantrone; Nataliz: natalizumab; Rebif: interferon beta-1a
(Rebif); Terifl: teriflunomide.
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Figure 11. Clustered ranking plot based on cluster analysis of surface under the cumulative ranking curve
(SUCRA) values for benefit (disability worsening) and acceptability (treatment discontinuation due to AEs)
over 24 months. Each colour represents a group of treatments that belong to the same cluster. Treatments
lying in the upper right corner are more effective and acceptable than the other treatments.
1. Primary outcomes
1.1 Benefit
Relapses over 12 and 24 months and disability worsening
over 24 months
Pairwise meta-analysis (direct comparisons)
Treatment estimates for pairwise meta-analyses are reported in
Analysis 1.1, Analysis 1.2, and Analysis 1.3.
Network meta-analysis estimates (combination of direct and
indirect comparisons) of treatment effects against placebo
Wedid not find any evidence that important variables varied across
comparisons or altered the effectiveness of the treatments. Accord-
ingly, none of the corresponding analyses provided evidence that
any potential effect modifiers were possible sources of inconsis-
tency or heterogeneity. However, few studies per comparison were
available and the results from sensitivity and subgroup analyses
were very uncertain, so no firm conclusion can be drawn about
the presence or absence of transitivity and heterogeneity.
See: Summary of findings for the main comparison, Figure 4,
Figure 5, Figure 7, Figure 8, Figure 9, Figure 10 and Figure 11.
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a) Relapses over 12 months were provided in 29 studies involv-
ing 17,897 participants with relapsing-remitting multiple sclerosis
(RRMS) (71.3% of the participants in this review) (Achiron 1998;
ADVANCE 2014; AFFIRM 2006; BECOME 2009; Bornstein
1987; CAMMS223 2008; CARE-MS I 2012; CARE-MS II
2012; Comi 2001; CONFIRM2012; DEFINE 2012; Etemadifar
2007; EVIDENCE 2007; Fazekas 2008; FREEDOMS 2010;
FREEDOMS II 2014; GALA 2013; Goodkin 1991; Lewanska
2002;MAINTRIAL;Millefiorini 1997;MSCRG 1996; OWIMS
1999; PRISMS 1998; SELECT 2013; TEMSO 2011; TENERE
2014; TOWER 2014; TRASFORMS 2010). Nineteen studies of
12 treatments involving 12,100 participants were placebo-con-
trolled trials, nine studies of 12 treatments involving 4367 par-
ticipants were head-to-head trials directly comparing active treat-
ments, and one study involving 1430 participants had both a
placebo and two active treatment arms. Five of 15 treatments
(33%) were compared to placebo only. The majority of direct
comparisons between active treatments were not assessed in any
trial (Figure 4). Alemtuzumab was the best drug (risk ratio (RR)
versus placebo 0.40, 95% confidence interval (CI) 0.31 to 0.51;
SUCRA = 97%; moderate quality evidence), followed by mitox-
antrone (RR versus placebo 0.40, 95%CI 0.20 to 0.76; SUCRA =
93%; low quality evidence), natalizumab (RR versus placebo 0.56,
95%CI 0.43 to 0.73; SUCRA = 85%; high quality evidence), and
fingolimod (RR versus placebo 0.63, 95% CI 0.53 to 0.74; SU-
CRA = 80%; low quality evidence). The heterogeneity τ 2 for this
network overall was 0.01, which we considered low heterogeneity.
b) Relapses over 24 months were provided in 26 studies and
16,800 participants with RRMS (67% of those included in
this review) (Achiron 1998; AFFIRM 2006; ALLEGRO 2012;
BECOME 2009; BEYOND 2009; Bornstein 1987; BRAVO
2014; CAMMS223 2008; CARE-MS I 2012; CARE-MS II 2012;
CONFIRM 2012; DEFINE 2012; Fazekas 1997; FREEDOMS
2010; FREEDOMS II 2014; Goodkin 1991; IFNB MS Group
1993; INCOMIN 2002; Johnson 1995; Koch-Henriksen 2006;
MAINTRIAL;Millefiorini 1997;MSCRG 1996; PRISMS 1998;
REGARD 2008; TEMSO 2011). Fifteen studies of 12 treatments
involving 8562 participants were placebo-controlled trials, nine
studies of seven treatments involving 5477 participants were head-
to-head trials directly comparing active treatments, and two stud-
ies involving 2761 participants had both a placebo and two active
treatment arms each. Five of 14 treatments (36%) were compared
to placebo only. The majority of direct comparisons between ac-
tive treatments were not assessed in any trial (Figure 4). As for
the relapse over 12 months outcome, alemtuzumab was the best
drug (RR versus placebo 0.46, 95% CI 0.38 to 0.55; SUCRA =
96%; moderate quality evidence), followed by mitoxantrone (RR
versus placebo 0.47, 95% CI 0.27 to 0.81; SUCRA = 92%; very
low quality evidence), natalizumab (RR versus placebo 0.56, 95%
CI 0.47 to 0.66; SUCRA = 88%; high quality evidence), and fin-
golimod (RR versus placebo 0.72, 95% CI 0.64 to 0.81; SUCRA
= 71%; moderate quality evidence). The heterogeneity τ 2 for this
network overall was 0.0036, which we considered low heterogene-
ity.
c)Disabilityworsening over 24monthswas available from26 stud-
ies and 16,800 participants with RRMS (67% of those included
in this review) (Achiron 1998; AFFIRM 2006; ALLEGRO 2012;
BECOME 2009; BEYOND 2009; Bornstein 1987; BRAVO
2014; CAMMS223 2008; CARE-MS I 2012; CARE-MS II 2012;
CONFIRM 2012; DEFINE 2012; Fazekas 1997; FREEDOMS
2010; FREEDOMS II 2014; Goodkin 1991; IFNB MS Group
1993; INCOMIN 2002; Johnson 1995; Koch-Henriksen 2006;
MAINTRIAL;Millefiorini 1997;MSCRG 1996; PRISMS 1998;
REGARD 2008; TEMSO 2011). The network geometry for dis-
ability worsening over 24 months was as for relapses over 24
months (Figure 4). Mitoxantrone was the best drug (RR versus
placebo 0.20, 95% CI 0.05 to 0.84; SUCRA = 96%; low qual-
ity evidence), followed by alemtuzumab (RR versus placebo 0.35,
95% CI 0.26 to 0.48; SUCRA = 94%; low quality evidence),
and natalizumab (RR versus placebo 0.64, 95% CI 0.49 to 0.85;
SUCRA = 74%; moderate quality evidence). The heterogeneity τ
2 for this network overall was 0.0081, which we considered low
heterogeneity.
Relapses and disability worsening over 36 months
Relapses and disability worsening over 36 months were available
from two studies only: one on glatiramer acetate versus interferon
beta-1a (Avonex), with a RR of 0.71 (95% CI 0.57 to 0.88) for
relapses, and a RR of 0.91 (95% CI 0.75 to 1.10) for disability
worsening (CombiRx 2013); one on alemtuzumab versus inter-
feron beta-1a (Rebif ), with a RR of 0.48 (95% CI 0.33 to 0.68)
for relapses, and a RR of 0.42 (95% CI 0.30 to 0.57) for disability
worsening (CAMMS223 2008). We judged both studies at high
risk of bias (Figure 3).
1.2 Acceptability
Treatment discontinuation due to adverse events over 12 and
24 months
Pairwise meta-analysis (direct comparisons)
Treatment estimates for pairwise meta-analyses are reported in
Analysis 2.1 and Analysis 2.2.
Network meta-analysis estimates (combination of direct and
indirect comparisons) of treatment effects against placebo
See: Figure 4, Figure 6, Figure 7, Figure 8, Figure 9, Figure 10 and
Figure 11.
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Acceptability over 12 months was reported in 13 studies on 10
treatments involving 8105 participants: nine studies of seven treat-
ments involving 5718 participants were placebo-controlled trials,
and four studies of six treatments involving 2387 participants were
head-to-head trials directly comparing active treatments. Four of
10 treatments (40%)were compared to placebo only. Themajority
of direct comparisons between active treatments were not assessed
in any trial (Figure 4). The network geometry for acceptability
over 24monthswas as for relapses and disability worsening over 24
months (Figure 4). The network meta-analysis showed that over
12 months, compared to placebo, several treatments had a signifi-
cantly higher proportion of participants who withdrew due to any
adverse event, such as teriflunomide (RR versus placebo 2.24, 95%
CI 1.50 to 3.34), peg-interferon beta (RR versus placebo 2.80,
95% CI 1.39 to 5.64), interferon beta-1a (Avonex) (RR versus
placebo 4.36, 95% CI 1.98 to 9.60), interferon beta-1a (Rebif )
(RR versus placebo 4.83, 95% CI 2.59 to 9.00), and fingolimod
(RR versus placebo 8.26, 95%CI 3.25 to 20.97).Over 24months,
the networkmeta-analysis showed that, compared to placebo, only
fingolimod had a significantly higher proportion of participants
who withdrew due to any adverse event (RR versus placebo 1.69,
95% CI 1.32 to 2.17). The heterogeneity τ 2 for these networks
overall was < 0.0001, which we considered low heterogeneity.
1.3 Relationship between benefit and acceptability outcomes
for each comparison (network meta-analysis estimates)
See: Figure 7, Figure 8, Figure 9, Figure 10 and Figure 11.
a)Relapses and acceptability over 12months (Figure 7).Compared
to placebo and all other active agents, excluding mitoxantrone and
natalizumab, alemtuzumab showed a significantly lower propor-
tion of participants who experienced new relapses over 12 months,
but no data were available on the acceptability of alemtuzumab
over 12 months. Compared to placebo and several other active
agents, mitoxantrone, natalizumab, and fingolimod showed a sig-
nificantly lower proportion of participants who experienced new
relapses over 12 months. However, data on the acceptability of
these treatments over 12 months were available for fingolimod
only, showing a significantly higher proportion of participants
who withdrew due to any adverse event over 12 months with fin-
golimod compared to glatiramer acetate, teriflunomide, interferon
beta-1a (Avonex), and placebo.
b) Relapses and acceptability over 24 months (Figure 8 and Figure
9). Compared to placebo and all other active agents, excluding
mitoxantrone and natalizumab, alemtuzumab showed a signifi-
cantly lower proportion of participants who experienced new re-
lapses over 24 months, and did not show a significantly higher
proportion of participants who withdrew due to any adverse event
over 24 months. Compared to placebo and several other active
agents, mitoxantrone, natalizumab, and fingolimod showed a sig-
nificantly lower proportion of participants who experienced new
relapses over 24 months, and did not show a significantly higher
proportion of participants who withdrew due to any adverse event
over 24 months, with the exception of fingolimod versus placebo
(RR 1.69, 95% CI 1.32 to 2.17). Similar results are shown in
the plot representing the groups of treatments obtained from the
cluster analysis according to the SUCRA values for both benefit
and acceptability.
c) Disability worsening and acceptability over 24 months (Figure
10 and Figure 11). Compared to placebo and all other active
agents, excluding mitoxantrone, alemtuzumab showed a signifi-
cantly lower proportion of participants who experienced disabil-
ity worsening over 24 months, and did not show a significantly
higher proportion of participants who withdrew due to any ad-
verse event over 24 months. Compared to placebo and a few other
active agents, mitoxantrone showed a significantly lower propor-
tion of participants who experienced disability worsening over 24
months, and did not show a significantly higher proportion of par-
ticipants who withdrew due to any adverse event over 24 months.
Similar results are shown in the plot representing the groups of
treatments obtained from the cluster analysis according to the SU-
CRA values for both benefit and acceptability.
2. Secondary outcomes
2.1 Safety
Serious adverse events (SAEs)
Pairwise meta-analysis (direct comparisons)
Compared to the placebo group there was not a significant differ-
ence in the proportion of participants with serious adverse events.
Nevertheless, information on serious adverse events was scanty,
based on a very low number of events, poorly reported and char-
acterised by heterogeneous results (Analysis 3.1).
3. Assessment of heterogeneity and inconsistency
within the network analyses
We performed an assessment of heterogeneity and inconsistency
within the network analyses for relapses over 12 and 24 months,
for disability worsening over 24 months and for acceptability at
12 and 24 months.
We observed evidence of local statistical inconsistency, estimated
as a difference between direct and indirect treatment estimates in
networks, for two loops for relapses over 24 months and for three
for disability worsening over 24 months, and none for relapses
over 12 months and acceptability at 12 and 24 months (Figure
12 and Figure 13). However, due to the presence of imprecise
direct and network estimates, the absence of statistically significant
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inconsistency is not evidence against the presence of inconsistency.
The values for common heterogeneity (τ 2) for the network for
each outcome seem to show no evidence of heterogeneity. When
evaluating the inconsistency in the networks as a whole, there is
no indication of global inconsistency within any network (global
test for inconsistency: P value = 0.99 for relapses over 12 months;
P value = 0.97 for relapses over 24 months; P value = 0.08 for
disability worsening over 24 months), but we expected the power
to be low with few studies per comparison and few closed loops.
Hence, we decided to downgrade the quality of the evidence for
inconsistency in most comparisons.
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Figure 12. Inconsistency plots for relapses over 12 and 24 months and disability worsening over 24 months
assuming loop-specific heterogeneity estimates. RRR is calculated as the risk ratio for direct evidence over the
risk ratio for indirect evidence in the loop and it is reported together with its 95% confidence interval (CI). RRR
values close to one indicate the absence of evidence for disagreement between direct and indirect evidence.
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Figure 13. Inconsistency plots for acceptability over 12 and 24 months assuming loop-specific heterogeneity
estimates. RRR is calculated as the risk ratio for direct evidence over the risk ratio for indirect evidence in the
loop and it is reported together with its 95% confidence interval (CI). RRR values close to one indicate the
absence of evidence for disagreement between direct and indirect evidence.
4. Subgroup and sensitivity analyses
None of the pre-defined subgroup analyses (i.e. by diagnostic crite-
ria, previous treatments, definition of relapse and pre-trial relapse
rate) and sensitivity analyses (i.e. including only trials at low risk
of bias, excluding studies that did not provide complete and clear
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reporting of dropout data, and excluding trials with a total sample
size of fewer than 50 randomised participants) that we performed
provided any significantly different results, compared to the over-
all analyses (see Table 2 and Table 3 for the corresponding network
meta-analysis estimates for relapse outcome over 24 months for
the three best drugs, based on moderate to high quality evidence,
i.e. alemtuzumab, natalizumab, and fingolimod). However, few
studies per comparison were available and limitations in study re-
porting cannot exclude differences between subgroups.
5. Reporting bias
We did not produce a contour-enhanced funnel plot for each pair-
wise comparison due to the low number of studies. We employed
a comparison-adjusted funnel plot for all placebo-controlled trials
for relapses over 12 and 24 months and disability worsening over
24 months. Small study effects (not necessarily due to reporting
bias) appeared to be present for relapses over 12 and 24 months,
but not for disability worsening over 24 months (data not shown).
6. Grading of the evidence
We graded the evidence for relapses over 12 and 24 months and
for disability worsening over 24 months for each network estimate
of an immunomodulator or immunosuppressant used for RRMS
versus placebo (Summary of findings for themain comparison) ac-
cording to the approach proposed by Salanti 2014.We considered
the following domains: study limitations, indirectness, inconsis-
tency, imprecision of effect estimates, and risk of reporting bias.
We assessed the study limitations for each network estimate by
first evaluating the risk of bias for each direct estimate and then by
integrating these judgements with the contribution of each direct
estimate to the network estimates (Figure 14). The percentage
contribution of each direct estimate to the network estimates for
any considered outcome are reported in Figure 15, Figure 16 and
Figure 17. We also took these percentages into account for the
evaluation of the other domains, and determined the confidence
in an overall treatment ranking from each network meta-analysis.
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Figure 14. Study limitations distribution for each network estimate for pairwise comparisons versus
placebo on relapses over 12 and 24 months and disability worsening over 24 months outcomes. Calculations
are based on the contributions of direct evidence to the network estimates and the overall risks of bias
considering our predefined criteria (allocation concealment, blinding of outcome assessor, and incomplete
outcome data) within studies contributing to the direct evidence. The colours represent risk (green, low;
yellow, moderate; red, high). The direct comparisons against placebo are described in the vertical axis.
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Figure 15. Contribution matrix: percentage contribution of each direct estimate to the NMA estimates
versus placebo for relapses over 12 months outcome. Rows correspond to NMA risk ratios of each treatment
versus placebo (separated for mixed and indirect evidence) and the columns correspond to direct meta-
analysis risk ratios. The last row shows the number of included direct comparisons. The names of the
treatment comparisons are shown in the first column. For example, for relapses over 12 months, information
for the network estimate of interferon beta 1a (Avonex) versus placebo is derived from both direct and
indirect evidence (generating a mixed estimate). Of this mixed network estimate, trials directly comparing
interferon beta 1a (Avonex) versus placebo contribute 31.2% of the information to the network estimate of
effect and trials directly comparing interferon beta 1a (Rebif) versus interferon beta 1a (Avonex) contribute
18.8% of the network estimated effect, etc. The contribution matrix shows how much each direct comparison
in the network contributes to each network (mixed or indirect) estimate and to the entire network.
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Figure 16. Contribution matrix: percentage contribution of each direct estimate to the NMA estimates
versus placebo for relapses over 24 months outcome.
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Figure 17. Contribution matrix: percentage contribution of each direct estimate to the NMA estimates
versus placebo for disability worsening over 24 months outcome.
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We assessed indirectness by evaluating both indirectness of popu-
lations, interventions, and outcomes as in standard GRADE, and
transitivity by comparing the distribution of known effect modi-
fiers across comparisons that contribute evidence to estimation of
the network meta-analysis treatment effect, and across networks
that contribute evidence to estimation of the overall treatment
ranking from each network meta-analysis.
We assessed inconsistency by judging the extent of heterogeneity
(i.e. considering the comparison-specific heterogeneity variance
with other relevant metrics such as the I2 statistic, the network
meta-analysis estimate of variance and a prediction interval), and
by evaluating the extent towhich the comparison under evaluation
was involved in inconsistent loops of evidence, and the overall
inconsistency in the networks using global tests of inconsistency.
Evaluation of imprecision was focused on width of the CIs of
the network meta-analysis treatment effect estimates, and visually
examining ranking probabilities (i.e. rankograms) for overlap to
assess the precision of treatment rankings.
Due to the low number of studies for each comparison, we assessed
reporting bias through a comparison-adjusted funnel plot for the
treatment ranking estimates only.
For relapses at 24 months we judged the confidence in the treat-
ment estimate to be high for natalizumab only, moderate for alem-
tuzumab, fingolimod, dimethyl fumarate, glatiramer acetate, da-
clizumab, and interferon beta-1a (Avonex), and low or very low
for all the other treatment estimates. For disability worsening at
24 months the confidence in almost all of the treatment estimates
varied from low to very low, except for natalizumab, which we
evaluated as moderate quality.
In the ranking of the treatments we judged our confidence as low
for relapses over 12 and 24 months due to study limitations and
reporting bias, and low for disability worsening at 24 months due
to indirectness and imprecision.
D I S C U S S I O N
Summary of main results
This review of the effects of treatments for relapsing-remitting
multiple sclerosis (RRMS) included 39 studies involving 25,113
randomised adult participants. Themajority of studies were short-
term trials, with the median randomised controlled trial (RCT)
duration being 24 months. Only two studies reported a 36-month
follow-up, therefore the effects of these treatments beyond two
years remain uncertain.
1. Recurrence of relapses
Alemtuzumab, mitoxantrone, natalizumab, and fingolimod out-
performed other drugs, being statistically significantly more effec-
tive than placebo and the majority of other drugs, with risk ra-
tios (RRs) versus placebo ranging between 0.40 and 0.72 at both
12 and 24 months. Direct comparisons contributed to these net-
work estimates: 40% to alemtuzumab (three trials versus inter-
feron beta-1a (Rebif ) involving 1582 participants), and 100% to
fingolimod (two trials versus placebo involving 2355 participants),
to natalizumab (one study versus placebo involving 942 partici-
pants), and to mitoxantrone (one study versus placebo involving
51 participants). Furthermore, based on theGRADE approach for
network meta-analysis, we assessed our confidence in the evidence
for their beneficial effects as high for natalizumab, moderate for
alemtuzumab, moderate to low for fingolimod, and low to very
low for mitoxantrone.
2. Disability worsening
Themeasurement of this outcomewas based on a surrogatemarker
in the majority of the included studies, since they used disability
worsening confirmed at only threemonths’ follow-up, thus reflect-
ing an effect on relapse-related disability. Both direct and indirect
comparisons revealed that almost none of the treatments included
in this review were effective in preventing disability worsening
over two years, with the exception of mitoxantrone, alemtuzumab,
and natalizumab. Nevertheless, our confidence in the beneficial
effects was moderate for natalizumab and low for mitoxantrone
and alemtuzumab.
3. Acceptability and safety
Almost all of the agents included in this review were associated
with a higher proportion of participants who withdrew due to any
adverse event compared to placebo at 12 and 24 months. All the
treatments for which information on serious adverse events was
available were associated with a non-significantly higher propor-
tion of people with at least one SAE comparedwith placebo during
amedian two-year follow-up period. Lack of statistical significance
in our analyses was likely to have been caused by a low number
of events and short-term trials. Moreover, information on serious
adverse events was scanty, poorly reported and characterised by
heterogeneous results.
Overall completeness and applicability of
evidence
Many of the trials included in this review provided evidence on the
proportion of participants who experienced new relapses, disabil-
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ity worsening, and adverse events over 12 or 24 months’ follow-
up, but only two studies reported data on these outcomes over 36
months. This is an unwelcome finding considering that multiple
sclerosis (MS) is a disease of 30 to 40 years’ duration. Moreover,
scanty and poorly reported safety data did not provide complete
evidence, leading to uncertainty about the risk profile of the treat-
ments included in the review.
Evidence on 15 treatments included in this review was derived
from 39 trials (searched for up to September 2014), which is a
small number of studies relative to the number of treatments.
Furthermore, the evidence was derived primarily from 16 trials
(16,162 patients; 64.4% of those included in this review) on new
drugs mostly compared with placebo (60% of the trials included
in this review). There is therefore uncertainty that the results of
the review fit into the context of current practice since about 50%
of patients are treated with at least one of these treatments (Carroll
2014).
The reasons why there are few randomised studies for RRMS,
and these are mostly placebo-controlled, are probably due to: i)
approval of treatments for RRMS by many national regulatory
agencies based on results from as little as one placebo-controlled
trial; ii) the consequent lack of interest of pharmaceutical compa-
nies in conducting additional expensive studies; iii) the unlikely
advantage of pharmaceutical companies in conducting head-to-
head trials directly comparing active treatments.
Our review was not intended to be a comprehensive review of all
effects of treatments for RRMS. We focused on three main clini-
cal outcomes (relapses, disability worsening, and acceptability of
treatment) that we considered meaningful to patients and clini-
cians. Patient-reported outcomes, such as behavioural functions
or quality of life, were not included. They are certainly important
outcomes for participants but are reported rarely in clinical trials,
often without adequate monitoring and availability of appropriate
published results. The different scales used and different assess-
ment time points do not allow comparisons to be made. More-
over, these measures may be susceptible to bias in trials in which
many, if not most, treated participants have become aware of the
treatment they are receiving owing to the well-documented side
effects of the treatments included in our review.
Although magnetic resonance imaging (MRI) measures are widely
used in trials of MS, we decided to include only clinical outcomes
in this review.
Quality of the evidence
We frequently downgraded the quality of the evidence for relapses
at 12 and 24 months from high quality due to study limitations
and then either due to inconsistency or imprecision, resulting in
moderate or low quality evidence for most of the comparisons.
We only judged three out of 39 included trials (8%) to be at low
risk of bias, when criteria for allocation concealment, blinding
of outcome assessors, and complete outcome data were met. The
frequency of downgrading the quality of the evidence regarding
benefit for preventing relapses at 12 and 24 months was 40%
and 57% of treatment estimates respectively for inconsistency, and
40% and 21% respectively for imprecision.
Reasons for downgrading the quality of the evidence regarding
benefit for preventing disability worsening were similar to those
reported for relapses. Moreover, the majority of the included tri-
als required only three months’ follow-up to confirm sustained
disability worsening. Although we had to accept the definition
given in the original papers, we considered the three months cri-
terion to be at high risk of bias because this definition meant that
participants who recovered slowly from relapses were regarded as
having unremitting disability worsening (Ebers 2008). Thus, for
disability worsening at 24 months the confidence in almost all the
treatment estimates varied from low to very low, except for natal-
izumab, which we evaluated as moderate quality.
Potential biases in the review process
1. Transitivity assumption
We assumed that any patient who met the inclusion criteria was,
in principle, equally likely to have been randomised to any of the
eligible interventions.However, as we discussed in the Background
section, several participant characteristics have changed in newer
trials, and thus a transitivity hypothesis may have not been a rea-
sonable assumption to make due to differences in patient or trial
characteristics. Thus, we evaluated the assumption of transitiv-
ity by assessing differences in patient characteristics such as age,
disease duration, and baseline Expanded Disability Status Scale
(EDSS) scores across the trials, and by comparing the pre-defined
potential effect modifiers across the different comparisons in the
networks. We did not find any evidence that important variables
varied across comparisons or altered the effectiveness of the treat-
ments; although some confounders may be hidden and unmea-
sured, it might be reasonable to analyse the network as a whole.
Thus, we assumed that the transitivity held and a network meta-
analytical approachwas reasonable.However, few studies per com-
parison were available and limitations in study reporting cannot
exclude the possibility of intransitivity.
2. Heterogeneity and inconsistency
Wedid not find any strong evidence of the presence of heterogene-
ity either in direct pairwise comparisons or in the entire networks.
Similarly, the loop-specific approach and the ’design-by-treatment’
model did not provide any clear indication of the presence of in-
consistency either locally or in the entire networks. Thus, we be-
lieve that the consistency assumption is reasonable for this type of
data. However, the power of these tests and approaches to detect
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inconsistency is low, particularly for networks with a small num-
ber of included studies per comparison. Accordingly, we decided
to downgrade the evidence for inconsistency on many occasions.
3. Subgroup and sensitivity analyses
None of the analyses performed on any of the hypothesised effect
modifiers, such as different diagnostic criteria, prevalence in the
included trials of participants who had received first- or second-
line treatments, and definitions of relapse and pre-trial relapse
rates, provided any significantly different results compared to the
overall analyses. This unexpected result was probably due to the
fact that, although there are differences in the characteristics of
participants included in older andnewer studies, the relative effects
of treatments are not affected by any of the effect modifiers we
hypothesised.
4. Reporting bias
The possible presence of reporting bias, partially supported by the
contour-enhanced funnel plot for relapses over 12 and 24 months,
could not be totally excluded.
Agreements and disagreements with other
studies or reviews
In this review, which included RCTs of 15 pharmacological treat-
ments for patients with RRMS, we found that patients receiving
natalizumab or alemtuzumab had significantly lower risk of expe-
riencing new relapses over 12 or 24 months compared to placebo,
based on high or moderate quality evidence respectively.Currently
there is insufficient evidence concerning the superiority of any in-
cluded treatment in preventing irreversible disability worsening
over 24months compared to placebo; such evidence is of low qual-
ity for all the included treatments, with the exception moderate
qualityevidence for natalizumab.
In our previous Cochrane review of RCTs, including only trials of
the nine drugs firstly approved for RRMS,we evaluated the quality
of evidence for benefit derived from pairwise comparisons because
theGRADE approachwas available only for traditionalmeta-anal-
ysis (Filippini 2013). In that reviewwe foundhigh quality evidence
that natalizumab and interferon beta-1a (Rebif ) were superior to
all other treatments for preventing new relapses in RRMS over 12
and 24 months compared to placebo. Moderate quality evidence
also supported a protective effect of natalizumab and interferon
beta-1a (Rebif ) against disability worsening in RRMS over 24
months compared to placebo. In this new review we were able to
assess the quality of the evidence using an adaptation of the stan-
dard GRADE approach to the results from network meta-analy-
sis, which is now available (Salanti 2014). By using this method
we could confirm the superiority of natalizumab for preventing
new relapses over 12 and 24 months (high quality evidence) and
for disability worsening over 24 months (moderate quality evi-
dence).We cannot confirm the previous results for interferon beta-
1a (Rebif ), which we now judge to be low or very low quality evi-
dence. Accordingly, for relapses over 12months interferon beta-1a
(Rebif ) has been compared in trials with placebo, interferon beta-
1a (Avonex), teriflunomide, and alemtuzumab. We have judged
the evidence for interferon beta-1a (Rebif ) versus placebo as low
quality due to limitations of the studies included in the loopswhere
interferon beta-1a (Rebif ) was involved. Heterogeneity was also
present within the loops. We found a similar scenario for relapses
and disability worsening over 24 months.
One network meta-analysis examined 48 RCTs (20,455 partici-
pants), published before 12 November 2012, of interferons beta,
glatiramer acetate, natalizumab, fingolimod, teriflunomide, and
mitoxantrone for patients with RRMS, secondary-progressive MS
(SPMS) with relapses and progressive-relapsing MS (PRMS) or
combinations of the previous types of MS (Hadjigeorgiou 2013).
The direct analysis showed that fingolimod was more beneficial
than interferon beta-1a (Avonex) (odds ratio (OR) 2.02, 95% con-
fidence interval (CI) 1.46 to 2.79) for preventing new relapses,
and interferon beta-1bwasmore beneficial than interferon beta-1a
(Avonex) (OR2.77, 95%CI 1.33 to 5.88) for preventing disability
worsening. The indirect analysis indicated that natalizumab may
have better relative benefit compared with the other treatments for
preventing new relapses. The authors reported that no data were
available for any comparisons regarding adverse events with those
treatments. Most of our findings cannot be compared to Hadjige-
orgiou’s networkmeta-analysis since this focused on different types
of participants and did not include all of the treatments that are
now available for RRMS, which we have included in our review.
Moreover, the authors did not assess the quality of the evidence
for the results arising from their network meta-analysis.
The network meta-analysis published by Zintzaras 2012 is a pre-
vious version of the article published by Hadjigeorgiou 2013. In
Zintzaras 2012, treatments without marketing authorisation have
been also included, resulting in 109 studies comparing different
therapies commonly used for MS, but also many agents that are
not currently in clinical use, such as bovine myelin, or that were
rejected by the US Food and Drug Administration (FDA) and
the European Medicines Agency (EMA) because they were found
to cause toxicity, such as cladribine. The meta-analysis considered
145 arms as different treatments (that is one for each dose of each
treatment) compared to interferon beta-1b (250 µg) (that is the
chosen reference treatment for analysis) and provided about 90
estimates based on eight direct comparisons with interferon beta-
1b. Thus, the remaining estimates were obtained through the use
of indirect analysis. The authors reported that their results needed
to be interpreted with caution because the network was dominated
by indirect comparisons, but they claimed that combination ther-
apies could be more promising than monotherapies. Important
facts invalidate this conclusion in our opinion. First, this claim
came only from indirect comparisons. Second, combined thera-
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pies were not superior to a single compared treatment or resulted
in a worst outcome. For example, methylprednisolone in combi-
nation with interferon beta-1a did not improve disability wors-
ening any more than interferon beta-1a alone (Ravnborg 2010),
or atorvastatin combined with interferon beta-1a resulted in in-
creasedMRI and clinical disease activity (Birnbaum 2008). Third,
some of the primary studies included in the indirect analysis were
small phase two trials (Birnbaum 2008; Goodman 2009; Weiner
1993), or used no validated clinical outcomes to assess treatment
effects (Khoury 2010). Fourth, combination therapies increased
the frequency of serious adverse events.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Some conservative interpretation of these results is warranted,
since most of the included treatments have been evaluated in few
trials. Nevertheless, we used a comprehensive, transparent, and
pragmatic system for rating the quality of the evidence (i.e. the
GRADE approach), so the results of this reviewmay provide guid-
ance to clinicians and patients. According to the GRADE ap-
proach, implications for practice should be based on moderate to
high quality evidence since any estimate of effect based on low to
very low quality evidence is very uncertain and further research
is likely to change the estimate. The results of this review show
that for preventing clinical relapses in the short term (24 months),
alemtuzumab, natalizumab, and fingolimod are superior to sev-
eral other treatments, on the basis of moderate to high quality
evidence. For preventing disability worsening in the short term
(24 months) natalizumab is superior to placebo on the basis of
moderate quality evidence only.
In addition to the available evidence for benefit provided above,
there are two major concerns that have to be considered. First, the
benefit of all of these treatments beyond two years is uncertain
and this is a relevant issue for a disease with a duration of 30 to 40
years. Second, short-term trials provide scanty and poorly reported
safety data and do not provide useful evidence to obtain a reliable
risk profile of treatments. In order to provide information on the
long-term safety of the treatments included in this review, it will
be necessary also to evaluate non-randomised studies.
Finally, more than 70% of the studies included in this review
were sponsored by pharmaceutical companies and this may have
influenced the results.
Implications for research
There are three needs that the research agenda should address.
First, randomised trials of direct comparisons between active
agents would be useful, avoiding further placebo-controlled stud-
ies that do not now comply with the principle of clinical equipoise
for relapsing-remitting multiple sclerosis (RRMS). Second, fol-
low-up of the original trial cohorts should be mandatory. Third,
more studies are needed to evaluate the medium and long-term
benefit and safety of immunotherapies and the comparative sa-
fety of the different agents. As the number of drugs, including
biologics, that are available for the treatment of RRMS increases,
more options will become available to participants and clinicians.
In the absence of comparative trials, national and international
registries and other types of large non-randomised studies might
be relevant sources for providing complementary data regarding
the long-term benefit and safety of immunotherapies for RRMS.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Achiron 1998
Methods RCT
Participants Age: 19 to 60 years; definite RRMS; mean disease duration 4 years; mean EDSS 3.0;
prior use of DMT not reported
Interventions Loading dose of immunoglobulins 0.4 g/kg body weight intravenously daily for 5 con-
secutive days followed by additional booster doses of immunoglobulins 0.4 g/kg body
weight intravenously daily every 2 months for 24 months (n = 20)
Placebo consisting of 0.9% saline administered with the same schedule as the active
treatment (n = 20)
Outcomes Relapse at 12 and 24 months. Disability worsening at 24 months
Notes Funding: Miles Inc. Cutter Biological, Bayer and Promedico
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were assigned to receive immunoglobulin or placebo by a
block-stratified randomisation procedure, designed to ensure groups
balanced for YER, age, and disease duration” (Page 399)
Allocation concealment (selection bias) Unclear risk “Randomization was performed at the pharmacy, and the bottles
of immunoglobulin or placebo were wrapped in sealed opaque bags
and brought to the patients’ rooms. The entire IV set was covered by
an opaque plastic bag to ensure that any possible fluid turbidity or
frothing would not be evident to the investigators or patients” (Page
399)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All patients and evaluators were blinded to treatment” (Page 399)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “A relapse was confirmed only when the patient’s symptoms were
accompanied by objective changes on neurologic examination by
the treating neurologist who was blind to the patient’s treatment”,
and “Upon entry, and monthly thereafter, every patient underwent
a neurologic examination by two examining neurologists, and an
independent EDSS score was recorded by each” (Page 399)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 5.0%were lost to follow-up (5.0% in immunoglobulins
and 5.0% in placebo), without indication of the differences in
reasons
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Achiron 1998 (Continued)
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - The study was sponsored by Triton Biosciences and the role of
the study sponsor was unclear
- The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both in
the number of patients who discontinued the study and in time
to discontinuation, which they did not report
- Relapse and disability worsening confirmed at 3 months out-
comeswere reported incompletely, anddisabilityworsening con-
firmed at 6 months was not assessed
ADVANCE 2014
Methods RCT
Participants Age: 18 to 65 years; definite RRMS; mean disease duration 7 years; mean EDSS 2.5;
prior use of any MS medication at any time prior to the start of study: 17%
Interventions Peg-interferon beta-1a 125 µg subcutaneously once every 2 weeks for 12 months (n =
512)
Peg-interferon beta-1a 125 µg subcutaneously once every 4 weeks for 12 months (n =
500)
Placebo subcutaneously once every 2 weeks for 12 months (n = 500)
Outcomes Relapse at 12 months
Notes Funding: Biogen Idec
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomly assigned (1:1:1) to receive subcutaneous
injections with pre-filled syringes of placebo, peginterferon beta-1a
at a dose of 125 µg once every 2 weeks, or peginterferon beta-1a
125 µg once every 4 weeks, stratified by site” (Page 658)
Allocation concealment (selection bias) Low risk “Randomisation was done by a centralised interactive voice response
and web system. Placebo was a matched diluent, given with a
matched pre-filled syringe. Patients received either study drug or
placebo every 2 weeks to maintain masking; those assigned to receive
study drug every 4 weeks received alternate injections of placebo and
peginterferon beta-1a every 2 weeks” (Page 658)
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ADVANCE 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All study management and site personnel, investigators, and pa-
tients were masked to treatment assignment” (Page 658)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Each site had separate examining and treating neurologists, thereby
maintaining rater masking for all treatment groups” and “relapse
was confirmed by the independent neurological evaluation commit-
tee” (Page 658)
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall, 11.9% were lost-to follow-up (14.5% in peg-interferon
beta-1a 125 µg every 2 weeks, 12.4% in peg-interferon beta-
1a 125 µg every 4 weeks, and 8.8% in placebo), with some
indication of the differences in reasons: adverse events of 4.8%
in peg-interferon beta-1a 125 µg every 2 weeks, 4.7% in peg-
interferon beta-1a 125 µg every 4 weeks, and 1.0% in placebo
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - The study was sponsored by Biogen Idec, “Biogen Idec collected,
analysed, and contributed to the interpretation of the data” (Page
659), and 5 co-authors of the published paper were affiliated to
the pharmaceutical company
- The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both in
the number of patients who discontinued the study and in time
to discontinuation, which they did not report
AFFIRM 2006
Methods RCT
Participants Age: 18 to 50 years; definite RRMS; median disease duration 5 years (range, 0 to 34
years); mean EDSS 2.3; prior use of DMT not reported
Interventions Natalizumab 300 mg by intravenous infusion once every 4 weeks for up to 116 weeks
(n = 627)
Placebo (unspecified) (n = 315)
Outcomes Relapse at 12 and 24 months. Disability worsening at 24 months
Notes Funding: Biogen Idec, Inc. and Elan Pharmaceutica
Risk of bias
Bias Authors’ judgement Support for judgement
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AFFIRM 2006 (Continued)
Random sequence generation (selection
bias)
Low risk “Patients were randomly assigned to treatment that was stratified
according to study site in blocks of three (two active, one placebo)
with the use of a computer-generated block randomization schedule”
(Page 900)
Allocation concealment (selection bias) Low risk “Amultidigit identification number, implemented by an interactive
voice-response system was used” (Page 900)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All study personnel, patients, sponsor personnel involved in the con-
duct of the study, and the investigator advisory committee were un-
aware of treatment assignments throughout the study”, and “Treat-
ing neurologists were responsible for all aspects of patient care, in-
cluding the management of adverse events and the treatment of re-
lapsing disease” (Pages 900-1)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Examining neurologists performed objective evaluation with use
of the EDSS and neurologic examination during all study visits;
they were not in contact with patients in any other capacity, so as to
reduce the possibility of being unblinded by side effects or laboratory
assessments”, “Patients visited the clinic every 12weeks for scoring on
the EDSS”, and “If a relapse was suspected, the patient was referred
to the examining neurologist, who evaluated the patient within five
days after the event” (Page 901)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 9.1% were lost-to follow-up (8.3% in natalizumab and
10.8% in placebo), without indication of the differences in rea-
sons
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - The study was sponsored by Biogen Idec and Elan Pharmaceu-
ticals, “Data were analyzed by Biogen Idec and Elan Pharmaceu-
ticals” (Page 909) and 4 co-authors of the published paper were
affiliated to the pharmaceutical company
- The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both
in the number of participants who discontinued the study and
in time to discontinuation, which they did not report
- Relapse and disability worsening confirmed at 3 months out-
comes were reported incompletely
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ALLEGRO 2012
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; mean disease duration 9 years; mean EDSS 2.6;
prior use of DMT at any time prior to the start of study: 39.0% (38.2% in laquinimod
and 39.7% in placebo)
Interventions Laquinimod 0.6 mg oral capsule once daily for 24 months (n = 550)
Placebo oral capsule once daily for 24 months (n = 556)
Outcomes Relapse at 24 months. Disability worsening at 24 months
Notes Funding: Teva Pharmaceutical Industries
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization list, stratified according to study center, was
computer-generated” (Page 1002)
Allocation concealment (selection bias) Low risk “The subject was allocated a screening number by the investigator
using an Interactive Voice Response System (IVRS)” (Page 44 of
Protocol)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Patients and investigators were unaware of the study assignments”
(Page 1002)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Neurologic assessments and general medical evaluations were con-
ducted by two neurologists in order to minimize the possibility of
unblinding: an examining neurologist assessed neurologic condition,
and the treating neurologist determined whether a patient had a
relapse”, and “the treating neurologist was unaware of the study-
group assignment” (Page 1002)
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall, 21.9% were lost-to follow-up (20.5% in laquinimod
and 23.2% in placebo), with some indication of the differences
in reasons: adverse event(s) in 7.6% in laquinimod and 5.0% in
placebo
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - “The sponsor designed and monitored the study” and “The data
were collected and analyzed by the sponsor” (Page 1001)
- The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both
in the number of participants who discontinued the study and
in time to discontinuation, which they did not report
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ALLEGRO 2012 (Continued)
- Relapse and disability worsening confirmed at 6 months out-
comes were reported incompletely, and no additional data were
provided on request
BECOME 2009
Methods RCT
Participants Age: 18 to 55; definite RRMS or CIS; median time since MS onset 1 year; mean EDSS
2.0; all participants (except 1) were previously untreated patients
Interventions Interferon beta-1b (Betaseron) 250 µg subcutaneously every other day for 24 months
(n = 36)
Glatiramer acetate 20 mg subcutaneous daily for 24 months (n = 39)
Outcomes Relapse at 12 and 24 months. Disability worsening at 24 months
Notes Funding: Bayer Schering Pharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was stratified by clinical site (Newark or Teaneck)
and the presence of enhancement on screening MRI” (Page 1977)
Allocation concealment (selection bias) Unclear risk Nothing was said about allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Patients could not be blinded because of the characteristic injection
reactions to IFN-1b or GA” (Page 1977)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Subjective relapses that were confirmed by a blinded examining
neurologist using worsening scores on either the Scripps Neurologi-
cal Rating Scale (SNRS) or the Expanded Disability Status Scale
(EDSS) were considered objective relapses” (Page 1977). However,
it is not clear how and when the examining neurologist evalu-
ated subjective relapses and EDSS scores
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 14.7% were lost-to follow-up (19.4% in interferon
beta-1b and 10.3% in glatiramer acetate), without indication of
the differences in reasons
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
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BECOME 2009 (Continued)
Other bias High risk - “The BECOME study was supported by Bayer Schering Pharma,
distributors of IFN-1b, but was investigator-initiated and remains
the intellectual property of New Jersey Medical School/University of
Medicine & Dentistry of New Jersey. The sponsor of the study was
allowed to comment on data interpretation and had the opportunity
to review and comment on the final manuscript prior to submission.
The sponsor was not allowed to participate in any of the following
phases of the study: conduct of the study, data collection, data man-
agement, data analysis, and preparation of the manuscript” (Page
1981)
- Relapse outcome was reported incompletely, and no additional
data were provided on request
BEYOND 2009
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; mean disease duration 5 years; mean EDSS 2.3;
prior use of DMT not reported
Interventions Interferon beta-1b (Betaseron) 250 µg subcutaneous every other day for 24 months (n
= 897)
Interferon beta-1b (Betaseron) 500 µg subcutaneous every other day for 24 months (n
= 899)
Glatiramer acetate 20 mg subcutaneous daily for 24 months (n = 448)
Outcomes Relapse at 24 months. Disability worsening at 24 months
Notes Funding: Bayer HealthCare Pharmaceuticals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Use of SAS-based block randomisation with regional stratification”
(Page 890)
Allocation concealment (selection bias) Unclear risk “Patients were randomly assigned in a 2:2:1 ratio ... by the central
randomisation group...” (Page 890)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Physicians and patients were double-blind to comparisons between
the two doses of IFNß-1b... Ibuprofen or acetaminophen were given
at the same time as random assignment to IFNß-1b, at least during
the rst 3months, to reduce u-like symptoms. The treating physicians
and the patients were therefore aware of treatment assignments”
(Page 891)
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BEYOND 2009 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The masked evaluating physicians did all neurological assessments
and ascertained functional system and EDSS scores...The evaluating
physicians were not involved in the care of patients and had no access
to patient les or previous assessments”, and “Patients covered their
injection sites during neurological examination and did not discuss
any adverse events with the evaluating physician” (Pages 891-2)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 16.0% were lost-to follow-up (19.2% in interferon
beta-1b 500 µg, 12.6% in interferon beta-1b 250 µg, and 16.
5% in glatiramer acetate), without indication of the differences
in reasons
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk Relapse and disability worsening outcomes were reported in-
completely
Bornstein 1987
Methods RCT
Participants Age: 20 to 35 years; definite RRMS; mean disease duration 6 years; mean EDSS 3.1;
prior use of DMT not reported
Interventions Glatiramer acetate 20 mg subcutaneous daily for 24 months (n = 25)
Placebo bacteriostatic saline subcutaneous daily for 24 months (n = 25)
Outcomes Relapse at 12 and 24 months. Disability worsening at 24 months
Notes Funding: grants from the NINCDS and the NIH, Bethesda, Md
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The random assignment of the first patient of a pair determined
the assignment of both” (Page 409)
Allocation concealment (selection bias) High risk An open allocation schedule was used: “Treatment assignments
were made known to the clinical assistant responsible for the pro-
duction, labelling and distribution of medication” (Page 409)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “The patient’s self evaluation of ... side effects were reported to the
clinical assistant, who was not blinded to the treatment” (Page 409)
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Bornstein 1987 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Patients visited the clinic every three months for two years. At
each visit, a neurologist unaware of the patient’s treatment group
completed a neurologic examination and status evaluation” and
“Patients were also seen at the time of suspected exacerbations ...
the neurologist verified exacerbations on the basis of study criteria”
(Page 409)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 4.0% were lost-to follow-up (0% in glatiramer acetate
and 8.0% in placebo), without indication of the differences in
reasons
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias Low risk The study appears to be free of other sources of bias
BRAVO 2014
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; median disease duration 5 years; median EDSS 2.
5; prior use of DMT at any time prior to the start of study: 7.4% (6.9% in laquinimod,
9.4% in interferon beta-1a and 6.0% in placebo)
Interventions Laquinimod 0.6 mg oral capsule once daily for 24 months (n = 434)
Interferon beta-1a (Avonex) 30 µg intramuscular once a week for 24 months (n = 447)
Placebo oral capsule once daily for 24 months (n = 450)
Outcomes Relapse at 24 months. Disability worsening at 24 months
Notes Funding: Teva Pharmaceutical Industries
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The computer-generated randomization scheme prepared by the
Teva Global Biostatistics Unit” (Page 775)
Allocation concealment (selection bias) Unclear risk “1:1:1 treatment assignment ratio stratified by study center, to
laquinimod 0.6 mg capsule once-daily, matching oral placebo, or
IFNß-1a IM 30 µg once-weekly injection” (Page 775)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Patients and treating neurologists were blinded to oral treatment
assignment (laquinimod or placebo), but not to IFNb-1a IM assign-
ment”, and “All patients, including those receiving oral treatment,
wore clothing and/or a robe that ensured coverage of all potential
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BRAVO 2014 (Continued)
IM injection sites during examination and were instructed not to
discuss adverse events (AEs), routes of administration, or treatment
assignments with the examining neurologist” (Page 775)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The examining neurologist was blinded to all treatments”, and
“The examining neurologist performed an EDSS assessment for re-
lapse confirmation within 7 days of symptom onset” (Page 775)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 18.1% were lost-to follow-up (18.7% in laquinimod,
15.4% in interferon beta-1a, and 20.2% in placebo), without
indication of the differences in reasons
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - “N. Sasson of Teva Pharmaceutical Industries provided statistical
support for the manuscript” (Page 773), and 2 co-authors of the
published paper were affiliated to the pharmaceutical company
- The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both
in the number of participants who discontinued the study and
in time to discontinuation, which they did not report
CAMMS223 2008
Methods RCT
Participants Age: 18 to 50; definite RRMS; median time since first relapse 1 year; mean EDSS 1.9;
all participants were previously untreated patients
Interventions Alemtuzumab 24 mg per day intravenously on 5 consecutive days during the first month
and on 3 consecutive days at months 12 and 24 (n = 110)
Alemtuzumab 12 mg per day intravenously on 5 consecutive days during the first month
and on 3 consecutive days at months 12 and 24 (n = 113)
Interferon beta-1a (Rebif ) 44 µg subcutaneous 3 times a week for 36 months (n = 111)
All participants received 1 g of intravenous methylprednisolone for 3 days at baseline
and at months 12 and 24
Outcomes Relapse at 12, 24, and 36 months. Disability worsening at 24 and 36 months
Notes Funding: Genzyme (a Sanofi company) and Bayer Schering Pharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Eligible patients were randomly assigned in a 1:1:1 ratio to receive
alemtuzumab (at a dose of either 12 mg per day or 24 mg per
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CAMMS223 2008 (Continued)
day) or interferon beta-1a with the use of the Pocock and Simon
minimization algorithm to balance the study groups with regard to
age (<30 years or ≥30 years), sex, and baseline EDSS score (<2.0
or ≥2.0)” (Page 1787)
Allocation concealment (selection bias) Low risk “Patients were allocated via an interactive voice response system
(IVRS)” (Information provided on request by Genzyme)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Patients wore clothing that covered injection sites”, and “Safety
was assessed quarterly by the treating neurologist, who was aware of
study-group assignment” (Page 1787)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “EDSS scores were determined quarterly in a blinded fashion by
a neurologist who also adjudicated possible relapses. Patients wore
clothing that covered injection sites” (Page 1787). It is not clear
how potential relapses were assessed
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall, 25.1% were lost to follow-up (16.4% in alemtuzumab
24 mg, 18.6% in alemtuzumab 12 mg, and 40.5% in interferon
beta-1a), with some indication of the differences in reasons: ad-
verse events of 0.01% in alemtuzumab 24 mg, 1.8% in alem-
tuzumab 12 mg, and 11.7% in interferon beta-1a; and lack of
benefit of 1.8% in alemtuzumab 24 mg, 1.8% in alemtuzumab
12 mg, and 14.4% in interferon beta-1a
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes.Missingdata not reported in the publishedpaperwere
provided on request by Genzyme
Other bias High risk “Genzyme employees analyzed the data” (Page 1789), and 5 co-
authors of the published paper were affiliated to the pharmaceu-
tical company
CARE-MS I 2012
Methods RCT
Participants Age: 18 to 50 years; definite RRMS; mean disease duration 2 years; mean EDSS 2.0; all
participants were previously untreated patients
Interventions Alemtuzumab 12 mg per day intravenously on 5 consecutive days at month 0 and 3
consecutive days at month 12 (n = 386)
Interferon beta-1a (Rebif ) 44 µg subcutaneous 3 times a week for 24 months (n = 195)
Participants in both groups received 1 g per day of intravenous methylprednisolone
on 3 consecutive days at baseline and at month 12. After a protocol amendment in
January 2009, alemtuzumab patients received oral aciclovir 200 mg twice daily during
alemtuzumab infusion and for 28 days thereafter as prophylaxis against herpes infection
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CARE-MS I 2012 (Continued)
Outcomes Relapse at 12 and 24 months. Disability worsening at 24 months
Notes Funding: Genzyme (a Sanofi company)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “We randomly allocated patients in a 2:1 ratio” and “Randomisa-
tion was stratified by site” (Page 1820)
Allocation concealment (selection bias) Low risk “We randomly allocated patients using an interactive voice response
system” (Page 1820)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Because both study drugs have adverse effects that precluded mask-
ing of patients and treating clinicians to treatment assignment, and
because subcutaneous interferon beta 1a was available only in pro-
prietary prefilled syringes that could not effectively be duplicated for
placebo...” (Page 1820)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “We secured clinical data integrity by stringent clinical and MRI
rater masking, and adjudication of relapses by a committee com-
prising six independent and masked neurologists. In the absence of
a masked rater, unmasked raters could submit EDSS assessments”
(Page 1820). Moreover, it is not clear how and when the com-
mittee evaluated potential relapses
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall, 7.1% were lost to follow-up (4.9% in alemtuzumab
12 mg and 11.3% in interferon beta-1a), with some indication
of the differences in reasons: adverse events of 2.6% in alem-
tuzumab and 0% in interferon beta-1a
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk “The study sponsor (Genzyme) was involved in the design and un-
dertaking of the trial, data analysis and interpretation, writing of
themanuscript, and the decision to submit themanuscript for publi-
cation. Bayer Schering Pharma participated in the design and over-
sight of the trial”, “The sponsor did the statistical analyses” (Page
1822), and 4 co-authors of the published paper were affiliated
to the pharmaceutical company
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CARE-MS II 2012
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; mean disease duration 5 years; mean EDSS 2.7; all
patients were previously treated: “at least one relapse while on interferon beta or glatiramer
after at least 6 months of treatment”
Interventions Alemtuzumab 24 mg per day intravenously on 5 consecutive days at month 0 and 3
consecutive days at month 12 (n = 170; data presented for safety assessment only)
Alemtuzumab 12 mg per day intravenously on 5 consecutive days at month 0 and 3
consecutive days at month 12 (n = 436)
Interferon beta-1a (Rebif ) 44 µg subcutaneous 3 times a week for 24 months (n = 231)
Participants in both groups received 1 g per day of intravenous methylprednisolone
on 3 consecutive days at baseline and at month 12. After a protocol amendment in
December 2008, alemtuzumab patients received oral aciclovir 200 mg twice daily during
alemtuzumab infusion and for 28 days thereafter as prophylaxis against herpes infection
Outcomes Relapse at 12 and 24 months. Disability worsening at 24 months
Notes Funding: Genzyme (a Sanofi company)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “2:1 randomisation allocation stratified by site” (Pages 1830-1)
Allocation concealment (selection bias) Low risk “We randomly allocated patients with an interactive voice response
system” (Page 1830)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Because both study drugs had adverse effects that precluded dou-
ble-blinding, and interferon beta 1a proprietary syringes could not
effectively be duplicated for placebo...” (Page 1831)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Clinical data integrity was secured by stringent rater-masking and
independent adjudication of relapses. Raters, who were masked
to treatment-group assignment, did the EDSS assessments every 3
months and when a relapse was suspected” and “In the absence of
a masked rater, unmasked raters could submit EDSS assessments”
(Page 1831). Moreover, it is not clear how and when the raters
evaluated potential relapses
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall, 11.4%were lost to follow-up (4.6% in alemtuzumab 12
mg and 24.2% in interferon beta-1a), with some indication of
the differences in reasons: lack of benefit of 0% in alemtuzumab
12 mg and 2.6% in interferon beta-1a
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
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CARE-MS II 2012 (Continued)
Other bias High risk - “Genzyme (Sanofi) was involved in the design and undertak-
ing of the trial, data analysis and interpretation, writing of the
manuscript, and the decision to submit the manuscript for publica-
tion” (Page 1833), and 4 co-authors of the published paper were
affiliated to the pharmaceutical company
- Sample size reported in the article was not that estimated in
the protocol but calculated after an amendment in December
2008
CombiRx 2013
Methods RCT
Participants Age: 18 to 60 years; definite RRMS; mean disease duration 1 year; mean EDSS 2.0; all
participants were previously untreated patients
Interventions Interferon beta-1a (Avonex) 30 µg intramuscular once a week with matched placebo
preparation for 36 months (n = 250)
Glatiramer acetate 20 mg subcutaneous daily with matched placebo preparation for 36
months (n = 259)
Outcomes Relapse at 36 months. Disability worsening at 36 months
Notes Funding: National Institutes of Health (NIH)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participants were randomized via a computerized data entry system
using a permuted block design within sites with block sizes of 6 and
12” (Page 328)
Allocation concealment (selection bias) Low risk “Participants were randomized via a computerized data entry system
that masked treatment arm allocation” (Page 328)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Participants were randomized via a computerized data entry system
that masked drug dispensing to participants and all site personnel
for the entire duration of the trial period” (Page 328)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Treating clinician and an examining clinician were both blinded
to treatment assignment”, “confirmed progression was assessed by
the blinded EDSS examiner and confirmed centrally”, and “The
designation of the type of relapse was determined centrally according
to data entered onto a relapse assessment form and the change in
EDSS” (Page 328-329). The blinding of central commission was
not reported
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CombiRx 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall, 18.1%were lost to follow-up (22.4% in interferon beta-
1a and 13.9% in glatiramer acetate; P value for proportion ter-
minating early = 0.029), with some indication of the differences
in reasons: adverse event(s) of 7.2% in interferon beta-1a and 4.
6% in glatiramer acetate
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both in
the number of patients who discontinued the study and in time
to discontinuation, which they did not report
- Relapse and disability worsening confirmed at 6 months out-
comes were reported incompletely, and no additional data were
provided on request
Comi 2001
Methods RCT
Participants Age 18 to 50 years; definite RRMS; mean disease duration 8 years; mean EDSS 2.4;
prior use of DMT not reported
Interventions Glatiramer acetate 20 mg subcutaneous daily for 9 months (n = 119)
Placebo (not described) (n = 120)
Outcomes Relapse at 9 months
Notes Funding: Teva Pharmaceutical
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization list, stratified by centers, was computer-gen-
erated by the TEVA Statistical Data Management Department.
Equal allocation of the two treatment groups was used” (Page 291)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “A treating neurologist was responsible for the overall medical man-
agement of the patient including safety monitoring ... All personnel
were unaware of treatment allocation... both the treating neurologist
and the patient were informed on the importance of not discussing
safety issue with the examining neurologist” (Page 291)
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Comi 2001 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “An examining neurologist was responsible for all scheduled neuro-
logical examinations and exacerbation follow-up” (Page 291)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 5.9% were lost to follow-up (5.9% in glatiramer acetate
and 5.8% in placebo), without indication of the differences in
reasons
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - The study was sponsored by Teva Pharmaceutical, and “Drs
Stark, Gurevich, Kadosh, Zak, Pinchassi, and Ladkani are employ-
ees of Teva Pharmaceutical, Ltd., involved in trial design and ex-
ecution, study management, database management, and statistical
analysis” (Page 296)
- Relapse outcome was reported incompletely
CONFIRM 2012
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; mean disease duration (time since diagnosis) 5
years; mean EDSS 2.6; prior use of any MS medication at any time prior to the start of
study: 40% to 41% across study groups
Interventions Dimethyl fumarate 240 mg oral capsule 3 times daily for 24 months (n = 345)
Dimethyl fumarate 240 mg oral capsule 2 times daily for 24 months (n = 362)
Glatiramer acetate 20 mg subcutaneous daily for 24 months (n = 350)
Placebo oral capsule 3 times daily for 24 months (n = 363)
Outcomes Relapse at 12 and 24 months. Disability worsening at 24 months
Notes Funding: Biogen Idec
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomly assigned in a 1:1:1:1 ratio to receive oral
placebo, BG-12 at a dose of 240 mg two times daily, BG-12 at a
dose of 240 mg three times daily, or subcutaneous daily injections of
20 mg of glatiramer acetate for 96 weeks” (Page 1088); and “The
randomization was stratified by site” (Page 33 of Protocol)
Allocation concealment (selection bias) Low risk “Randomization took place across all study sites using a centralized
Interactive Voice Response System (IVRS)” (Page 33 of Protocol)
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CONFIRM 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Patients receiving glatiramer acetate were aware of their treatment
assignment. All study management and site personnel, investigators,
and patients were unaware of assignment to the BG-12 and placebo
groups”, and “To ensure that the assignments to the BG-12 and
placebo groups would not be revealed, patients in those groups were
instructed not to take the study medication within 4 hours before
each study visit, since a flushing reaction is known to be more com-
mon with BG-12” (Page 1088). Since flushing is a known side
effect of dimethyl fumarate, patients were possibly not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “An independent neurologic evaluation committee, whose members
were unaware of the study-group assignments, provided confirma-
tion of relapses of multiple sclerosis” and “examining neurologists
and members of the independent neurologic evaluation committee
were unaware of all study-group assignments” (Page 1088)
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall, 20.3% were lost to follow-up (20.8% in dimethyl fu-
marate 240 mg 3 times daily, 20.7% in dimethyl fumarate 240
mg 2 times daily, 16.1% in glatiramer acetate, and 23.4% in
placebo), with some indication of the differences in reasons: ad-
verse events of 8.1% in dimethyl fumarate 240 mg 3 times daily,
6.1% in dimethyl fumarate 240 mg 2 times daily, 3.6% in glati-
ramer acetate, and 3.3% in placebo
Selective reporting (reporting bias) High risk The published report included all pre-specified primary benefit
outcomes. However, disability confirmed at 6 months was not
reported in the published report, it was reported by the FDA in
terms of survival probabilities
Other bias High risk - The study was sponsored by Biogen Idec, “data were analyzed
by the sponsor” (Page 1088), and 6 co-authors of the published
paper were affiliated to the pharmaceutical company
- The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both
in the number of participants who discontinued the study and
in time to discontinuation, which they did not report
DEFINE 2012
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; mean disease duration (time since diagnosis) 6
years; mean EDSS 2.4; prior use of DMT at any time prior to the start of study: 40.7%
(40.4% in dimethyl fumarate 240 mg 3 times daily, 39.5% in dimethyl fumarate 240
mg 2 times daily, and 42.2% in placebo)
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DEFINE 2012 (Continued)
Interventions Dimethyl fumarate 240 mg oral capsule 3 times daily for 24 months (n = 416)
Dimethyl fumarate 240 mg oral capsule 2 times daily for 24 months (n = 411)
Placebo oral capsule 3 times daily for 24 months (n = 410)
Outcomes Relapse at 12 and 24 months. Disability worsening at 24 months
Notes Funding: Biogen Idec
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomly assigned, in a 1:1:1 ratio, to receive BG-
12 at a dose of 240 mg twice daily, BG-12 at a dose of 240 mg three
times daily, or placebo. Randomization was performed centrally and
was stratified according to site” (Page 1100)
Allocation concealment (selection bias) Low risk “Randomization was performed centrally” (Page 1100), and “Ran-
domization took place across all study sites using a centralized In-
teractive Voice Response System (IVRS)” (Page 33 of Protocol)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind”, and “To ensure that the study-group assignments
would not be revealed, patients were instructed to take the assigned
study drug at least 4 hours before study visits, in case patients in
the BG-12 groups had a side effect of flushing” (Page 1100). Since
flushing is a known side effect of dimethyl fumarate, patients
were possibly not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “To maintain concealment of the study-group assignments, each
study center used separate examining and treating neurologists (all
of whom remained unaware of the assignments throughout the trial)
. The examining neurologists conducted neurologic assessments, in-
cluding assessment of the EDSS score, whereas the treating neu-
rologists were responsible for all aspects of patient care, including
the treatment of relapses and other disease symptoms” and “relapses
were evaluated by an independent neurologic evaluation commit-
tee, whose members reviewed a standardized set of blinded clinical
records (which did not include MRI data) from the treating and
examining neurologists” (Page 1100)
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall, 23.0% were lost to follow-up (23.1% in dimethyl fu-
marate 240 mg 3 times daily, 23.4% in dimethyl fumarate 240
mg 2 times daily, and 22.7% in placebo), with some indication
of the differences in reasons: adverse events of 8.7% in dimethyl
fumarate 240 mg 3 times daily, 9.8% in dimethyl fumarate 240
mg 2 times daily, and 5.4% in placebo
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DEFINE 2012 (Continued)
Selective reporting (reporting bias) High risk The published report included all pre-specified primary benefit
outcomes. However, disability confirmed at 6 months was not
reported in the published report, it was reported by the FDA in
terms of survival probabilities
Other bias High risk The study was sponsored by Biogen Idec, “data were analyzed
by the sponsor” (Page 1099), and 4 co-authors of the published
paper were affiliated to the pharmaceutical company
Etemadifar 2007
Methods RCT
Participants Age: 13 to 50 years; definiteRRMS;meandisease duration not reported (“short duration”)
; mean EDSS 1.5; all participants were previously untreated patients
Interventions Azathioprine 3 mg/kg body weight oral daily for 12 months (n = 47)
Interferons beta (Betaseron, Avonex, or Rebif ) for 12 months (n = 47: 15 Betaseron 250
µg subcutaneously every other day, 19 Avonex 30 µg intramuscular once a week, 13
Rebif 44 µg subcutaneous 3 times a week)
Outcomes Relapse at 12 months
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized according to a preexisting list produced
by a computer program that differed from a random number gen-
erator only in that it assigned equal numbers of patients into each
treatment group” (Page 1724)
Allocation concealment (selection bias) Unclear risk “The first treatment group received IFNβ products regimen. The
second group received AZA” (Page 1724)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “The trial was single blinded in that patients were aware but physi-
cians who assessed the outcome were unaware of treatment type that
the patient was receiving” (Page 1724)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The trial was single blinded in that patients were aware but physi-
cians who assessed the outcome were unaware of treatment type that
the patient was receiving”, and “Two neurologists (ME and VS)
who do not know which patients had received which treatment clin-
ically evaluated all patients” (Page 1724-5)
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Etemadifar 2007 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 6.4% were lost to follow-up (6.4% in azathioprine and
6.4% in interferon beta), without indication of the differences
in reasons
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias Low risk The study appears to be free of other sources of bias
EVIDENCE 2007
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; mean disease duration 7 years; mean EDSS 2.3;
prior use of DMT not reported
Interventions Interferon beta-1a (Rebif ) 44 µg subcutaneous 3 times a week for 12 months (n = 339)
Interferon beta-1a (Avonex) 30 µg intramuscular once a week for 12 months (n = 338)
Outcomes Relapse at 12 months
Notes Funding: Serono Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated scheme with block size of 6 followed by block
size of 4” (Page 2033)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Patients and a treating physician who was not involved in end
point assessment were aware of treatment assignments” (Page 2033)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Evaluating physicians who were blinded to the patients’ treatment
and symptoms performed all clinical exams” (Page 2033)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 10.6% were lost to follow-up (11.8% in Rebif and 9.
5% in Avonex), without indication of the differences in reasons
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
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EVIDENCE 2007 (Continued)
Other bias High risk - The study was sponsored by Serono Inc., “The sponsor designed
and implemented the study and managed the data” (Page 2047)
- Relapse outcome was reported incompletely
Fazekas 1997
Methods RCT
Participants Age: 15 to 64 years; definite RRMS; mean disease duration 7 years; mean EDSS 3.3;
prior use of DMT not reported
Interventions Immunoglobulins 0.15 to 0.20 g/kg body weight intravenously monthly for 24 months
(n = 75)
Placebo intravenously monthly for 24 months (n = 75)
Outcomes Relapse at 24 months. Disability worsening at 24 months
Notes Funding: Sero-Merieux (Vienna, Austria)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Centralised computer-generated randomisation schedule with
stratification by centre, age, sex, and deterioration rate” (Page 590)
Allocation concealment (selection bias) Low risk “Randomly and centrally allocated” and “Infusions of IVIg and
placebo were identical in appearance and were stored in plastic bags
for concealment during administration” (Page 590)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “At each monthly visit a neurologist who was aware of treatment
allocation (treating physician) administered the study medication
and asked the patient about any side-effects” (Page 590)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Patients were assessed on the first day of treatment, every 6 months,
and at the end of the 2-year study by a different neurologist (as-
sessing physician) who was unaware of treatment allocation”, and
“All patients were told to contact their centre as soon as there was
any change in their condition. In such cases, the assessing physician
examined the patient to confirm a possible relapse and to assess the
severity of the disability” (Page 590)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 1.3% were lost to follow-up (0% in immunoglobulins
and 2.7% in placebo), without indication of the differences in
reasons
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Fazekas 1997 (Continued)
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias Unclear risk - The study was sponsored by Triton Biosciences and the role of
the study sponsor was unclear
- Definition of sustained disability worsening was not clearly
reported
Fazekas 2008
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; mean disease duration 3 years; mean EDSS 2.0;
prior use of DMT not reported
Interventions Immunoglobulins 0.2 g/kg body weight intravenously monthly for 12 months (n = 45)
Immunoglobulins 0.4 g/kg body weight intravenously monthly for 12 months (n = 42)
Placebo intravenously monthly for 12 months (n = 41)
Outcomes Relapse at 12 months
Notes Funding: Bayer HealthCare AG
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The random code number was computer generated by the Statistics
and Data System Department of Bayer” (Page 266)
Allocation concealment (selection bias) Unclear risk “Randomisation performed by an unblinded pharmacist who as-
signed code numbers from sealed envelopes in a sequential manner”
(Page 266)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Considerable effort was made to achieve optimal blinding, includ-
ing the provision that all patients received a total volume of 4 mL/
kg body weight per infusion, which was adjusted by the addition of
dextrose 5%” (Page 266)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Endpoints “assessed by an evaluating physician who was otherwise
not involved in patient care” (Page 266)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 12.5% were lost to follow-up (9.5% in immunoglob-
ulins 0.4 g/kg, 17.8% in immunoglobulins 0.2 g/kg, and 9.8%
in placebo), without indication of the differences in reasons
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Fazekas 2008 (Continued)
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - The study was sponsored by Bayer HealthCare AG and the role
of the study sponsor was unclear. 3 co-authors of the published
paper were affiliated to the pharmaceutical company
- Relapse outcome was reported incompletely
FREEDOMS 2010
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; mean disease duration 8 years; mean EDSS 2.4;
prior use of DMT at any time prior to the start of study: 40.9% (39.6% in fingolimod
1.25 mg, 42.6% in fingolimod 0.5 mg, and 40.4% in placebo)
Interventions Fingolimod 1.25 mg oral capsule once daily for 24 months (n = 429)
Fingolimod 0.5 mg oral capsule once daily for 24 months (n = 425)
Placebo oral capsule once daily for 24 months (n = 418)
Outcomes Relapse at 12 and 24 months. Disability worsening at 24 months
Notes Funding: Novartis Pharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomly assigned, in a 1:1:1 ratio, to receive oral
fingolimod capsules in a dose of 0.5 mg or 1.25 mg or matching
placebo ... Randomization was performed ... with the use of strati-
fication according to site, with a block size of six within each site”
(Page 388)
Allocation concealment (selection bias) Unclear risk “Randomizationwas performed centrally, with the use of a validated
system ” (Page 388)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double blind” (Page 388)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “To ensure that all assessments remained unbiased regarding the
study-group assignments (i.e., unaffected by awareness of them), an
independent, specially trained and certified examining neurologist
determined all the EDSS scores” (Page 388). “Relapses were veri-
fied by the examining neurologist within 7 days after the onset of
symptoms” (Page 389)
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FREEDOMS 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall, 18.8% were lost to follow-up (22.6% in fingolimod 1.
25 mg, 13.2% in fingolimod 0.5 mg, and 20.6% in placebo)
, with some indication of the differences in reasons: unsatisfac-
tory therapeutic effect 3.0% in fingolimod 1.25 mg, 1.4% in
fingolimod 0.5 mg, and 6.0% in placebo; and abnormal labora-
tory values(s) 4.7% in fingolimod 1.25 mg, 2.1% in fingolimod
0.5 mg, and 0.2% in placebo
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - The study was sponsored by Novartis Pharma, “data were an-
alyzed by the sponsor” (Page 388), and 4 co-authors of the pub-
lished paper were affiliated to the pharmaceutical company
- The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both
in the number of participants who discontinued the study and
in time to discontinuation, which they did not report
FREEDOMS II 2014
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; mean disease duration 11 years; mean EDSS 2.4;
prior use of DMT at any time prior to the start of study: 74.8% (77.6% in fingolimod
1.25 mg, 73.7% in fingolimod 0.5 mg, and 73.0% in placebo)
Interventions Fingolimod 1.25 mg oral capsule once daily for 24 months (n = 370)
Fingolimod 0.5 mg oral capsule once daily for 24 months (n = 358)
Placebo oral capsule once daily for 24 months (n = 355)
“After review of data from the FREEDOMS and TRANSFORMS phase 3 studies, completed
on Nov 12, 2009, after consultation with and at the recommendation of the data and safety
monitoring board, we decided to stop the 1·25 mg dose. Patients on the high dose were
subsequently switched to the 0·5 mg dose in a blinded manner” (Page 546)
Outcomes Relapse at 12 and 24 months. Disability worsening at 24 months
Notes Funding: Novartis Pharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “We randomly allocated patients (1:1:1; stratified by study centre)
to receive oral fingolimod capsules in a dose of 0.5 mg or 1.25 mg
or matching placebo, once daily for 24 months. The randomisation
sequence was generated with an automated system under the super-
vision of the Novartis Drug Supply Management team” (Page 546)
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FREEDOMS II 2014 (Continued)
Allocation concealment (selection bias) Unclear risk “To mask treatment allocation, both fingolimod and placebo were
dispensed in hard gelatin capsules of identical colour and size and
packed in identical bottles” (Page 546)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Patients, investigators, site personnel, independent evaluating
physician, first dose administrator and all Novartis personnel were
blinded to the study medication assignments from the time of ran-
domisation until the database lock and data analysis for the double-
blind Treatment Phase was completed” (Appendix, Page 2)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The efficacy assessments (ie, confirmation of relapses, scheduled
EDSS, ...) were done by an independent, specially trained, and
certified assessor not otherwise involved in the treatment of patients)
” (Page 546), “Patients were instructed not to discuss adverse events
with the independent evaluating physician”, “Another physician not
otherwise involved in the care of the study patientmonitored patients
for 6 or more hours after administration of the first dose of the
study drug to maintain blind for the known heart rate decrease with
fingolimod upon first dose administration”, “Clinical assessments
were performed at screening and at randomization (baseline), and
study visits were scheduled at 2 weeks and 1, 2, 3, 6, 9, 12, 15, 18,
21, and 24 months after randomization”, and “In the case of MS
relapse EDSS assessment was required at every unscheduled visit to
confirm relapse” (Appendix, Page 2)
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall, 28.2% were lost to follow-up (32.2% in fingolimod 1.
25 mg, 24.0% in fingolimod 0.5 mg, and 28.2% in placebo)
, with some indication of the differences in reasons: unsatisfac-
tory therapeutic effect 2.7% in fingolimod 1.25 mg, 1.7% in
fingolimod 0.5 mg, and 4.8% in placebo; and adverse events or
abnormal laboratory values(s) 12.7% in fingolimod 1.25 mg,
10.1% in fingolimod 0.5 mg, and 5.1% in placebo
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - The study was sponsored by Novartis Pharma, “The study spon-
sor participated in the design of the study, conduct of the study, data
collection, data management, data analysis and interpretation, and
preparation, review, and approval of the paper” (Page 550), and 4
co-authors of the published paper were affiliated to the pharma-
ceutical company
- The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both
in the number of participants who discontinued the study and
in time to discontinuation, which they did not report
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GALA 2013
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; mean disease duration 8 years; mean EDSS 2.8;
prior use of DMT at any time prior to the start of study: 13.6% (13.6% in glatiramer
acetate and 13.7% in placebo)
Interventions Glatiramer acetate 40 mg subcutaneous 3 times a week for 12 months (n = 943)
Placebo subcutaneous 3 times a week for 12 months (n = 461)
Outcomes Relapse at 12 months
Notes Funding: Teva Pharmaceutical Industries
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Eligible patients were assigned to treatment groups in a 2:1 ratio
(GA 40mg tiw or placebo) according to the randomization scheme
produced. The randomization scheme used constrained blocks strat-
ified by center” (Page 706)
Allocation concealment (selection bias) Unclear risk “Study drugs were packaged and labeled in a way that maintained
the masked nature of the study; the appearance, shape, color, and
smell were identical” (Page 706)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The investigators, the sponsor, and any personnel involved in pa-
tients’ assessments, monitoring, analysis, and datamanagement were
blinded to treatment assignment” (Page 706)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Patients’ general medical assessments were performed separately
from the neurological assessments by 2 neurologists or physicians.
The examining neurologist/physician was responsible for all neuro-
logical assessments” and “All follow-up neurological examinations
were performed by the blinded examining neurologist” (Page 706-
7)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 8.2% were lost to follow-up (8.9% in glatiramer acetate
and 6.7% in placebo), without indication of the differences in
reasons
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - “This study was funded by Teva Pharmaceutical Industries, Petah
Tikva, Israel. All members of the clinical advisory board, the country
principal investigators, the Data Monitoring Committee (DMC)
, and the MRI Reading Center were reimbursed for their specific
services on a contractual basis by Teva Pharmaceutical Industries”
89Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
GALA 2013 (Continued)
(Page 711)
- The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both
in the number of participants who discontinued the study and
in time to discontinuation, which they did not report
- Relapse outcome was reported incompletely, and no additional
data were provided on request
Goodkin 1991
Methods RCT
Participants Age: 18 to 65 years; definite RRMS; mean disease duration 6 years; mean EDSS 3.5;
prior use of DMT not reported
Interventions Azathioprine 3.0 mg/kg body weight oral daily for 24 months (n = 30)
Placebo oral daily for 24 months (n = 29)
Outcomes Relapse at 12 and 24 months. Disability worsening at 24 months
Notes Funding: Wellcome Company
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomised by the statistician using random number tables” (Page
21)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients and personnel were blinded, “group PLC received indis-
tinguishable placebo”, and “whenever the treating physician made
a dose change for an AZA patient, a similar dose change was simul-
taneously made for a matched placebo patient to preserve the blind”
(Pages 20-1)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Each patient had the same masked examining neurologist and un-
masked treating neurologist for the duration of the study. Standard-
ized neurologic examinations were recorded at study entry and at
6 month intervals by the examining neurologist unless the patient
reported subjective worsening, in which case an examination was
performed as soon as was practical” (Page 21)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 11.9% were lost to follow-up (10.0% in azathioprine
and 13.8% in placebo), without indication of the differences in
reasons
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Goodkin 1991 (Continued)
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias Unclear risk Definition of sustained disability worsening not clearly reported
IFNB MS Group 1993
Methods RCT
Participants Age: 18 to 50 years; definite RRMS; mean disease duration (time since diagnosis) 4
years; mean EDSS 2.9; prior use of DMT not reported
Interventions Interferon beta-1b (Betaseron) 250 µg subcutaneous every other day for 24 months (n
= 124)
Interferon beta-1b (Betaseron) 50 µg subcutaneous every other day for 24 months (n =
125)
Placebo subcutaneous every other day for 24 months (n = 123)
Outcomes Relapse at 24 months. Disability worsening at 24 months
Notes Funding: Triton Biosciences, Inc., Alameda, CA and Berlex Laboratories Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Each placebo vial contained only similar quantity of albumin and
dextrose”, “All personnel were blinded to treatment categories”, and
“One treating neurologist who knew about side effects, reviewed
laboratory findings for toxicity, and was responsible for overall care”
(Page 656)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “One neurologist who was not aware of drug side effects to do the
periodic examinations” (Page 656). However, it is not clear how
and when potential relapses and EDSS were assessed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Overall, 9.1%were lost to follow-up (7.3% in interferon beta-1b
250µg, 11.2% in interferonbeta-1b50µg, and8.9% in placebo)
. Nothing was said about the reasons for study discontinuation
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
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IFNB MS Group 1993 (Continued)
Other bias High risk - The study was sponsored by Triton Biosciences and the role of
the study sponsor was unclear
- The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both
in the number of participants who discontinued the study and
in time to discontinuation, which they did not report
- Disability worsening confirmed at 3 months outcome was re-
ported incompletely, and disability worsening confirmed at 6
months was not assessed
INCOMIN 2002
Methods RCT
Participants Age: 18 to 50 years; definite RRMS; mean disease duration (time since diagnosis) 6
years; mean EDSS 2.0; all participants were previously untreated patients
Interventions Interferon beta-1b (Betaseron) 250 µg subcutaneous every other day for 24 months (n
= 96)
Interferon beta-1a (Avonex) 30 µg intramuscular once a week for 24 months (n = 92)
Outcomes Relapse at 24 months. Disability worsening at 24 months
Notes Funding: The Italian Ministry of Health and the Italian MS Society
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation followed computer-generated random sequences of
digits that were different for each centre and for each sex, to achieve
centre and sex stratification” (Page 1454)
Allocation concealment (selection bias) Low risk “The codes were randomly assigned to treatments by an independent
team of statisticians unaware of the patient’s clinical characteristics”
(Page 1454)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “All clinical outcomes were assessed in an open-label manner” (Page
1454)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “All clinical outcomes were assessed in an open-label manner” (Page
1454)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Overall, 3.2% were lost to follow-up (2.1% in interferon beta-
1b and 4.3% in interferon beta-1a). Nothing was said about the
reasons for study discontinuation
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INCOMIN 2002 (Continued)
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias Unclear risk Relapse and disability worsening outcomes were reported in-
completely
Johnson 1995
Methods RCT
Participants Age: 18 to 45 years; definite RRMS; mean disease duration 7 years; mean EDSS 2.6;
prior use of DMT not reported
Interventions Glatiramer acetate 20 mg subcutaneous daily for 24 months (n = 125)
Placebo (not described) (n = 126)
Outcomes Relapse at 24 months. Disability worsening at 24 months
Notes Funding: Teva Pharmaceutical
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “A centralized randomization scheme was used” (Page 1270)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Treating neurologists were blinded” (Page 1270)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Examining neurologists were blinded” (Page 1270)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 14.3% were lost to follow-up (15.2% in glatiramer ac-
etate and 13.5% in placebo), without indication of the differ-
ences in reasons
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both
in the number of participants who discontinued the study and
in time to discontinuation, which they did not report
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Johnson 1995 (Continued)
- Relapse and disability worsening confirmed at 3 months out-
comeswere reported incompletely, anddisabilityworsening con-
firmed at 6 months was not assessed
Koch-Henriksen 2006
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; mean disease duration 8 years; mean EDSS 2.9;
prior use of DMT not reported
Interventions Interferon beta-1b (Betaseron) 250 µg subcutaneous every other day for 24 months (n
= 158)
Interferon beta-1a (Rebif ) 22 µg subcutaneous once a week for 24 months (n = 143)
Outcomes Relapse at 24 months. Disability worsening at 24 months
Notes Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization algorithm was adjusted to reduce deviations
from a 50/50 result in each center” (Page 1057)
Allocation concealment (selection bias) Low risk “A central computerized randomization schedule assigned patients
to treatment” (Page 1057)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Blinding was abandoned because it could not bemaintained owing
to the different administration schemes of the two study drugs” (Page
1057)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Open-label trial” (Page 1057)
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall, 25.6%were lost to follow-up (27.8% in interferon beta-
1b and 23.1% in interferon beta-1a), with some indication of
the differences in reasons: “The main cause of withdrawal in the
IFN-1b 250 g armwas side effects (24/158, 15.2%), and treatment
failure was the most frequent cause in the IFN-1a arm (15/143,
10.5%)” (Page 1057)
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
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Koch-Henriksen 2006 (Continued)
Other bias High risk - It is unclear if the study was sponsored
- The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both
in the number of participants who discontinued the study and
in time to discontinuation, which they did not report
- Relapse and disability worsening confirmed at 3 months out-
comeswere reported incompletely, anddisabilityworsening con-
firmed at 6 months was not assessed
- Rebif at very low dose that is not used in clinical practice
Lewanska 2002
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; mean disease duration 9 years; mean EDSS 3.0;
prior use of DMT not reported
Interventions Immunoglobulins 0.2 g/kg body weight intravenously monthly for 12 months (n = 17)
Immunoglobulins 0.4 g/kg body weight intravenously monthly for 12 months (n = 16)
Placebo intravenously monthly for 12 months (n = 18)
Outcomes Relapse at 12 months
Notes Funding: Supported by the KBN (State Research Committee)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The generation of allocation sequence was based on random-num-
ber table” (Page 566)
Allocation concealment (selection bias) Unclear risk “Infusions of intravenous immunoglobulins and placebo were stored
in identical opaque plastic bags for concealment during adminis-
tration” (Page 566)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Evaluating physician was unaware of the actual treatment alloca-
tion. Before entry to the study, and monthly thereafter during the
study and 3 months after the end of the study, each patient was ex-
amined blindly by the same neurologist who was unaware of treat-
ment allocation. Monitoring and recording of relapses, concomi-
tant treatment, side-e ects or other medical events were documented
throughout the study” (Page 566)
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Lewanska 2002 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 3.9% were lost to follow-up (6.3% in immunoglobu-
lins 0.4 g/kg, 0% in immunoglobulins 0.2 g/kg, and 5.6% in
placebo), without indication of the differences in reasons
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both
in the number of participants who discontinued the study and
in time to discontinuation, which they did not report
- Relapse outcome was reported incompletely
MAIN TRIAL
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; mean disease duration 6 years; mean EDSS 1.9;
prior use of DMT at any time prior to the start of study: 6.0% (6.5% in azathioprine
and 5.5% in interferon beta)
Interventions Azathioprine 3 mg/kg body weight oral daily for 24 months (n = 77)
Interferons beta (Betaseron, Avonex, or Rebif ) for 24 months (n = 73: 5 Betaseron 250
µg subcutaneously every other day, 26 Avonex 30 µg intramuscular once a week, 35
Rebif 22 µg subcutaneous 3 times a week, 7 Rebif 44 µg subcutaneous 3 times a week)
Outcomes Relapse at 12 and 24 months. Disability worsening at 24 months
Notes Funding: AIFA (Italian medicines agency)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were selected for AZA or IFNs using a randomization
list (1:1 ratio), in blocks of four and stratified by disability score
(EDSS≤3.5 or>3.5)”
Allocation concealment (selection bias) Low risk “Patients were selected for AZA or IFNs using a computer generated
central randomization list”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Single-masked”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Patients were assessed by an un-masked treating and a masked ex-
amining neurologist at their centers”, and “The masked examining
neurologist was responsible for the neurological examination and
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MAIN TRIAL (Continued)
EDSS scoring at scheduled (every six months) and unscheduled vis-
its, requested by the treating neurologist to confirm relapses”. Re-
lapse assessment was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 15.3% were lost to follow-up (19.5% in azathioprine
and 11.0% in interferon beta), without indication of the differ-
ences in reasons
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias Low risk The study appears to be free of other sources of bias
Millefiorini 1997
Methods RCT
Participants Age: 18 to 45 years; definite RRMS; mean disease duration 5 years; mean EDSS 3.6;
prior use of DMT not reported
Interventions Mitoxantrone 8 mg/m² of body surface intravenously monthly for 12 months (total
dosage of 96 mg/m² of body surface over 12 months) (n = 27)
Placebo intravenously monthly for 12 months (n = 24)
Outcomes Relapse at 12 and 24 months. Disability worsening at 24 months
Notes Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized to MTX or placebo using a scheme strat-
ified on age, sex and EDSS which resulted in eight different age/sex/
EDSS strata. According to the study protocol, within each stratum
the allocation of patients to treatment or placebo was balanced by
using a block design of size eight” (Page 154)
Allocation concealment (selection bias) Low risk “Central allocation and the intravenous bag and tubing were black
to ensure no differences between the treatment groups” (Page 154)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Treating physicians were not blinded. Unclear blinding of pa-
tients
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Monitoring and recording of exacerbations, concomitant therapy
or other medical events were documented throughout the study by a
treating physician selected in each centre before the beginning of the
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Millefiorini 1997 (Continued)
study. The treating physician was not blinded to study treatment”,
and “In order to maintain blindness, the interaction of the EDSS
physicians with the patient was strictly restricted to the neurological
examination. The neurologist was not allowed to talk with the pa-
tient about adverse events, or any other issue which could potentially
disclose the patient’s treatment” (Page 154)
Incomplete outcome data (attrition bias)
All outcomes
Low risk None were lost to follow-up
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - It is unclear if this study was sponsored
- Definition of sustained disability worsening was not clearly
reported
MSCRG 1996
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; mean disease duration 7 years; mean EDSS 2.4; all
participants were previously untreated patients
Interventions Interferon beta-1a (Avonex) 30 µg intramuscular once a week for 24 months (n = 158)
Placebo intramuscular once a week for 24 months (n = 143)
Outcomes Relapse at 12 and 24 months. Disability worsening at 24 months
Notes Funding: Biogen, Inc, Cambridge, MA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomisation performed at statistical centre of Buffalo General
Hospital, one of the participating centres (biased coin assignment
used for sequence generation)” (Page 286)
Allocation concealment (selection bias) Unclear risk “schedule sent to each clinical centre, included patients were sequen-
tially assigned the next ID number from the schedule”(Page 286)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Personnel and participants were blinded to treatment status” (Page
286)
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MSCRG 1996 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Evaluating physicians were blinded to treatment status” (Page 286)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 42.9%were lost to follow-up (46.2% in interferon beta-
1a and 39.2% in placebo). The study stopped early for benefit
without a formal-stopping rule
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk The study was sponsored by Biogen and “Personnel of the study
sponsor (Biogen) were involved in the conduct and data analysis”
(Page 293)
OWIMS 1999
Methods RCT
Participants Age: 18 to 50 years; definite RRMS; mean disease duration 7 years; mean EDSS 2.6;
prior use of DMT not reported
Interventions Interferon beta-1a (Rebif ) 44 µg subcutaneous 3 times a week for 12 months (n = 98)
Interferon beta-1a (Rebif ) 22 µg subcutaneous 3 times a week for 12 months (n = 95)
Placebo subcutaneous 3 times a week for 12 months (n = 100)
Outcomes Relapse at 12 months
Notes Funding: Ares-Serono International SA, Geneva, Switzerland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation performed at Corporate Biometrics Department of
Ares-Serono (computer-generated list)” (Page 680)
Allocation concealment (selection bias) Low risk “The randomization code for each patient was delivered to the in-
vestigator in sealed envelopes” (Page 680)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “If desired, patients could remain on blinded study medication for
another 24 weeks”, “Both active treatment and placebo were ad-
ministered as ready-to-use solutions in a volume of 0.5 mL”, and
“To preserve blinding, patients were instructed to cover injection
sites and to refrain from discussing any symptoms that might be in
any way related to treatment when visiting the evaluating physi-
cian” (Page 681)
99Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
OWIMS 1999 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The evaluating physician was responsible for neurologic assess-
ments, both at scheduled visits and during exacerbations. Through-
out the study, the evaluating physician remained unaware of adverse
event profiles and any changes in safety assessments” (Page 681)
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall, 8.2% were lost to follow-up (13.3% in interferon beta-
1a 44µg, 8.4% in interferonbeta-1a 22 µg, and3.0% in placebo)
, with some indication of the differences in reasons
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - The study was sponsored by Ares-Serono International SA,
Geneva, Switzerland
- Relapse outcome was reported incompletely
PRISMS 1998
Methods RCT
Participants Age: 18 to 50 years; definite RRMS; mean disease duration 7 years; mean EDSS 2.5;
prior use of DMT: “Only 3% of patients had received previous immunosuppressive therapy”
Interventions Interferon beta-1a (Rebif ) 44 µg subcutaneous 3 times a week for 24 months (n = 184)
Interferon beta-1a (Rebif ) 22 µg subcutaneous 3 times a week for 24 months (n = 189)
Placebo subcutaneous 3 times a week for 24 months (n = 187)
Outcomes Relapse at 12 and 24 months. Disability worsening at 24 months
Notes Funding: Ares-Serono International SA, Geneva, Switzerland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation at Corporate Biometrics Department of Ares-
Serono (computer-generated list, stratified by centre, equal alloca-
tion of the treatment groups by a block size of 6)” (Page 1499)
Allocation concealment (selection bias) Low risk “The study drug was packed accordingly to the randomisation list
and delivered to the centres so that treatment allocation remained
concealed” (Page 1499)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “All personnel involved in the study were unaware of treatment
allocation”, and “All injection sites were covered up at neurological
examinations to ensure that masking was not compromised because
of local reactions” (Page 1499)
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PRISMS 1998 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All personnel involved in the study were unaware of treatment
allocation”, “Patients were assessed by two physicians. A “treating”
neurologist was responsible for overall medical management of the
patient, including treatment of any side-effects, and an “assessing”
neurologist was responsible for neurological assessments and follow-
up of relapses”, and “All patients had a neurological assessment every
3 months. Additional assessments were done during relapses” (Page
1499)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 4.8%were lost to follow-up (2.7% in interferon beta-1a
44 µg, 6.3% in interferon beta-1a 22 µg, and 5.3% in placebo)
, without indication of the differences in reasons
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - The study was sponsored by Ares-Serono International SA,
Geneva, Switzerland
- The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both
in the number of participants who discontinued the study and
in time to discontinuation, which they did not report
- Relapse outcome was reported incompletely
REGARD 2008
Methods RCT
Participants Age: 18 to 60 years; definite RRMS; mean disease duration 6 years; mean EDSS 2.3;
prior use of DMT not reported
Interventions Interferon beta-1a (Rebif ) 44 µg subcutaneous 3 times a week for 24 months (n = 386)
Glatiramer acetate 20 mg subcutaneous daily for 24 months (n = 378)
Outcomes Relapse at 24 months. Disability worsening at 24 months
Notes Funding: EMD Serono and Pfizer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated randomisation list stratified by centre” (Page
904)
Allocation concealment (selection bias) Unclear risk Not described
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REGARD 2008 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Neither the patients nor the treating physicians were blinded to
treatment” (Page 904)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The physicians who assessed patients ...were blinded to treatment
and communicated with the patients only as needed to complete
the EDSS, Kurtzke functional scale (KFS), and relapse assessments.
Patients were asked not to discuss their treatment with the assessing
physician and they covered their injection sites” (Page 904)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Overall, 3.3% were lost to follow-up (5.2% in interferon beta-
1a and 1.3% in glatiramer acetate). Nothing was said about the
reasons for study discontinuation
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - “The study protocol was drafted and developed by the study spon-
sors, EMD Serono and Pzer, in conjunction with the investigator
steering committee. Data management and analysis were done by
the study sponsors” (Page 907), and 2 co-authors of the published
paper were affiliated to the pharmaceutical company
- Disability worsening confirmed at 6 months outcome was re-
ported incompletely
SELECT 2013
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; median disease duration (since diagnosis) 3 years;
mean EDSS 2.7; prior use of DMT at any time prior to the start of study: 23.7% (22.
5% in daclizumab 300 mg, 25.5% in daclizumab 150 mg, and 24.0% in placebo)
Interventions Daclizumab 300 mg subcutaneously once every 4 weeks for 12 months (n = 209)
Daclizumab 150 mg subcutaneously once every 4 weeks for 12 months (n = 208)
Placebo subcutaneously once every 4 weeks for 12 months (n = 204)
Outcomes Relapse at 12 months
Notes Funding: Biogen Idec and AbbVie Biotherapeutics Inc.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly assigned in a 1:1:1 ratio” (Page 2168)
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SELECT 2013 (Continued)
Allocation concealment (selection bias) Low risk “Patients were randomly assigned via a centralised interactive voice
response system” (Page 2168)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All personnel and patients were masked to treatment assignment”
(Page 2168)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Threemembers of an independentneurology assessment committee,
consisting of multiple sclerosis neurologists whoweremasked to group
assignment, adjudicated whether the protocol definition of relapse
was satisfied” (Page 2168)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Overall, 7.1% were lost to follow-up (5.7% in daclizumab 300
mg, 7.7% in daclizumab 150 mg, and 7.8% in placebo). Noth-
ing was said about the reasons for study discontinuation
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - The study was sponsored by Biogen Idec and AbbVie Bio-
therapeutics Inc, “The sponsor of the study provided assistance in
manuscript preparation. The study was designed by the sponsor; the
sponsor held and analysed data” (Page 2169), and 5 co-authors of
the published paper were affiliated to the pharmaceutical com-
pany
- The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both
in the number of participants who discontinued the study and
in time to discontinuation, which they did not report
TEMSO 2011
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; mean disease duration 9 years; mean EDSS 2.7;
prior use of DMT in the previous 2 years: 27.0% (28.4% in teriflunomide 14 mg, 27.
9% in teriflunomide 7 mg, and 24.8% in placebo)
Interventions Teriflunomide 14 mg oral capsule once daily for 25 months (n = 359)
Teriflunomide 7 mg oral capsule once daily for 25 months (n = 366)
Placebo oral capsule once daily for 25 months (n = 363)
Outcomes Relapse at 12 and 24 months. Disability worsening at 24 months
Notes Funding: Sanofi-Aventis
Risk of bias
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TEMSO 2011 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Eligible patients were randomly assigned (in a 1:1:1 ratio) to receive
a once-daily oral dose of placebo, 7 mg of teriflunomide, or 14
mg of teriflunomide for 108 weeks. Randomization was stratified
according to the baseline EDSS score (≤3.5 or >3.5) and according
to trial site, with a block size of 6.” (Page 1294)
Allocation concealment (selection bias) Low risk “The treatment allocation was determined according to the ran-
domization code provided by an interactive voice response system
(IVRS)” (Page 74 of Medical Review of FDA)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double blind” (Page 1294), and at Page 40 of the Protocol they
described blinding, packaging and labeling (“Eachmedication kit
was labeled with a two-part tear-off label...”). “Unblinding of 40
patients in TEMSO study, and the reasons provided do not appear
to justify the need of unblinding” (Page 230 of Statistical Review
of FDA)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “A treating neurologist at each site was responsible for evaluating
patient eligibility, supervising the administration of study medica-
tion, recording and managing adverse events, assessing relapses, and
monitoring safety assessments. An independent, specially trained and
certified examining neurologist determined all the EDSS scores and
performed all assessments of functional systems. Both treating and
examining neurologists were unaware of treatment assignments; only
the treating neurologist was aware of any side effects that could po-
tentially be related to active therapy” (Pages 1294-5), “Each episode
of relapsewas to be confirmed by the treating neurologist (unblinded)
, based on the objective assessments by an independent examining
neurologist (blinded)” (Page 207 of Statistical Review of FDA)
and “Patients were required to visit the study site within 7 days after
the onset of a suspected relapse, for assessments by the examining
neurologist” (Page 1295).
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Overall, 20.1% were lost to follow-up (21.2% in teriflunomide
14 mg, 19.1% in teriflunomide 7 mg, and 20.1% in placebo).
Nothing was said about the reasons for study discontinuation.
“Some patients discontinued study at the time of blind broken,
although it is not clear whether or not the discontinuation was due
to unblinding” (Page 208 of Statistical Review of FDA)
Selective reporting (reporting bias) High risk The published report included all pre-specified primary benefit
outcomes. However, disability confirmed at 6 months was not
reported in the published report, it was reported by the FDA in
terms of survival probabilities
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TEMSO 2011 (Continued)
Other bias High risk -The studywas sponsored by Sanofi-Aventis, “datawere analyzed
by the sponsor” (Page 1294), and 3 co-authors of the published
paper were affiliated to the pharmaceutical company
- The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both
in the number of participants who discontinued the study and
in time to discontinuation, which they did not report
TENERE 2014
Methods RCT
Participants Age: 18 years and older; definite RRMS; mean disease duration 7 years; mean EDSS 2.
1; prior use of DMT in the previous 2 years: 18.8% (11.7% in teriflunomide 14 mg,
21.1% in teriflunomide 7 mg, and 24.0% in interferon beta-1a)
Interventions Teriflunomide 14 mg oral capsule once daily for at least 12 months (n = 111)
Teriflunomide 7 mg oral capsule once daily for at least 12 months (n = 109)
Interferon beta-1a (Rebif ) 44 µg (“when the 44 µg dose was not tolerated, the dose was
reduced to 22 µg”) subcutaneous 3 times a week for at least 12 months (n = 104)
The study was completed 48 weeks after the last patient was randomised, resulting in a
variable duration of follow-up
Outcomes Relapse at 12 months
Notes Funding: Genzyme (a Sanofi company)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomised 1:1:1 to teriflunomide 7 mg or 14 mg
or IFNβ-1a, and stratified by country (Americas, Eastern Europe,
Western Europe and Africa) and baseline EDSS score (≤3.5 or >3.
5)” (Page 706)
Allocation concealment (selection bias) Low risk “A phone interactive voice response system was used to randomize
patients” (information provided on request by Genzyme)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Patients were randomised 1:1:1 to teriflunomide 7 mg or 14 mg
(double-blind) or IFNβ-1a (open-label)” (Page 706)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “The treating neurologist was responsible for relapse assessments,
while an examining neurologist scored the EDSS. The examining
neurologist remained blinded to treatment and associated AEs”, and
“Each relapse was confirmed by the treating neurologist based on
the objective assessment of the examining neurologist” (Page 706)
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TENERE 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall, at 1 year 17.9% were lost to follow-up (17.1% in ter-
iflunomide 14 mg, 10.1% in teriflunomide 7 mg, and 26.9%
in interferon beta-1a) (data provided on request by Genzyme),
with some indication of the differences in reasons
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes.Missingdata not reported in the publishedpaperwere
provided on request by Genzyme
Other bias High risk “This study was funded by Genzyme, a Sanofi company. Editorial
supportwas provided byMegChurch, Fishawack Communications,
Ltd, also funded by Genzyme, a Sanofi company” (Page 716), and
3 co-authors of the published paper were affiliated to the phar-
maceutical company
TOWER 2014
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; mean disease duration 8 years; mean EDSS 2.7;
prior use of DMT in the previous 2 years: 32.8% (33.9% in teriflunomide 14 mg, 30.
1% in teriflunomide 7 mg, and 34.7% in placebo)
Interventions Teriflunomide 14 mg oral capsule once daily for at least 12 months (n = 372)
Teriflunomide 7 mg oral capsule once daily for at least 12 months (n = 408)
Placebo oral capsule once daily for at least 12 months (n = 389)
The study was completed 48 weeks after the last patient was randomised, resulting in a
variable duration of follow-up
Outcomes Relapse at 12 months
Notes Funding: Genzyme (a Sanofi company)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was done using a permuted-block randomisation
schedule with stratification according to study site and baseline
EDSS score (≤3.5 or >3.5)” (Page 248)
Allocation concealment (selection bias) Low risk “Randomisation was done centrally, via an interactive voice recog-
nition system that generated an allocation sequence” and “investiga-
tors used the allocation sequence to randomly assign eligible patients
in a 1:1:1 ratio to receive once-daily oral placebo, teriflunomide 7
mg, or teriflunomide 14 mg (identical in taste and appearance)”
(Page 248)
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TOWER 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Patients and individuals administering the interventions were
masked to treatment assignment” (Page 248)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Those assessing the outcomes were masked to treatment assignment”
and “A treating neurologist was responsible for recording of adverse
events, and assessment of relapses. An examining neurologist assigned
EDSS scores at screening, randomisation, and every 12 weeks until
the last treatment visit, and on any unscheduled visits for assessment
of suspected relapse or disability worsening” (Page 248)
Incomplete outcome data (attrition bias)
All outcomes
High risk Overall, 29.8% were lost to follow-up (30.6% in teriflunomide
14 mg, 29.2% in teriflunomide 7 mg, and 29.6% in placebo)
, with some indication of the differences in reasons: adverse
events of 15.6% in teriflunomide 14mg, 13.2% in teriflunomide
7 mg, and 6.7% in placebo; and lack of benefit of 5.4% in
teriflunomide 14 mg, 7.4% in teriflunomide 7 mg, and 9.5%
in placebo
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes
Other bias High risk - The study was sponsored by Genzyme, “data were analyzed by
the sponsor” (Page 250), and 4 co-authors of the published paper
were affiliated to the pharmaceutical company
- The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both
in the number of participants who discontinued the study and
in time to discontinuation, which they did not report
TRASFORMS 2010
Methods RCT
Participants Age: 18 to 55 years; definite RRMS; mean disease duration 7 years; mean EDSS 2.2;
prior use of DMT at any time prior to the start of study: 56.7% (58.5% in fingolimod
1.25 mg, 55.2% in fingolimod 0.5 mg, and 56.3% in interferon beta-1a)
Interventions Fingolimod 1.25 mg oral capsule once daily for 12 months (n = 426)
Fingolimod 0.5 mg oral capsule once daily for 12 months (n = 431)
Interferon beta-1a (Avonex) 30 µg intramuscular once a week for 12 months (n = 435)
Outcomes Relapse at 12 months
Notes Funding: Novartis Pharma
Risk of bias
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TRASFORMS 2010 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was performed in blocks of six within each site and
was stratified according to site” (Page 403)
Allocation concealment (selection bias) Low risk “Randomization was performed centrally” and “Study-group as-
signments were performed with the use of an interactive voice-re-
sponse system” (Page 403)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Capsules, syringes and packaging materials for active and placebo
treatments were indistinguishable”, “During the trial, patients,
study personnel, steering-committee members, and the study statis-
tician were unaware of study-group assignments and leukocyte
counts”, and “An independent physician monitored patients after
the first dose of the oral study drug was administered and was in-
structed not to discuss heart-rate changes with patients or study per-
sonnel” (Page 404)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “At each site, a treating neurologist supervised medical manage-
ment”, “Patients were instructed to not to discuss adverse events with
clinical evaluators”, and “Potential relapses triggered an unsched-
uled visit and were confirmed by the treating neurologist on the basis
of blinded examination by the examining neurologist” (Pages 403-
4)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 10.8% were lost to follow-up (13.4% in fingolimod 1.
25 mg, 7.7% in fingolimod 0.5 mg, and 11.3% in interferon
beta-1a), with few indications of the differences in reasons: un-
satisfactory therapeutic effect of 0.7% in fingolimod 1.25 mg,
0.7% in fingolimod 0.5 mg, and 1.6% in interferon beta-1a;
adverse event(s) of 6.1% in fingolimod 1.25 mg, 2.1% in fin-
golimod 0.5 mg, and 2.1% in interferon beta-1a; and abnormal
laboratory values(s) of 0.9% in fingolimod 1.25 mg, 1.4% in
fingolimod 0.5 mg, and 0.2% in interferon beta-1a
Selective reporting (reporting bias) Low risk The published report included all pre-specified primary benefit
outcomes.Missingdata not reported in the publishedpaperwere
provided on request by Novartis Pharma
Other bias High risk - The study was sponsored by Novartis Pharma, “data were an-
alyzed by the sponsor” (Page 403), and 5 co-authors of the pub-
lished paper were affiliated to the pharmaceutical company
- The primary benefit outcome measure for relapse (ARR) was
strongly affected by differences among treatment groups both
in the number of participants who discontinued the study and
in time to discontinuation, which they did not report
ARR: annualised relapse rate
108Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
CIS: clinically isolated syndrome
DMT: disease modifying therapy
EDSS: Expanded Disability Status Scale
FDA: (US) Food and Drug Administration
MS: multiple sclerosis
RCT: randomised controlled trial
RRMS: relapsing-remitting multiple sclerosis
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ACT 2009 Study evaluating combination therapy (interferon beta-1a combined with methotrexate, methylprednisolone,
or both)
Ashtari 2011 Study on interferon beta-1a versus methotrexate; methotrexate is not relevant to the review
ATAMS 2014 Study on atacicept versus placebo; atacicept is not relevant to the review
Calabrese 2012 Non-randomised study
CHOICE 2010 Follow-up of 6 months
Etemadifar 2006 Non-randomised study
FORTE 2011 Study evaluating 2 doses of glatiramer acetate (40 mg compared to 20 mg) without a control group
Freedman 2012 Study evaluating combination therapy (interferon beta-1a alone and combined with teriflunomide), with a
follow-up of 6 months
Havrdova 2009 Study evaluating combination therapy (interferon beta-1a alone and combined with low-dose azathioprine alone
or low-dose azathioprine and low-dose corticosteroids)
Kappos 2006 Follow-up of 6 months
The patients were possibly included in the FREEDOMS study
Kappos 2008 Follow-up of 6 months
Kappos 2011 Follow-up of 6 months
Khoury 2010 Study evaluating combination therapy (glatiramer acetate alone and combined with albuterol)
Knobler 1993 Follow-up of 6 months
Saida 2012 Follow-up of 6 months
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(Continued)
SENTINEL 2006 Study evaluating combination therapy (natalizumab combined with interferon beta-1a versus interferon beta-
1a alone)
Sorensen 2014 Follow-up of 6 months
Characteristics of ongoing studies [ordered by study ID]
DECIDE
Trial name or title Multicenter, double-blind, randomized, parallel-group, monotherapy, active-control study to determine the
efficacy and safety of daclizumab high yield process (DACHYP) versus Avonex® (interferon β 1a) in patients
with relapsing-remitting multiple sclerosis
Methods RCT
Participants Inclusion criteria:
• Aged 18 to 55 years old
• Must have a confirmed diagnosis of relapsing remitting multiple sclerosis, and a cranial MRI
demonstrating lesion(s) consistent with MS
• Must have a baseline EDSS between 0.0 and 5.0
• Male subjects and female subjects of childbearing potential must be willing to practice effective
contraception during the study and be willing and able to continue contraception for 4 months after their
last dose of study treatment
Exclusion criteria:
• Known intolerance, contraindication to, or history of non compliance with Avonex 30 µg
• History of treatment with daclizumab
• History of malignancy
• History of severe allergic or anaphylactic reactions
• Known hypersensitivity to study drugs or their excipients
• History of abnormal laboratory results indicative of any significant disease
• History of human immunodeficiency virus (HIV) or other immunodeficient conditions
• History of drug or alcohol abuse (as defined by the investigator) within the 2 years prior to
randomisation
• History of seizure disorder or unexplained blackouts or history of a seizure within 6 months prior to
baseline
• History of suicidal ideation or an episode of clinically severe depression (as determined by the
investigator) within 3 months prior to day 1
• A MS relapse that has occurred within the 50 days prior to randomisation and/or the subject has not
stabilised from a previous relapse prior to randomisation
• Known history of, or positive screening test result for, hepatitis C virus or hepatitis B virus
• Varicella or herpes zoster virus infection or any severe viral infection within 6 weeks before screening
• Exposure to varicella zoster virus within 21 days before screening
Interventions Daclizumab 150 mg subcutaneously once every 4 weeks for 24 to 36 months
Interferon beta-1a (Avonex) 30 µg intramuscular once a week for 24 to 36 months
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DECIDE (Continued)
Outcomes Primary outcome measures:
• Annualised relapse rate (ARR) at 3 years.
Secondary outcome measures (time frame: 2 years):
• Number of new or newly enlarging T2 hyperintense lesions on brain MRI
• Proportion of subjects with sustained (for 3 months) disability worsening
• Proportion of subjects who are relapse-free
• Proportion of subjects with a ≥ 7.5 point worsening from baseline in the MSIS-29 physical score
Starting date May 2010
Contact information Biogen Idec
Notes Sponsor: Biogen Idec
ClinicalTrials.gov Identifier: NCT01064401
NCT01247324
Trial name or title A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of
Ocrelizumab in comparison to Interferon Beta-1a (Rebif®) in patients with relapsing multiple sclerosis
Methods RCT
Participants Inclusion criteria:
• Aged 18 to 55 years old
• Diagnosis of multiple sclerosis, in accordance with the revised McDonald criteria (2010)
• At least 2 documented clinical attacks within the last 2 years prior to screening or 1 clinical attack in
the years prior to screening (but not within 30 days prior to screening)
• Neurologic stability for >/= 30 days prior to both screening and baseline
• Expanded Disability Status Scale (EDSS) score 0 to 5.5
Exclusion criteria:
• Primary progressive multiple sclerosis
• Disease duration of more than 10 years in patients with EDSS </= 2.0 at screening
• Contraindications for MRI
• Known presence of other neurological disorders that may mimic multiple sclerosis
• Pregnancy or lactation
• Requirement for chronic treatment with systemic corticosteroids or immunosuppressants during the
course of the study
• History of or currently active primary or secondary immunodeficiency
• History of severe allergic or anaphylactic reactions to humanised or murine monoclonal antibodies
• Active infection, or history of or known presence of recurrent or chronic infection (e.g. hepatitis B or
C, HIV, syphilis, tuberculosis)
• History of progressive multifocal leukoencephalopathy
• Contraindications to or intolerance of oral or intravenous corticosteroids
• Contraindications to Rebif or incompatibility with Rebif use
Interventions Ocrelizumab 600 mg intravenously every 24 weeks for 24 months
Interferon beta-1a (Rebif ) 8.8 µg (weeks 1 + 2)/22 µg (weeks 3 + 4)/44 µg (week 5 and following) subcutaneous
3 times a week for 24 months
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NCT01247324 (Continued)
Outcomes Primary outcome measures:
• Annualised Relapse Rate (ARR) at 2 years
Secondary outcome measures (time frame: 2 years):
• Time to onset of sustained disability worsening for at least 3 months
• Time to onset of sustained disability worsening for at least 6 months
• Proportion of relapse-free patients
• Change in total T2 lesion volume as detected by brain MRI
• Total number of new and/or enlarging T2 hyperintense lesions as detected by brain MRI
• Change in Multiple Sclerosis Functional Composite Scale (MSFCS) score
• Change in brain volume as detected by MRI
• Safety: incidence of adverse events
• Pharmacokinetics: exposure to ocrelizumab (area under the concentration - time curve)
• Immunogenicity: human anti-human antibodies (HAHA) levels
Starting date August 2011
Contact information Hoffmann-La Roche
Notes Sponsor: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01247324
NCT01412333
Trial name or title A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of
ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis
Methods RCT
Participants Inclusion criteria:
• Aged 18 to 55 years old
• Diagnosis of multiple sclerosis, in accordance with the revised McDonald criteria (2010)
• At least 2 documented clinical attacks within the last 2 years prior to screening or 1 clinical attack in
the years prior to screening (but not within 30 days prior to screening)
• Neurologic stability for >/= 30 days prior to both screening and baseline
• Expanded Disability Status Scale (EDSS) score 0 to 5.5
Exclusion criteria:
• Primary progressive multiple sclerosis
• Disease duration of more than 10 years in patients with EDSS </= 2.0 at screening
• Contraindications for MRI
• Known presence of other neurological disorders which may mimic multiple sclerosis
• Pregnancy or lactation
• Requirement for chronic treatment with systemic corticosteroids or immunosuppressants during the
course of the study
• History of or currently active primary or secondary immunodeficiency
• History of severe allergic or anaphylactic reactions to humanised or murine monoclonal antibodies
• Active infection, or history of or known presence of recurrent or chronic infection (e.g. hepatitis B or
C, HIV, syphilis, tuberculosis)
• History of progressive multifocal leukoencephalopathy
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NCT01412333 (Continued)
• Contraindications to or intolerance of oral or intravenous corticosteroids
• Contraindications to Rebif or incompatibility with Rebif use
Interventions Ocrelizumab 600 mg intravenously every 24 weeks for 24 months
Interferon beta-1a (Rebif ) 8.8 µg (weeks 1 + 2)/22 µg (weeks 3 + 4)/44 µg (week 5 and following) subcutaneous
3 times a week for 24 months
Outcomes Primary outcome measures:
• Annualised Relapse Rate (ARR) at 2 years
Secondary outcome measures (time frame: 2 years):
• Time to onset of sustained disability worsening for at least 3 months
• Time to onset of sustained disability worsening for at least 6 months
• Proportion of relapse-free patients
• Change in total T2 lesion volume as detected by brain MRI
• Total number of new and/or enlarging T2 hyperintense lesions as detected by brain MRI
• Change in Multiple Sclerosis Functional Composite Scale (MSFCS) score
• Change in brain volume as detected by MRI
• Safety: incidence of adverse events
• Pharmacokinetics: exposure to ocrelizumab (area under the concentration - time curve)
• Immunogenicity: human anti-human antibodies (HAHA) levels
Starting date September 2011
Contact information Hoffmann-La Roche
Notes Sponsor: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01412333
EDSS: Expanded Disability Status Scale
MRI: magnetic resonance imaging
MS: multiple sclerosis
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Treatment benefit within pairwise comparisons
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Comparisons for relapses over
12 months
29 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Interferon beta-1a
(Avonex) versus placebo
1 301 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.73, 1.05]
1.2 Interferon beta-1a (Rebif )
versus placebo
2 853 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.66, 1.19]
1.3 Glatiramer acetate versus
placebo
4 2416 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.66, 0.95]
1.4 Natalizumab versus
placebo
1 942 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.47, 0.66]
1.5 Mitoxantrone versus
placebo
1 51 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.21, 0.74]
1.6 Fingolimod versus placebo 2 2355 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.48, 0.82]
1.7 Teriflunomide versus
placebo
2 2257 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.78, 0.95]
1.8 Dimethyl fumarate versus
placebo
2 2307 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.71, 0.88]
1.9 Pegylated interferon
beta-1a versus placebo
1 1512 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.78, 1.01]
1.10 Daclizumab versus
placebo
1 621 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.68, 0.92]
1.11 Azathioprine versus
placebo
1 59 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.61, 1.24]
1.12 Immunoglobulins versus
placebo
3 219 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.47, 1.36]
1.13 Interferon beta-1a
(Rebif ) versus interferon
beta-1a (Avonex)
1 677 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.80, 1.03]
1.14 Glatiramer acetate versus
interferon beta-1b (Betaseron)
1 75 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.48, 1.38]
1.15 Azathioprine versus
interferons beta (Avonex, Rebif
or Betaseron)
2 244 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.49, 1.33]
1.16 Fingolimod versus
interferon beta-1a (Avonex)
1 1292 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.57, 0.79]
1.17 Teriflunomide versus
interferon beta-1a (Rebif )
1 324 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.69, 1.18]
1.18 Dimethyl fumarate
versus glatiramer acetate
1 1067 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.80, 1.14]
1.19 Alemtuzumab versus
interferon beta-1a (Rebif )
3 1582 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.39, 0.55]
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2 Comparisons for relapses over
24 months
26 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Interferon beta-1b
(Betaseron) versus placebo
1 372 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.81, 0.99]
2.2 Interferon beta-1a
(Avonex) versus placebo
2 1198 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.76, 1.04]
2.3 Interferon beta-1a (Rebif )
versus placebo
1 560 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.77, 0.92]
2.4 Glatiramer acetate versus
placebo
3 1024 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.75, 0.98]
2.5 Natalizumab versus
placebo
1 942 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.49, 0.64]
2.6 Mitoxantrone versus
placebo
1 51 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.27, 0.80]
2.7 Fingolimod versus placebo 2 2355 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.67, 0.78]
2.8 Teriflunomide versus
placebo
1 1088 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.79, 0.98]
2.9 Dimethyl fumarate versus
placebo
2 2307 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.81, 0.97]
2.10 Laquinimod versus
placebo
2 1990 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.75, 0.99]
2.11 Azathioprine versus
placebo
1 59 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.56, 1.05]
2.12 Immunoglobulins versus
placebo
2 190 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.61, 0.90]
2.13 Interferon beta-1a
(Avonex) versus interferon
beta-1b (Betaseron)
1 188 Risk Ratio (M-H, Random, 95% CI) 1.34 [1.06, 1.71]
2.14 Interferon beta-1a
(Rebif ) versus interferon
beta-1b (Betaseron)
1 301 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.89, 1.11]
2.15 Glatiramer acetate versus
interferon beta-1b (Betaseron)
2 2319 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.47, 1.38]
2.16 Glatiramer acetate versus
interferon beta-1a (Rebif )
1 764 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.78, 1.09]
2.17 Dimethyl fumarate
versus glatiramer acetate
1 1067 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.98, 1.21]
2.18 Alemtuzumab versus
interferon beta-1a (Rebif )
3 1582 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.39, 0.65]
2.19 Laquinimod versus
interferon beta-1a (Avonex)
1 881 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.97, 1.32]
2.20 Azathioprine versus
interferons beta (Avonex, Rebif
or Betaseron)
1 150 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.64, 1.16]
3 Comparisons for disability
worsening over 24 months
26 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Interferon beta-1b
(Betaseron) versus placebo
1 372 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.72, 1.32]
3.2 Interferon beta-1a
(Avonex) versus placebo
2 1198 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.70, 1.09]
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3.3 Interferon beta-1a (Rebif )
versus placebo
1 560 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.61, 0.96]
3.4 Glatiramer acetate versus
placebo
3 1024 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.61, 1.09]
3.5 Natalizumab versus
placebo
1 942 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.52, 0.80]
3.6 Mitoxantrone versus
placebo
1 51 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.05, 0.83]
3.7 Fingolimod versus placebo 2 2355 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.76, 0.99]
3.8 Teriflunomide versus
placebo
1 1088 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.75, 1.01]
3.9 Dimethyl fumarate versus
placebo
2 2307 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.72, 0.90]
3.10 Laquinimod versus
placebo
2 1990 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.73, 0.95]
3.11 Azathioprine versus
placebo
1 59 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.31, 1.34]
3.12 Immunoglobulins versus
placebo
2 190 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.39, 1.24]
3.13 Interferon beta-1a
(Avonex) versus interferon
beta-1b (Betaseron)
1 188 Risk Ratio (M-H, Random, 95% CI) 2.23 [1.29, 3.83]
3.14 Interferon beta-1a
(Rebif ) versus interferon
beta-1b (Betaseron)
1 301 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.78, 1.25]
3.15 Glatiramer acetate versus
interferon beta-1b (Betaseron)
2 2319 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.86, 1.13]
3.16 Glatiramer acetate versus
interferon beta-1a (Rebif )
1 764 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.39, 0.85]
3.17 Dimethyl fumarate
versus glatiramer acetate
1 1067 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.83, 1.22]
3.18 Alemtuzumab versus
interferon beta-1a (Rebif )
3 1582 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.32, 0.54]
3.19 Laquinimod versus
interferon beta-1a (Avonex)
1 881 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.85, 1.33]
3.20 Azathioprine versus
interferons beta (Avonex, Rebif
or Betaseron)
1 150 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.49, 1.23]
Comparison 2. Treatment acceptability within pairwise comparisons
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Comparisons for treatment
discontinuation due to AEs
over 12 months
13 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Interferon beta-1a
(Avonex) 30 µg versus placebo
1 301 Risk Ratio (M-H, Random, 95% CI) 3.17 [0.67, 15.00]
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1.2 Interferon beta-1a (Rebif )
22 µg versus placebo
1 195 Risk Ratio (M-H, Random, 95% CI) 3.16 [0.13, 76.54]
1.3 Interferon beta-1a (Rebif )
44 µg versus placebo
1 198 Risk Ratio (M-H, Random, 95% CI) 11.22 [0.63, 200.27]
1.4 Glatiramer acetate 20 mg
daily versus placebo
1 239 Risk Ratio (M-H, Random, 95% CI) 1.51 [0.26, 8.89]
1.5 Glatiramer 40 mg three
times per week versus placebo
1 1404 Risk Ratio (M-H, Random, 95% CI) 2.36 [0.99, 5.65]
1.6 Teriflunomide 7 mg versus
placebo
1 797 Risk Ratio (M-H, Random, 95% CI) 2.06 [1.31, 3.24]
1.7 Teriflunomide 14 mg
versus placebo
1 761 Risk Ratio (M-H, Random, 95% CI) 2.51 [1.61, 3.91]
1.8 Pegylated interferon
beta-1a every 4 weeks versus
placebo
1 1000 Risk Ratio (M-H, Random, 95% CI) 2.78 [1.31, 5.89]
1.9 Pegylated interferon
beta-1a every 2 weeks versus
placebo
1 1012 Risk Ratio (M-H, Random, 95% CI) 2.82 [1.34, 5.96]
1.10 Daclizumab 150 mg
versus placebo
1 412 Risk Ratio (M-H, Random, 95% CI) 3.43 [0.72, 16.33]
1.11 Daclizumab 300 mg
versus placebo
1 413 Risk Ratio (M-H, Random, 95% CI) 4.39 [0.96, 20.08]
1.12 Immunoglobulins 0.2 g
versus placebo
2 163 Risk Ratio (M-H, Random, 95% CI) 2.14 [0.23, 19.96]
1.13 Immunoglobulins 0.4 g
versus placebo
1 34 Risk Ratio (M-H, Random, 95% CI) 3.35 [0.15, 76.93]
1.14 Interferon beta-1a
(Rebif ) 44 µg versus interferon
beta-1a (Avonex) 30 µg
1 677 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.56, 1.97]
1.15 Fingolimod 0.5 mg
versus interferon beta-1a
(Avonex) 30 µg
1 866 Risk Ratio (M-H, Random, 95% CI) 1.43 [0.81, 2.54]
1.16 Fingolimod 1.25 mg
versus interferon beta-1a
(Avonex) 30 µg
1 861 Risk Ratio (M-H, Random, 95% CI) 2.36 [1.40, 3.98]
1.17 Teriflunomide 7 mg
versus interferon beta-1a
(Rebif ) 44 µg
1 213 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.19, 0.81]
1.18 Teriflunomide 14 mg
versus interferon beta-1a
(Rebif ) 44 µg
1 215 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.27, 0.98]
1.19 Azathioprine versus
interferons beta (Avonex, Rebif
or Betaseron)
1 94 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.21, 4.70]
2 Comparisons for treatment
discontinuation due to AEs
over 24 months
23 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Interferon beta-1b
(Betaseron) 50 µg versus
placebo
1 248 Risk Ratio (M-H, Random, 95% CI) 4.92 [0.58, 41.51]
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2.2 Interferon beta-1b
(Betaseron) 250 µg versus
placebo
1 247 Risk Ratio (M-H, Random, 95% CI) 9.92 [1.29, 76.32]
2.3 Interferon beta-1a
(Avonex) 30 µg versus placebo
1 897 Risk Ratio (M-H, Random, 95% CI) 1.43 [0.81, 2.54]
2.4 Interferon beta-1a (Rebif )
22 µg versus placebo
1 376 Risk Ratio (M-H, Random, 95% CI) 2.31 [0.61, 8.79]
2.5 Interferon beta-1a (Rebif )
44 µg versus placebo
1 371 Risk Ratio (M-H, Random, 95% CI) 3.05 [0.84, 11.08]
2.6 Glatiramer acetate 20 mg
daily versus placebo
3 1024 Risk Ratio (M-H, Random, 95% CI) 1.74 [0.49, 6.13]
2.7 Natalizumab versus
placebo
1 942 Risk Ratio (M-H, Random, 95% CI) 1.53 [0.93, 2.53]
2.8 Mitoxantrone versus
placebo
1 51 Risk Ratio (M-H, Random, 95% CI) 9.82 [0.57, 168.84]
2.9 Fingolimod 0.5 mg versus
placebo
2 1556 Risk Ratio (M-H, Random, 95% CI) 1.42 [0.89, 2.25]
2.10 Fingolimod 1.25 mg
versus placebo
2 1572 Risk Ratio (M-H, Random, 95% CI) 1.93 [1.48, 2.52]
2.11 Teriflunomide 7 mg
versus placebo
1 729 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.77, 1.96]
2.12 Teriflunomide 14 mg
versus placebo
1 722 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.86, 2.15]
2.13 Dimethyl fumarate 480
mg versus placebo
2 1546 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.91, 1.51]
2.14 Dimethyl fumarate 720
mg versus placebo
2 1534 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.93, 1.54]
2.15 Laquinimod versus
placebo
2 1990 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.96, 2.00]
2.16 Azathioprine versus
placebo
1 59 Risk Ratio (M-H, Random, 95% CI) 5.8 [0.74, 45.26]
2.17 Immunoglobulins 0.15
to 0.20 g versus placebo
1 150 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.32, 28.19]
2.18 Interferon beta-1a
(Avonex) 30 µg versus
interferon beta-1b (Betaseron)
250 µg
1 188 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.02, 1.75]
2.19 Glatiramer acetate 20 mg
daily versus interferon beta-1b
(Betaseron) 250 µg
2 1420 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.56, 2.53]
2.20 Glatiramer acetate 20 mg
daily versus interferon beta-1b
(Betaseron) 500 µg
1 1347 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.37, 1.68]
2.21 Glatiramer acetate 20 mg
daily versus interferon beta-1a
(Rebif ) 44 µg
1 764 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.47, 1.52]
2.22 Dimethyl fumarate 480
mg versus glatiramer acetate 20
mg daily
1 722 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.80, 1.84]
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2.23 Dimethyl fumarate 720
mg versus glatiramer acetate 20
mg daily
1 705 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.80, 1.85]
2.24 Alemtuzumab 12 mg
versus interferon beta-1a
(Rebif ) 44 µg
3 1472 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.22, 0.68]
2.25 Alemtuzumab 24 mg
versus interferon beta-1a
(Rebif ) 44 µg
2 625 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.10, 1.09]
2.26 Laquinimod versus
interferon beta-1a (Avonex) 30
µg
1 881 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.49, 1.45]
2.27 Azathioprine versus
interferons beta (Avonex, Rebif
or Betaseron)
1 150 Risk Ratio (M-H, Random, 95% CI) 2.21 [0.90, 5.45]
Comparison 3. Treatment safety against placebo within pairwise comparisons
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serious adverse events 16 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Interferons beta (Avonex,
Rebif or Betaseron) versus
placebo
3 870 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.67, 2.37]
1.2 Glatiramer acetate versus
placebo
2 490 Risk Ratio (M-H, Random, 95% CI) 1.87 [0.73, 4.74]
1.3 Natalizumab versus
placebo
1 939 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.81, 1.73]
1.4 Fingolimod versus placebo 2 1572 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.72, 1.30]
1.5 Teriflunomide versus
placebo
1 718 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.87, 1.83]
1.6 Dimethyl fumarate versus
placebo
2 1531 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.76, 1.55]
1.7 Pegylated interferon
beta-1a versus placebo
1 1012 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.57, 1.68]
1.8 Daclizumab versus
placebo
1 413 Risk Ratio (M-H, Random, 95% CI) 1.55 [0.77, 3.10]
1.9 Laquinimod versus
placebo
2 1988 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.67, 1.41]
1.10 Immunoglobulins versus
placebo
1 83 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.11, 3.70]
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Analysis 1.1. Comparison 1 Treatment benefit within pairwise comparisons, Outcome 1 Comparisons for
relapses over 12 months.
Review: Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
Comparison: 1 Treatment benefit within pairwise comparisons
Outcome: 1 Comparisons for relapses over 12 months
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Interferon beta-1a (Avonex) versus placebo
MSCRG 1996 88/158 91/143 100.0 % 0.88 [ 0.73, 1.05 ]
Subtotal (95% CI) 158 143 100.0 % 0.88 [ 0.73, 1.05 ]
Total events: 88 (Experimental), 91 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
2 Interferon beta-1a (Rebif) versus placebo
OWIMS 1999 130/193 65/100 47.4 % 1.04 [ 0.87, 1.23 ]
PRISMS 1998 227/373 148/187 52.6 % 0.77 [ 0.69, 0.86 ]
Subtotal (95% CI) 566 287 100.0 % 0.89 [ 0.66, 1.19 ]
Total events: 357 (Experimental), 213 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 8.18, df = 1 (P = 0.004); I2 =88%
Test for overall effect: Z = 0.81 (P = 0.42)
3 Glatiramer acetate versus placebo
Bornstein 1987 7/25 19/25 6.4 % 0.37 [ 0.19, 0.72 ]
Comi 2001 57/119 64/120 25.0 % 0.90 [ 0.70, 1.15 ]
CONFIRM 2012 123/360 143/363 31.4 % 0.87 [ 0.72, 1.05 ]
GALA 2013 301/943 190/461 37.2 % 0.77 [ 0.67, 0.89 ]
Subtotal (95% CI) 1447 969 100.0 % 0.79 [ 0.66, 0.95 ]
Total events: 488 (Experimental), 416 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.88, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 2.50 (P = 0.012)
4 Natalizumab versus placebo
AFFIRM 2006 178/627 160/315 100.0 % 0.56 [ 0.47, 0.66 ]
Subtotal (95% CI) 627 315 100.0 % 0.56 [ 0.47, 0.66 ]
Total events: 178 (Experimental), 160 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 6.91 (P < 0.00001)
5 Mitoxantrone versus placebo
Millefiorini 1997 8/27 18/24 100.0 % 0.40 [ 0.21, 0.74 ]
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(. . . Continued)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 27 24 100.0 % 0.40 [ 0.21, 0.74 ]
Total events: 8 (Experimental), 18 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.91 (P = 0.0036)
6 Fingolimod versus placebo
FREEDOMS 2010 197/854 176/418 49.8 % 0.55 [ 0.46, 0.65 ]
FREEDOMS II 2014 225/728 152/355 50.2 % 0.72 [ 0.61, 0.85 ]
Subtotal (95% CI) 1582 773 100.0 % 0.63 [ 0.48, 0.82 ]
Total events: 422 (Experimental), 328 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 5.43, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 3.36 (P = 0.00079)
7 Teriflunomide versus placebo
TEMSO 2011 295/725 169/363 48.4 % 0.87 [ 0.76, 1.01 ]
TOWER 2014 309/780 183/389 51.6 % 0.84 [ 0.73, 0.97 ]
Subtotal (95% CI) 1505 752 100.0 % 0.86 [ 0.78, 0.95 ]
Total events: 604 (Experimental), 352 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 3.08 (P = 0.0021)
8 Dimethyl fumarate versus placebo
CONFIRM 2012 231/707 143/363 46.7 % 0.83 [ 0.70, 0.98 ]
DEFINE 2012 255/827 167/410 53.3 % 0.76 [ 0.65, 0.88 ]
Subtotal (95% CI) 1534 773 100.0 % 0.79 [ 0.71, 0.88 ]
Total events: 486 (Experimental), 310 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 4.08 (P = 0.000045)
9 Pegylated interferon beta-1a versus placebo
ADVANCE 2014 396/1012 220/500 100.0 % 0.89 [ 0.78, 1.01 ]
Subtotal (95% CI) 1012 500 100.0 % 0.89 [ 0.78, 1.01 ]
Total events: 396 (Experimental), 220 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
10 Daclizumab versus placebo
SELECT 2013 194/417 120/204 100.0 % 0.79 [ 0.68, 0.92 ]
Subtotal (95% CI) 417 204 100.0 % 0.79 [ 0.68, 0.92 ]
Total events: 194 (Experimental), 120 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.98 (P = 0.0029)
11 Azathioprine versus placebo
Goodkin 1991 19/30 21/29 100.0 % 0.87 [ 0.61, 1.24 ]
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(. . . Continued)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 30 29 100.0 % 0.87 [ 0.61, 1.24 ]
Total events: 19 (Experimental), 21 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
12 Immunoglobulins versus placebo
Fazekas 2008 49/87 17/41 32.4 % 1.36 [ 0.90, 2.04 ]
Achiron 1998 12/20 19/20 33.5 % 0.63 [ 0.44, 0.92 ]
Lewanska 2002 18/33 16/18 34.1 % 0.61 [ 0.43, 0.87 ]
Subtotal (95% CI) 140 79 100.0 % 0.80 [ 0.47, 1.36 ]
Total events: 79 (Experimental), 52 (Control)
Heterogeneity: Tau2 = 0.18; Chi2 = 11.77, df = 2 (P = 0.003); I2 =83%
Test for overall effect: Z = 0.82 (P = 0.41)
13 Interferon beta-1a (Rebif) versus interferon beta-1a (Avonex)
EVIDENCE 2007 188/339 207/338 100.0 % 0.91 [ 0.80, 1.03 ]
Subtotal (95% CI) 339 338 100.0 % 0.91 [ 0.80, 1.03 ]
Total events: 188 (Experimental), 207 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
14 Glatiramer acetate versus interferon beta-1b (Betaseron)
BECOME 2009 15/39 17/36 100.0 % 0.81 [ 0.48, 1.38 ]
Subtotal (95% CI) 39 36 100.0 % 0.81 [ 0.48, 1.38 ]
Total events: 15 (Experimental), 17 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.44)
15 Azathioprine versus interferons beta (Avonex, Rebif or Betaseron)
Etemadifar 2007 14/47 23/47 43.8 % 0.61 [ 0.36, 1.03 ]
MAIN TRIAL 31/77 29/73 56.2 % 1.01 [ 0.68, 1.50 ]
Subtotal (95% CI) 124 120 100.0 % 0.81 [ 0.49, 1.33 ]
Total events: 45 (Experimental), 52 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 2.32, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 0.83 (P = 0.41)
16 Fingolimod versus interferon beta-1a (Avonex)
TRASFORMS 2010 217/857 164/435 100.0 % 0.67 [ 0.57, 0.79 ]
Subtotal (95% CI) 857 435 100.0 % 0.67 [ 0.57, 0.79 ]
Total events: 217 (Experimental), 164 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.68 (P < 0.00001)
17 Teriflunomide versus interferon beta-1a (Rebif)
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(. . . Continued)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
TENERE 2014 90/220 47/104 100.0 % 0.91 [ 0.69, 1.18 ]
Subtotal (95% CI) 220 104 100.0 % 0.91 [ 0.69, 1.18 ]
Total events: 90 (Experimental), 47 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
18 Dimethyl fumarate versus glatiramer acetate
CONFIRM 2012 231/707 123/360 100.0 % 0.96 [ 0.80, 1.14 ]
Subtotal (95% CI) 707 360 100.0 % 0.96 [ 0.80, 1.14 ]
Total events: 231 (Experimental), 123 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
19 Alemtuzumab versus interferon beta-1a (Rebif)
CAMMS223 2008 20/223 31/111 10.7 % 0.32 [ 0.19, 0.54 ]
CARE-MS I 2012 65/386 68/195 30.7 % 0.48 [ 0.36, 0.65 ]
CARE-MS II 2012 111/436 122/231 58.6 % 0.48 [ 0.39, 0.59 ]
Subtotal (95% CI) 1045 537 100.0 % 0.46 [ 0.39, 0.55 ]
Total events: 196 (Experimental), 221 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 2.19, df = 2 (P = 0.33); I2 =9%
Test for overall effect: Z = 8.86 (P < 0.00001)
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Analysis 1.2. Comparison 1 Treatment benefit within pairwise comparisons, Outcome 2 Comparisons for
relapses over 24 months.
Review: Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
Comparison: 1 Treatment benefit within pairwise comparisons
Outcome: 2 Comparisons for relapses over 24 months
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Interferon beta-1b (Betaseron) versus placebo
IFNB MS Group 1993 190/249 105/123 100.0 % 0.89 [ 0.81, 0.99 ]
Subtotal (95% CI) 249 123 100.0 % 0.89 [ 0.81, 0.99 ]
Total events: 190 (Experimental), 105 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
2 Interferon beta-1a (Avonex) versus placebo
BRAVO 2014 183/447 223/450 45.1 % 0.83 [ 0.71, 0.96 ]
MSCRG 1996 126/158 120/143 54.9 % 0.95 [ 0.85, 1.06 ]
Subtotal (95% CI) 605 593 100.0 % 0.89 [ 0.76, 1.04 ]
Total events: 309 (Experimental), 343 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.08, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 1.42 (P = 0.16)
3 Interferon beta-1a (Rebif) versus placebo
PRISMS 1998 268/373 159/187 100.0 % 0.85 [ 0.77, 0.92 ]
Subtotal (95% CI) 373 187 100.0 % 0.85 [ 0.77, 0.92 ]
Total events: 268 (Experimental), 159 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.77 (P = 0.00016)
4 Glatiramer acetate versus placebo
Bornstein 1987 11/25 19/25 7.0 % 0.58 [ 0.35, 0.95 ]
CONFIRM 2012 204/360 241/363 51.1 % 0.85 [ 0.76, 0.96 ]
Johnson 1995 89/125 97/126 41.9 % 0.92 [ 0.80, 1.07 ]
Subtotal (95% CI) 510 514 100.0 % 0.86 [ 0.75, 0.98 ]
Total events: 304 (Experimental), 357 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.44, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 2.18 (P = 0.029)
5 Natalizumab versus placebo
AFFIRM 2006 225/627 203/315 100.0 % 0.56 [ 0.49, 0.64 ]
Subtotal (95% CI) 627 315 100.0 % 0.56 [ 0.49, 0.64 ]
Total events: 225 (Experimental), 203 (Control)
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Heterogeneity: not applicable
Test for overall effect: Z = 8.63 (P < 0.00001)
6 Mitoxantrone versus placebo
Millefiorini 1997 10/27 19/24 100.0 % 0.47 [ 0.27, 0.80 ]
Subtotal (95% CI) 27 24 100.0 % 0.47 [ 0.27, 0.80 ]
Total events: 10 (Experimental), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.79 (P = 0.0052)
7 Fingolimod versus placebo
FREEDOMS 2010 396/854 273/418 60.1 % 0.71 [ 0.64, 0.78 ]
FREEDOMS II 2014 308/728 204/355 39.9 % 0.74 [ 0.65, 0.83 ]
Subtotal (95% CI) 1582 773 100.0 % 0.72 [ 0.67, 0.78 ]
Total events: 704 (Experimental), 477 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 8.26 (P < 0.00001)
8 Teriflunomide versus placebo
TEMSO 2011 387/725 220/363 100.0 % 0.88 [ 0.79, 0.98 ]
Subtotal (95% CI) 725 363 100.0 % 0.88 [ 0.79, 0.98 ]
Total events: 387 (Experimental), 220 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.020)
9 Dimethyl fumarate versus placebo
CONFIRM 2012 437/707 241/363 46.5 % 0.93 [ 0.85, 1.02 ]
DEFINE 2012 507/827 295/410 53.5 % 0.85 [ 0.79, 0.92 ]
Subtotal (95% CI) 1534 773 100.0 % 0.89 [ 0.81, 0.97 ]
Total events: 944 (Experimental), 536 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.98, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 2.69 (P = 0.0072)
10 Laquinimod versus placebo
ALLEGRO 2012 317/550 395/556 56.9 % 0.81 [ 0.74, 0.89 ]
BRAVO 2014 201/434 223/450 43.1 % 0.93 [ 0.81, 1.07 ]
Subtotal (95% CI) 984 1006 100.0 % 0.86 [ 0.75, 0.99 ]
Total events: 518 (Experimental), 618 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.94, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 2.09 (P = 0.037)
11 Azathioprine versus placebo
Goodkin 1991 19/30 24/29 100.0 % 0.77 [ 0.56, 1.05 ]
Subtotal (95% CI) 30 29 100.0 % 0.77 [ 0.56, 1.05 ]
Total events: 19 (Experimental), 24 (Control)
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Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
12 Immunoglobulins versus placebo
Achiron 1998 15/20 20/20 55.3 % 0.76 [ 0.58, 0.98 ]
Fazekas 1997 35/75 49/75 44.7 % 0.71 [ 0.53, 0.96 ]
Subtotal (95% CI) 95 95 100.0 % 0.74 [ 0.61, 0.90 ]
Total events: 50 (Experimental), 69 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 3.05 (P = 0.0023)
13 Interferon beta-1a (Avonex) versus interferon beta-1b (Betaseron)
INCOMIN 2002 63/92 49/96 100.0 % 1.34 [ 1.06, 1.71 ]
Subtotal (95% CI) 92 96 100.0 % 1.34 [ 1.06, 1.71 ]
Total events: 63 (Experimental), 49 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.016)
14 Interferon beta-1a (Rebif) versus interferon beta-1b (Betaseron)
Koch-Henriksen 2006 117/143 130/158 100.0 % 0.99 [ 0.89, 1.11 ]
Subtotal (95% CI) 143 158 100.0 % 0.99 [ 0.89, 1.11 ]
Total events: 117 (Experimental), 130 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
15 Glatiramer acetate versus interferon beta-1b (Betaseron)
BECOME 2009 15/39 24/36 41.6 % 0.58 [ 0.36, 0.91 ]
BEYOND 2009 258/448 1023/1796 58.4 % 1.01 [ 0.92, 1.11 ]
Subtotal (95% CI) 487 1832 100.0 % 0.80 [ 0.47, 1.38 ]
Total events: 273 (Experimental), 1047 (Control)
Heterogeneity: Tau2 = 0.13; Chi2 = 5.54, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.80 (P = 0.42)
16 Glatiramer acetate versus interferon beta-1a (Rebif)
REGARD 2008 152/378 168/386 100.0 % 0.92 [ 0.78, 1.09 ]
Subtotal (95% CI) 378 386 100.0 % 0.92 [ 0.78, 1.09 ]
Total events: 152 (Experimental), 168 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
17 Dimethyl fumarate versus glatiramer acetate
CONFIRM 2012 437/707 204/360 100.0 % 1.09 [ 0.98, 1.21 ]
Subtotal (95% CI) 707 360 100.0 % 1.09 [ 0.98, 1.21 ]
Total events: 437 (Experimental), 204 (Control)
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Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
18 Alemtuzumab versus interferon beta-1a (Rebif)
CAMMS223 2008 26/223 40/111 20.8 % 0.32 [ 0.21, 0.50 ]
CARE-MS I 2012 99/386 94/195 36.5 % 0.53 [ 0.43, 0.67 ]
CARE-MS II 2012 170/436 152/231 42.7 % 0.59 [ 0.51, 0.69 ]
Subtotal (95% CI) 1045 537 100.0 % 0.50 [ 0.39, 0.65 ]
Total events: 295 (Experimental), 286 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 6.87, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 5.15 (P < 0.00001)
19 Laquinimod versus interferon beta-1a (Avonex)
BRAVO 2014 201/434 183/447 100.0 % 1.13 [ 0.97, 1.32 ]
Subtotal (95% CI) 434 447 100.0 % 1.13 [ 0.97, 1.32 ]
Total events: 201 (Experimental), 183 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
20 Azathioprine versus interferons beta (Avonex, Rebif or Betaseron)
MAIN TRIAL 38/77 42/73 100.0 % 0.86 [ 0.64, 1.16 ]
Subtotal (95% CI) 77 73 100.0 % 0.86 [ 0.64, 1.16 ]
Total events: 38 (Experimental), 42 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
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disability worsening over 24 months.
Review: Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
Comparison: 1 Treatment benefit within pairwise comparisons
Outcome: 3 Comparisons for disability worsening over 24 months
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Interferon beta-1b (Betaseron) versus placebo
IFNB MS Group 1993 83/249 42/123 100.0 % 0.98 [ 0.72, 1.32 ]
Subtotal (95% CI) 249 123 100.0 % 0.98 [ 0.72, 1.32 ]
Total events: 83 (Experimental), 42 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.88)
2 Interferon beta-1a (Avonex) versus placebo
BRAVO 2014 112/447 144/450 48.0 % 0.78 [ 0.64, 0.97 ]
MSCRG 1996 91/158 85/143 52.0 % 0.97 [ 0.80, 1.17 ]
Subtotal (95% CI) 605 593 100.0 % 0.87 [ 0.70, 1.09 ]
Total events: 203 (Experimental), 229 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.35, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 1.21 (P = 0.23)
3 Interferon beta-1a (Rebif) versus placebo
PRISMS 1998 118/373 77/187 100.0 % 0.77 [ 0.61, 0.96 ]
Subtotal (95% CI) 373 187 100.0 % 0.77 [ 0.61, 0.96 ]
Total events: 118 (Experimental), 77 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
4 Glatiramer acetate versus placebo
Bornstein 1987 5/25 13/25 9.8 % 0.38 [ 0.16, 0.92 ]
CONFIRM 2012 111/360 135/363 53.7 % 0.83 [ 0.68, 1.02 ]
Johnson 1995 42/125 44/126 36.4 % 0.96 [ 0.68, 1.36 ]
Subtotal (95% CI) 510 514 100.0 % 0.81 [ 0.61, 1.09 ]
Total events: 158 (Experimental), 192 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 3.72, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 1.40 (P = 0.16)
5 Natalizumab versus placebo
AFFIRM 2006 137/627 107/315 100.0 % 0.64 [ 0.52, 0.80 ]
Subtotal (95% CI) 627 315 100.0 % 0.64 [ 0.52, 0.80 ]
Total events: 137 (Experimental), 107 (Control)
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Heterogeneity: not applicable
Test for overall effect: Z = 4.05 (P = 0.000051)
6 Mitoxantrone versus placebo
Millefiorini 1997 2/27 9/24 100.0 % 0.20 [ 0.05, 0.83 ]
Subtotal (95% CI) 27 24 100.0 % 0.20 [ 0.05, 0.83 ]
Total events: 2 (Experimental), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P = 0.026)
7 Fingolimod versus placebo
FREEDOMS 2010 228/854 139/418 43.8 % 0.80 [ 0.67, 0.96 ]
FREEDOMS II 2014 290/728 154/355 56.2 % 0.92 [ 0.79, 1.07 ]
Subtotal (95% CI) 1582 773 100.0 % 0.87 [ 0.76, 0.99 ]
Total events: 518 (Experimental), 293 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.32, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 2.15 (P = 0.031)
8 Teriflunomide versus placebo
TEMSO 2011 284/725 163/363 100.0 % 0.87 [ 0.75, 1.01 ]
Subtotal (95% CI) 725 363 100.0 % 0.87 [ 0.75, 1.01 ]
Total events: 284 (Experimental), 163 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
9 Dimethyl fumarate versus placebo
CONFIRM 2012 220/707 135/363 39.7 % 0.84 [ 0.70, 0.99 ]
DEFINE 2012 294/827 186/410 60.3 % 0.78 [ 0.68, 0.90 ]
Subtotal (95% CI) 1534 773 100.0 % 0.80 [ 0.72, 0.90 ]
Total events: 514 (Experimental), 321 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 3.92 (P = 0.000090)
10 Laquinimod versus placebo
ALLEGRO 2012 160/550 195/556 58.7 % 0.83 [ 0.70, 0.99 ]
BRAVO 2014 116/434 144/450 41.3 % 0.84 [ 0.68, 1.03 ]
Subtotal (95% CI) 984 1006 100.0 % 0.83 [ 0.73, 0.95 ]
Total events: 276 (Experimental), 339 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 2.73 (P = 0.0064)
11 Azathioprine versus placebo
Goodkin 1991 8/30 12/29 100.0 % 0.64 [ 0.31, 1.34 ]
Subtotal (95% CI) 30 29 100.0 % 0.64 [ 0.31, 1.34 ]
Total events: 8 (Experimental), 12 (Control)
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Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
12 Immunoglobulins versus placebo
Achiron 1998 4/20 4/20 21.5 % 1.00 [ 0.29, 3.45 ]
Fazekas 1997 12/75 19/75 78.5 % 0.63 [ 0.33, 1.21 ]
Subtotal (95% CI) 95 95 100.0 % 0.70 [ 0.39, 1.24 ]
Total events: 16 (Experimental), 23 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
13 Interferon beta-1a (Avonex) versus interferon beta-1b (Betaseron)
INCOMIN 2002 32/92 15/96 100.0 % 2.23 [ 1.29, 3.83 ]
Subtotal (95% CI) 92 96 100.0 % 2.23 [ 1.29, 3.83 ]
Total events: 32 (Experimental), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.89 (P = 0.0038)
14 Interferon beta-1a (Rebif) versus interferon beta-1b (Betaseron)
Koch-Henriksen 2006 69/143 77/158 100.0 % 0.99 [ 0.78, 1.25 ]
Subtotal (95% CI) 143 158 100.0 % 0.99 [ 0.78, 1.25 ]
Total events: 69 (Experimental), 77 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
15 Glatiramer acetate versus interferon beta-1b (Betaseron)
BECOME 2009 11/39 7/36 2.6 % 1.45 [ 0.63, 3.33 ]
BEYOND 2009 164/448 672/1796 97.4 % 0.98 [ 0.85, 1.12 ]
Subtotal (95% CI) 487 1832 100.0 % 0.99 [ 0.86, 1.13 ]
Total events: 175 (Experimental), 679 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
16 Glatiramer acetate versus interferon beta-1a (Rebif)
REGARD 2008 35/378 62/386 100.0 % 0.58 [ 0.39, 0.85 ]
Subtotal (95% CI) 378 386 100.0 % 0.58 [ 0.39, 0.85 ]
Total events: 35 (Experimental), 62 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.77 (P = 0.0056)
17 Dimethyl fumarate versus glatiramer acetate
CONFIRM 2012 220/707 111/360 100.0 % 1.01 [ 0.83, 1.22 ]
Subtotal (95% CI) 707 360 100.0 % 1.01 [ 0.83, 1.22 ]
Total events: 220 (Experimental), 111 (Control)
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Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.92)
18 Alemtuzumab versus interferon beta-1a (Rebif)
CAMMS223 2008 30/223 43/111 28.5 % 0.35 [ 0.23, 0.52 ]
CARE-MS I 2012 41/386 37/195 28.3 % 0.56 [ 0.37, 0.84 ]
CARE-MS II 2012 61/436 86/231 43.2 % 0.38 [ 0.28, 0.50 ]
Subtotal (95% CI) 1045 537 100.0 % 0.41 [ 0.32, 0.54 ]
Total events: 132 (Experimental), 166 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 3.21, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 6.57 (P < 0.00001)
19 Laquinimod versus interferon beta-1a (Avonex)
BRAVO 2014 116/434 112/447 100.0 % 1.07 [ 0.85, 1.33 ]
Subtotal (95% CI) 434 447 100.0 % 1.07 [ 0.85, 1.33 ]
Total events: 116 (Experimental), 112 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
20 Azathioprine versus interferons beta (Avonex, Rebif or Betaseron)
MAIN TRIAL 22/77 27/73 100.0 % 0.77 [ 0.49, 1.23 ]
Subtotal (95% CI) 77 73 100.0 % 0.77 [ 0.49, 1.23 ]
Total events: 22 (Experimental), 27 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
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Analysis 2.1. Comparison 2 Treatment acceptability within pairwise comparisons, Outcome 1 Comparisons
for treatment discontinuation due to AEs over 12 months.
Review: Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
Comparison: 2 Treatment acceptability within pairwise comparisons
Outcome: 1 Comparisons for treatment discontinuation due to AEs over 12 months
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Interferon beta-1a (Avonex) 30 g versus placebo
MSCRG 1996 7/158 2/143 100.0 % 3.17 [ 0.67, 15.00 ]
Subtotal (95% CI) 158 143 100.0 % 3.17 [ 0.67, 15.00 ]
Total events: 7 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
2 Interferon beta-1a (Rebif) 22 g versus placebo
OWIMS 1999 1/95 0/100 100.0 % 3.16 [ 0.13, 76.54 ]
Subtotal (95% CI) 95 100 100.0 % 3.16 [ 0.13, 76.54 ]
Total events: 1 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
3 Interferon beta-1a (Rebif) 44 g versus placebo
OWIMS 1999 5/98 0/100 100.0 % 11.22 [ 0.63, 200.27 ]
Subtotal (95% CI) 98 100 100.0 % 11.22 [ 0.63, 200.27 ]
Total events: 5 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
4 Glatiramer acetate 20 mg daily versus placebo
Comi 2001 3/119 2/120 100.0 % 1.51 [ 0.26, 8.89 ]
Subtotal (95% CI) 119 120 100.0 % 1.51 [ 0.26, 8.89 ]
Total events: 3 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
5 Glatiramer 40 mg three times per week versus placebo
GALA 2013 29/943 6/461 100.0 % 2.36 [ 0.99, 5.65 ]
Subtotal (95% CI) 943 461 100.0 % 2.36 [ 0.99, 5.65 ]
Total events: 29 (Experimental), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.053)
6 Teriflunomide 7 mg versus placebo
TOWER 2014 54/408 25/389 100.0 % 2.06 [ 1.31, 3.24 ]
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Subtotal (95% CI) 408 389 100.0 % 2.06 [ 1.31, 3.24 ]
Total events: 54 (Experimental), 25 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.12 (P = 0.0018)
7 Teriflunomide 14 mg versus placebo
TOWER 2014 60/372 25/389 100.0 % 2.51 [ 1.61, 3.91 ]
Subtotal (95% CI) 372 389 100.0 % 2.51 [ 1.61, 3.91 ]
Total events: 60 (Experimental), 25 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.06 (P = 0.000049)
8 Pegylated interferon beta-1a every 4 weeks versus placebo
ADVANCE 2014 25/500 9/500 100.0 % 2.78 [ 1.31, 5.89 ]
Subtotal (95% CI) 500 500 100.0 % 2.78 [ 1.31, 5.89 ]
Total events: 25 (Experimental), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0077)
9 Pegylated interferon beta-1a every 2 weeks versus placebo
ADVANCE 2014 26/512 9/500 100.0 % 2.82 [ 1.34, 5.96 ]
Subtotal (95% CI) 512 500 100.0 % 2.82 [ 1.34, 5.96 ]
Total events: 26 (Experimental), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.72 (P = 0.0066)
10 Daclizumab 150 mg versus placebo
SELECT 2013 7/208 2/204 100.0 % 3.43 [ 0.72, 16.33 ]
Subtotal (95% CI) 208 204 100.0 % 3.43 [ 0.72, 16.33 ]
Total events: 7 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
11 Daclizumab 300 mg versus placebo
SELECT 2013 9/209 2/204 100.0 % 4.39 [ 0.96, 20.08 ]
Subtotal (95% CI) 209 204 100.0 % 4.39 [ 0.96, 20.08 ]
Total events: 9 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.056)
12 Immunoglobulins 0.2 g versus placebo
Fazekas 2008 1/87 0/41 49.3 % 1.43 [ 0.06, 34.41 ]
Lewanska 2002 1/17 0/18 50.7 % 3.17 [ 0.14, 72.80 ]
Subtotal (95% CI) 104 59 100.0 % 2.14 [ 0.23, 19.96 ]
Total events: 2 (Experimental), 0 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
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Test for overall effect: Z = 0.67 (P = 0.50)
13 Immunoglobulins 0.4 g versus placebo
Lewanska 2002 1/16 0/18 100.0 % 3.35 [ 0.15, 76.93 ]
Subtotal (95% CI) 16 18 100.0 % 3.35 [ 0.15, 76.93 ]
Total events: 1 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
14 Interferon beta-1a (Rebif) 44 g versus interferon beta-1a (Avonex) 30 g
EVIDENCE 2007 19/339 18/338 100.0 % 1.05 [ 0.56, 1.97 ]
Subtotal (95% CI) 339 338 100.0 % 1.05 [ 0.56, 1.97 ]
Total events: 19 (Experimental), 18 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
15 Fingolimod 0.5 mg versus interferon beta-1a (Avonex) 30 g
TRASFORMS 2010 27/431 19/435 100.0 % 1.43 [ 0.81, 2.54 ]
Subtotal (95% CI) 431 435 100.0 % 1.43 [ 0.81, 2.54 ]
Total events: 27 (Experimental), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
16 Fingolimod 1.25 mg versus interferon beta-1a (Avonex) 30 g
TRASFORMS 2010 44/426 19/435 100.0 % 2.36 [ 1.40, 3.98 ]
Subtotal (95% CI) 426 435 100.0 % 2.36 [ 1.40, 3.98 ]
Total events: 44 (Experimental), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.24 (P = 0.0012)
17 Teriflunomide 7 mg versus interferon beta-1a (Rebif) 44 g
TENERE 2014 9/109 22/104 100.0 % 0.39 [ 0.19, 0.81 ]
Subtotal (95% CI) 109 104 100.0 % 0.39 [ 0.19, 0.81 ]
Total events: 9 (Experimental), 22 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.53 (P = 0.011)
18 Teriflunomide 14 mg versus interferon beta-1a (Rebif) 44 g
TENERE 2014 12/111 22/104 100.0 % 0.51 [ 0.27, 0.98 ]
Subtotal (95% CI) 111 104 100.0 % 0.51 [ 0.27, 0.98 ]
Total events: 12 (Experimental), 22 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.043)
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Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
19 Azathioprine versus interferons beta (Avonex, Rebif or Betaseron)
Etemadifar 2007 3/47 3/47 100.0 % 1.00 [ 0.21, 4.70 ]
Subtotal (95% CI) 47 47 100.0 % 1.00 [ 0.21, 4.70 ]
Total events: 3 (Experimental), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 45.92, df = 18 (P = 0.00), I2 =61%
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Analysis 2.2. Comparison 2 Treatment acceptability within pairwise comparisons, Outcome 2 Comparisons
for treatment discontinuation due to AEs over 24 months.
Review: Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
Comparison: 2 Treatment acceptability within pairwise comparisons
Outcome: 2 Comparisons for treatment discontinuation due to AEs over 24 months
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Interferon beta-1b (Betaseron) 50 g versus placebo
IFNB MS Group 1993 5/125 1/123 100.0 % 4.92 [ 0.58, 41.51 ]
Subtotal (95% CI) 125 123 100.0 % 4.92 [ 0.58, 41.51 ]
Total events: 5 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
2 Interferon beta-1b (Betaseron) 250 g versus placebo
IFNB MS Group 1993 10/124 1/123 100.0 % 9.92 [ 1.29, 76.32 ]
Subtotal (95% CI) 124 123 100.0 % 9.92 [ 1.29, 76.32 ]
Total events: 10 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
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Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Interferon beta-1a (Avonex) 30 g versus placebo
BRAVO 2014 27/447 19/450 100.0 % 1.43 [ 0.81, 2.54 ]
Subtotal (95% CI) 447 450 100.0 % 1.43 [ 0.81, 2.54 ]
Total events: 27 (Experimental), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
4 Interferon beta-1a (Rebif) 22 g versus placebo
PRISMS 1998 7/189 3/187 100.0 % 2.31 [ 0.61, 8.79 ]
Subtotal (95% CI) 189 187 100.0 % 2.31 [ 0.61, 8.79 ]
Total events: 7 (Experimental), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
5 Interferon beta-1a (Rebif) 44 g versus placebo
PRISMS 1998 9/184 3/187 100.0 % 3.05 [ 0.84, 11.08 ]
Subtotal (95% CI) 184 187 100.0 % 3.05 [ 0.84, 11.08 ]
Total events: 9 (Experimental), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.090)
6 Glatiramer acetate 20 mg daily versus placebo
Bornstein 1987 2/25 0/25 14.1 % 5.00 [ 0.25, 99.16 ]
CONFIRM 2012 36/360 39/363 62.9 % 0.93 [ 0.61, 1.43 ]
Johnson 1995 5/125 1/126 23.0 % 5.04 [ 0.60, 42.53 ]
Subtotal (95% CI) 510 514 100.0 % 1.74 [ 0.49, 6.13 ]
Total events: 43 (Experimental), 40 (Control)
Heterogeneity: Tau2 = 0.61; Chi2 = 3.48, df = 2 (P = 0.18); I2 =43%
Test for overall effect: Z = 0.86 (P = 0.39)
7 Natalizumab versus placebo
AFFIRM 2006 58/627 19/315 100.0 % 1.53 [ 0.93, 2.53 ]
Subtotal (95% CI) 627 315 100.0 % 1.53 [ 0.93, 2.53 ]
Total events: 58 (Experimental), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.094)
8 Mitoxantrone versus placebo
Millefiorini 1997 5/27 0/24 100.0 % 9.82 [ 0.57, 168.84 ]
Subtotal (95% CI) 27 24 100.0 % 9.82 [ 0.57, 168.84 ]
Total events: 5 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
9 Fingolimod 0.5 mg versus placebo
FREEDOMS 2010 38/425 34/418 46.8 % 1.10 [ 0.71, 1.71 ]
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Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
FREEDOMS II 2014 66/358 37/355 53.2 % 1.77 [ 1.22, 2.57 ]
Subtotal (95% CI) 783 773 100.0 % 1.42 [ 0.89, 2.25 ]
Total events: 104 (Experimental), 71 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 2.58, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 1.46 (P = 0.14)
10 Fingolimod 1.25 mg versus placebo
FREEDOMS 2010 70/429 34/418 47.6 % 2.01 [ 1.36, 2.95 ]
FREEDOMS II 2014 72/370 37/355 52.4 % 1.87 [ 1.29, 2.70 ]
Subtotal (95% CI) 799 773 100.0 % 1.93 [ 1.48, 2.52 ]
Total events: 142 (Experimental), 71 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 4.84 (P < 0.00001)
11 Teriflunomide 7 mg versus placebo
TEMSO 2011 36/366 29/363 100.0 % 1.23 [ 0.77, 1.96 ]
Subtotal (95% CI) 366 363 100.0 % 1.23 [ 0.77, 1.96 ]
Total events: 36 (Experimental), 29 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
12 Teriflunomide 14 mg versus placebo
TEMSO 2011 39/359 29/363 100.0 % 1.36 [ 0.86, 2.15 ]
Subtotal (95% CI) 359 363 100.0 % 1.36 [ 0.86, 2.15 ]
Total events: 39 (Experimental), 29 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
13 Dimethyl fumarate 480 mg versus placebo
CONFIRM 2012 44/362 39/363 39.9 % 1.13 [ 0.75, 1.70 ]
DEFINE 2012 66/411 55/410 60.1 % 1.20 [ 0.86, 1.67 ]
Subtotal (95% CI) 773 773 100.0 % 1.17 [ 0.91, 1.51 ]
Total events: 110 (Experimental), 94 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
14 Dimethyl fumarate 720 mg versus placebo
CONFIRM 2012 42/345 39/363 38.9 % 1.13 [ 0.75, 1.71 ]
DEFINE 2012 69/416 55/410 61.1 % 1.24 [ 0.89, 1.71 ]
Subtotal (95% CI) 761 773 100.0 % 1.20 [ 0.93, 1.54 ]
Total events: 111 (Experimental), 94 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
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Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
15 Laquinimod versus placebo
ALLEGRO 2012 42/550 28/556 62.6 % 1.52 [ 0.95, 2.41 ]
BRAVO 2014 22/434 19/450 37.4 % 1.20 [ 0.66, 2.19 ]
Subtotal (95% CI) 984 1006 100.0 % 1.39 [ 0.96, 2.00 ]
Total events: 64 (Experimental), 47 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.079)
16 Azathioprine versus placebo
Goodkin 1991 6/30 1/29 100.0 % 5.80 [ 0.74, 45.26 ]
Subtotal (95% CI) 30 29 100.0 % 5.80 [ 0.74, 45.26 ]
Total events: 6 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.094)
17 Immunoglobulins 0.15 to 0.20 g versus placebo
Fazekas 1997 3/75 1/75 100.0 % 3.00 [ 0.32, 28.19 ]
Subtotal (95% CI) 75 75 100.0 % 3.00 [ 0.32, 28.19 ]
Total events: 3 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
18 Interferon beta-1a (Avonex) 30 g versus interferon beta-1b (Betaseron) 250 g
INCOMIN 2002 1/92 5/96 100.0 % 0.21 [ 0.02, 1.75 ]
Subtotal (95% CI) 92 96 100.0 % 0.21 [ 0.02, 1.75 ]
Total events: 1 (Experimental), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
19 Glatiramer acetate 20 mg daily versus interferon beta-1b (Betaseron) 250 g
BECOME 2009 2/39 3/36 19.1 % 0.62 [ 0.11, 3.47 ]
BEYOND 2009 9/448 13/897 80.9 % 1.39 [ 0.60, 3.22 ]
Subtotal (95% CI) 487 933 100.0 % 1.19 [ 0.56, 2.53 ]
Total events: 11 (Experimental), 16 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
20 Glatiramer acetate 20 mg daily versus interferon beta-1b (Betaseron) 500 g
BEYOND 2009 9/448 23/899 100.0 % 0.79 [ 0.37, 1.68 ]
Subtotal (95% CI) 448 899 100.0 % 0.79 [ 0.37, 1.68 ]
Total events: 9 (Experimental), 23 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
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n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
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21 Glatiramer acetate 20 mg daily versus interferon beta-1a (Rebif) 44 g
REGARD 2008 19/378 23/386 100.0 % 0.84 [ 0.47, 1.52 ]
Subtotal (95% CI) 378 386 100.0 % 0.84 [ 0.47, 1.52 ]
Total events: 19 (Experimental), 23 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
22 Dimethyl fumarate 480 mg versus glatiramer acetate 20 mg daily
CONFIRM 2012 44/362 36/360 100.0 % 1.22 [ 0.80, 1.84 ]
Subtotal (95% CI) 362 360 100.0 % 1.22 [ 0.80, 1.84 ]
Total events: 44 (Experimental), 36 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
23 Dimethyl fumarate 720 mg versus glatiramer acetate 20 mg daily
CONFIRM 2012 42/345 36/360 100.0 % 1.22 [ 0.80, 1.85 ]
Subtotal (95% CI) 345 360 100.0 % 1.22 [ 0.80, 1.85 ]
Total events: 42 (Experimental), 36 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
24 Alemtuzumab 12 mg versus interferon beta-1a (Rebif) 44 g
CAMMS223 2008 3/113 13/111 19.5 % 0.23 [ 0.07, 0.77 ]
CARE-MS I 2012 6/386 11/195 29.1 % 0.28 [ 0.10, 0.73 ]
CARE-MS II 2012 16/436 15/231 51.4 % 0.57 [ 0.28, 1.12 ]
Subtotal (95% CI) 935 537 100.0 % 0.38 [ 0.22, 0.68 ]
Total events: 25 (Experimental), 39 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.37, df = 2 (P = 0.31); I2 =16%
Test for overall effect: Z = 3.28 (P = 0.0010)
25 Alemtuzumab 24 mg versus interferon beta-1a (Rebif) 44 g
CAMMS223 2008 2/110 13/111 39.3 % 0.16 [ 0.04, 0.67 ]
CARE-MS II 2012 6/173 15/231 60.7 % 0.53 [ 0.21, 1.35 ]
Subtotal (95% CI) 283 342 100.0 % 0.33 [ 0.10, 1.09 ]
Total events: 8 (Experimental), 28 (Control)
Heterogeneity: Tau2 = 0.39; Chi2 = 2.00, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 1.82 (P = 0.069)
26 Laquinimod versus interferon beta-1a (Avonex) 30 g
BRAVO 2014 22/434 27/447 100.0 % 0.84 [ 0.49, 1.45 ]
Subtotal (95% CI) 434 447 100.0 % 0.84 [ 0.49, 1.45 ]
Total events: 22 (Experimental), 27 (Control)
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n/N n/N
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H,Random,95%
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M-
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CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
27 Azathioprine versus interferons beta (Avonex, Rebif or Betaseron)
MAIN TRIAL 14/77 6/73 100.0 % 2.21 [ 0.90, 5.45 ]
Subtotal (95% CI) 77 73 100.0 % 2.21 [ 0.90, 5.45 ]
Total events: 14 (Experimental), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.084)
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Analysis 3.1. Comparison 3 Treatment safety against placebo within pairwise comparisons, Outcome 1
Serious adverse events.
Review: Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
Comparison: 3 Treatment safety against placebo within pairwise comparisons
Outcome: 1 Serious adverse events
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Interferons beta (Avonex, Rebif or Betaseron) versus placebo
MSCRG 1996 25/158 14/143 40.2 % 1.62 [ 0.87, 2.99 ]
OWIMS 1999 7/98 3/100 16.9 % 2.38 [ 0.63, 8.94 ]
PRISMS 1998 19/184 25/187 42.9 % 0.77 [ 0.44, 1.35 ]
Subtotal (95% CI) 440 430 100.0 % 1.26 [ 0.67, 2.37 ]
Total events: 51 (Experimental), 42 (Control)
Heterogeneity: Tau2 = 0.16; Chi2 = 4.28, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 0.71 (P = 0.48)
2 Glatiramer acetate versus placebo
Comi 2001 10/119 6/120 90.5 % 1.68 [ 0.63, 4.48 ]
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Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Johnson 1995 2/125 0/126 9.5 % 5.04 [ 0.24, 103.93 ]
Subtotal (95% CI) 244 246 100.0 % 1.87 [ 0.73, 4.74 ]
Total events: 12 (Experimental), 6 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
3 Natalizumab versus placebo
AFFIRM 2006 81/627 34/312 100.0 % 1.19 [ 0.81, 1.73 ]
Subtotal (95% CI) 627 312 100.0 % 1.19 [ 0.81, 1.73 ]
Total events: 81 (Experimental), 34 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.38)
4 Fingolimod versus placebo
FREEDOMS 2010 49/429 57/418 51.3 % 0.84 [ 0.59, 1.20 ]
FREEDOMS II 2014 53/370 45/355 48.7 % 1.13 [ 0.78, 1.64 ]
Subtotal (95% CI) 799 773 100.0 % 0.97 [ 0.72, 1.30 ]
Total events: 102 (Experimental), 102 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.30, df = 1 (P = 0.25); I2 =23%
Test for overall effect: Z = 0.21 (P = 0.83)
5 Teriflunomide versus placebo
TEMSO 2011 54/358 43/360 100.0 % 1.26 [ 0.87, 1.83 ]
Subtotal (95% CI) 358 360 100.0 % 1.26 [ 0.87, 1.83 ]
Total events: 54 (Experimental), 43 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
6 Dimethyl fumarate versus placebo
CONFIRM 2012 25/344 29/363 47.8 % 0.91 [ 0.54, 1.52 ]
DEFINE 2012 34/416 26/408 52.2 % 1.28 [ 0.78, 2.10 ]
Subtotal (95% CI) 760 771 100.0 % 1.09 [ 0.76, 1.55 ]
Total events: 59 (Experimental), 55 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
7 Pegylated interferon beta-1a versus placebo
ADVANCE 2014 25/512 25/500 100.0 % 0.98 [ 0.57, 1.68 ]
Subtotal (95% CI) 512 500 100.0 % 0.98 [ 0.57, 1.68 ]
Total events: 25 (Experimental), 25 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
8 Daclizumab versus placebo
SELECT 2013 19/209 12/204 100.0 % 1.55 [ 0.77, 3.10 ]
Subtotal (95% CI) 209 204 100.0 % 1.55 [ 0.77, 3.10 ]
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Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 19 (Experimental), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
9 Laquinimod versus placebo
ALLEGRO 2012 61/550 53/556 52.8 % 1.16 [ 0.82, 1.65 ]
BRAVO 2014 40/433 52/449 47.2 % 0.80 [ 0.54, 1.18 ]
Subtotal (95% CI) 983 1005 100.0 % 0.97 [ 0.67, 1.41 ]
Total events: 101 (Experimental), 105 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.00, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 0.14 (P = 0.89)
10 Immunoglobulins versus placebo
Fazekas 2008 2/42 3/41 100.0 % 0.65 [ 0.11, 3.70 ]
Subtotal (95% CI) 42 41 100.0 % 0.65 [ 0.11, 3.70 ]
Total events: 2 (Experimental), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
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A D D I T I O N A L T A B L E S
Table 1. Assessment of adverse events monitoring
Study Risk of bias Did the researchers actively
monitor for adverse events
(AEs) or did they sim-
ply provide spontaneous
reporting of AEs that arose?
Risk of bias Did the authors define serious AEs (SAEs)
according to an accepted international
classification and report the number of
SAEs?
Achiron 1998 Unclear Not reported High SAEs not reported
ADVANCE 2014 Unclear Not reported Low Categorisation of SAEs conformed to ICH
guidelines (International Conference on
Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Hu-
man Use)
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Table 1. Assessment of adverse events monitoring (Continued)
AFFIRM 2006 Low “Treating neurologists were re-
sponsible for all aspects of pa-
tient care, including the man-
age-
ment of adverse events”.Partic-
ipants“visited the clinic every
12 weeks for ... blood chemi-
cal and hematologic analyses,
evaluation of adverse events...
” (Page 901)
Unclear Insufficient information on SAEs definition
ALLEGRO 2012 Low “Safety assessments were per-
formed at screening, at base-
line, and every 3 months until
month 24” (Page 1002)
Low Categorisation of SAEs conformed to ICH
guidelines (International Conference on
Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Hu-
man Use)
BECOME 2009 Low “After the initial interim anal-
ysis failed to raise any sa-
fety concerns with the use of
monthly triple dose gadolin-
ium, all patients still in the
study were offered the option of
obtaining additional monthly
MRI scans for a second year of
treatment” (Page 1977)
High SAEs not reported
BEYOND 2009 Low “Clinic visits were scheduled
every 3 months to assess ... sa-
fety, and tolerability. The oc-
currence of new neurological
symptoms and adverse events
was assessed by telephone, 6
weeks after each visit” (Page
891)
Low Categorisation of SAEs conformed to ICH
guidelines (International Conference on
Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Hu-
man Use)
Bornstein 1987 High “Self-evaluation reported to a
clinical assistant” (Page 409)
High SAEs not reported
BRAVO 2014 Low “Patients were evaluated at
12 scheduled visits: months
-1 (screening), 0 (baseline),
1, 2, 3, 6, 9, 12, 15, 18,
21, and 24. Safety assess-
ments (laboratory measures,
vital signs) were performed at
all visits, and electrocardio-
grams (ECGs) were performed
Unclear Insufficient information on SAEs definition
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Table 1. Assessment of adverse events monitoring (Continued)
at months -1, 0, 1, 2, 3, 6, 12,
18, and 24/early termination”
(Page 775)
CAMMS223 2008 Low “Safety was assessed quarterly
by
the treating neurologist, who
was aware of study-group as-
signment” (Page 1787), “Thy-
roid function and levels of an-
tithyrotropinreceptor antibod-
ies and lymphocyte subpopula-
tions were measured quarterly
at a central laboratory”, and
“All adverse events with an on-
set up to 36 months are re-
ported. In addition, all seri-
ous adverse events and autoim-
mune-associated disorders oc-
curring beforeMarch 1, 2008,
are listed” (Page 1788)
Low Categorisation of SAEs conformed to ICH
guidelines (International Conference on
Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Hu-
man Use)
CARE-MS I 2012 Low “To assess safety, we undertook
monthly questionnaire follow-
up of patients, and did com-
plete blood counts, serum cre-
atinine, urinalysis, and mi-
croscopy monthly (every three
months in patients in the in-
terferon beta 1a group), and
thyroid function tests every
3 months”, “Circulating lym-
phocyte subsets were assessed
every 3 months in all pa-
tients and 1month after alem-
tuzumab administration. We
screened for antialemtuzumab
antibodies with a bridging
ELISA before and at 1 month,
3months, and 12months after
each dosing”, and “We mea-
sured interferon beta 1a-neu-
tralising antibodies at baseline
and at 24 months with a cyto-
pathic effect inhibition assay”
(Page 1821)
Low Categorisation of SAEs conformed to ICH
guidelines (International Conference on
Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Hu-
man Use)
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Table 1. Assessment of adverse events monitoring (Continued)
CARE-MS II 2012 Low “To assess safety, we undertook
monthly questionnaire follow-
up of patients, and did com-
plete blood counts, serum cre-
atinine, and urinalysis with
microscopy monthly (every 3
months in patients in the in-
terferon beta 1a group), and
thyroid function tests every 3
months”, “We assessed circu-
lating lymphocyte subsets ev-
ery 3 months in all patients
and 1month after every course
of alemtuzumab. We screened
for anti-alemtuzumab anti-
bodies with ELISA before and
at 1 month, 3 months and 12
months after each dosing”, and
“We measured interferon beta
1a-neutralising antibodies at
baseline and at 24 months
with a cytopathic effect inhibi-
tion assay” (Page 1832)
Low Categorisation of SAEs conformed to ICH
guidelines (International Conference on
Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Hu-
man Use)
CombiRx 2013 Low “Safety was assessed by record-
ing all adverse events, serious
and nonserious” (Page 329)
Unclear No information on SAE definition
Comi 2001 Unclear “The treating physician mon-
itored safety...” (Page 291)
Unclear Insufficient information on SAEs definition
CONFIRM 2012 Low “Throughout the course of the
study, every effort was made
to remain alert to possible ad-
verse events (AEs)” and “Any
AE or SAE experienced by the
subject was recorded on the
CRF, regardless of the severity
of the event or its relationship
to study treatment” (Pages 66-
7 of Protocol)
Low Categorisation of SAEs conformed to ICH
guidelines (International Conference on
Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Hu-
man Use)
DEFINE 2012 Low “Study visits were scheduled
every 4 weeks for safety assess-
ments, including the monitor-
ing of laboratory values” (Page
1100)
Low Categorisation of SAEs conformed to ICH
guidelines (International Conference on
Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Hu-
man Use)
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Table 1. Assessment of adverse events monitoring (Continued)
Etemadifar 2007 Low “Adverse events, vital signs
and blood tests were monitored
monthly” (Page 1724)
High SAEs not reported
EVIDENCE 2007 High “Adverse events were deter-
mined by spontaneous report-
ing and monthly laboratory
testing during the comparative
phase” (Page 2031)
Unclear Insufficient information on SAEs definition
Fazekas 1997 Low Participants “asked about sa-
fety monthly...” (Page 590)
High SAEs not reported
Fazekas 2008 Unclear Not reported Unclear Insufficient information on SAEs definition
FREEDOMS 2010 Low “An independent data and sa-
fety monitoring board evalu-
ated the safety” and “Study
visits, including safety assess-
ments, were scheduled at 2
weeks and 1, 2, 3, 6, 9, 12, 15,
18, 21, and 24 months after
randomization” (Page 389)
Low Categorisation of SAEs conformed to ICH
guidelines (International Conference on
Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Hu-
man Use)
FREEDOMS II 2014 Low “...safety assessments,
were scheduled at 2 weeks and
1, 2, 3, 6, 9, 12, 15, 18, 21,
and 24 months after random-
ization” (Appendix, Page 2)
Low Categorisation of SAEs conformed to ICH
guidelines (International Conference on
Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Hu-
man Use)
GALA 2013 Low “Safety assessments included
adverse events (AEs), standard
clinical laboratory tests, vital
signs, and electrocardiographic
(ECG) measurements” (Page
707)
Unclear No information on SAE definition
Goodkin 1991 High “Side effect were reported to
the treating neurologist every 6
months” (Page 21)
High SAEs not reported
IFNB MS Group 1993 Low “Treating neurologist reviewed
side effects, laboratory findings
for toxicity ...” (Page 656)
High SAEs not reported
INCOMIN 2002 Low “Safety assessments included
adverse events, vital signs,
physical examination, and
High SAEs not reported
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Table 1. Assessment of adverse events monitoring (Continued)
concomitant medications. Pa-
tients underwent haematology
and biochemical tests, includ-
ing liver-function tests, every 2
weeks for the first 8 weeks, and
then every 3 months” (Page
1455)
Johnson 1995 Low “The evaluating
physician monitored safety ev-
ery 3 month...” (Page 1270)
Unclear Insufficient information on SAEs definition
Koch-Henriksen 2006 Low “Patients were interviewed
about side effects and had
routine blood tests including
hematology and liver function
tests every 3 months and thy-
roid tests and neutralizing an-
tibodies every 6 months” (Page
1057)
High SAEs not reported
Lewanska 2002 Unclear “Laboratory safety examina-
tions were made at the begin-
ning and at the end of the study
period” (Page 566)
Unclear Insufficient information on SAEs definition
MAIN TRIAL Low “At scheduled (quarterly) and
unscheduled (i.e., at the on-
set of new symptoms or com-
plications) follow-up visits the
treating neurologist recorded
symptoms, blood test results,
clinical AEs and theirmanage-
ment”
Low Categorisation of SAEs conformed to ICH
guidelines (International Conference on
Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Hu-
man Use)
Millefiorini 1997 Low “The safety of the treatment
was assessed on the basis of ad-
verse events volunteered by the
patient either spontaneously or
on questioning and monitor-
ing of the main laboratory pa-
rameters” (Page 155)
Unclear Insufficient information on SAEs definition
MSCRG 1996 Low “Study visits were scheduled at
baseline and every 6 months.
Treating physicians reviewed
toxicity test results, examined
patients, and made all medi-
cal decision” (Page 286)
Unclear Insufficient information on SAEs definition
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Table 1. Assessment of adverse events monitoring (Continued)
OWIMS 1999 Unclear “The treating
physician recorded and treated
AEs...” (Page 680)
Unclear Insufficient information on SAEs definition
PRISMS 1998 Unclear “A “treating” neurologist was
responsible for overall medi-
cal management of the pa-
tient, including treatment of
any side-effects” (Page 1499)
Unclear Insufficient information on SAEs definition
REGARD 2008 Unclear “Adverse events (including
pregnancy), withdrawals ow-
ing to adverse events, serious
adverse events, and laboratory
results were obtained for safety
comparisons” (Page 905)
Unclear Insufficient information on SAEs definition
SELECT 2013 Low “Safety parameters were as-
sessed at all visits” (Page 2168)
Unclear No information on SAE definition
TEMSO 2011 Low “A treating neurologist at each
site was responsible for record-
ing and managing adverse
events and monitoring sa-
fety assessments” and “Safety
was evaluated on the basis
of adverse events reported by
study participants or investiga-
tors. Laboratory tests were per-
formed at the time of screen-
ing, at baseline, every 2 weeks
for the first 24 weeks, and then
every 6 weeks until study com-
pletion. Physical and neuro-
logic examinations were per-
formed at week 12 and then
every 24 weeks. An abdominal
ultrasonographic examination
to asses for pancreatic abnor-
malities was performed before
the study and then every 24
weeks, because of previous in-
frequent reports of pancreati-
tis associated with leflunomide
use” (Pages 1294-5)
Low Categorisation of SAEs conformed to ICH
guidelines (International Conference on
Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Hu-
man Use)
TENERE 2014 Low “Safety and tolerability were
assessed using AE reporting, vi-
Low Categorisation of SAEs conformed to ICH
guidelines (International Conference on
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Table 1. Assessment of adverse events monitoring (Continued)
tal signs and laboratory as-
sessments. Adverse event re-
ports were collected at ran-
domisation, Weeks 2, 6, 12,
18, 24, 36 and every 12
weeks thereafter. Vital signs
were documented at screen-
ing, randomisation and every
12 weeks thereafter; clinical
laboratory results were assessed
throughout the study. Adverse
events and vital signs were also
recorded during unscheduled
relapse visits” (Page 707)
Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Hu-
man Use) [information provided on request
by Genzyme]
TOWER 2014 Low “Safety was assessed through
adverse event reporting (upon
occurrence), clinical labora-
tory tests (every 2 weeks until
week 24, then every 6 weeks
while still on treatment), vi-
tal signs (at weeks 2 and 6,
then every 6 weeks until week
24, then every 12 weeks while
still on treatment), abdomi-
nal ultrasonography (at week
24, then every 24 weeks), and
electrocardiography (at base-
line and end of treatment)”
(Page 248)
Low Categorisation of SAEs conformed to ICH
guidelines (International Conference on
Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Hu-
man Use)
TRASFORMS 2010 Low “An independent data and sa-
fety monitoring board evalu-
ated overall safety in the fin-
golimod phase 3 program” and
“Safety assessments were con-
ducted during screening, at
baseline, and at months 1, 2,
3, 6, 9, and 12” (Page 404)
Low Categorisation of SAEs conformed to ICH
guidelines (International Conference on
Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Hu-
man Use)
Table 2. Subgroup analyses: network meta-analysis estimates for relapse outcome over 24 months for the three best drugs
based on moderate to high quality evidence
Interven-
tion
Subgroup analysis by
Diagnostic criteria
RR (95% CI)
Previous treatments
RR (95% CI)
Definition of relapse
RR (95% CI)
Pre-trial relapse rate
RR (95% CI)
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Table 2. Subgroup analyses: network meta-analysis estimates for relapse outcome over 24 months for the three best drugs
based on moderate to high quality evidence (Continued)
Poser crite-
ria
McDonald
criteria
No Yes 24-hour
definition
48-hour
definition
≥ 1 during
the year
before ran-
domisation
≥ 2 dur-
ing the 2/3
years
before ran-
domisation
Alem-
tuzumab
- 0.48 (0.33
to 0.68)
0.46 (0.28
to 0.76)
0.47 (0.27
to 0.79)
- 0.46 (0.27
to 0.78)
0.63 (0.48
to 0.81)
0.28 (0.16
to 0.49)
Natal-
izumab
- 0.56 (0.45
to 0.69)
- 0.70 (0.56
to 0.88)
0.63 (0.52
to 0.77)
- 0.68 (0.54
to 0.85)
-
Fingolimod - 0.72 (0.63
to 0.83)
- 0.72 (0.65
to 0.80)
0.81 (0.67
to 0.97)
- - 0.72 (0.60
to 0.87)
CI: confidence interval; NMA: network meta-analysis; RR: risk ratio.
Table 3. Sensitivity analyses: NMA estimates for relapse outcome over 24 months for the three best drugs based on moderate
to high quality evidence
Intervention Sensitivity analysis
Including only trials of low risk of
bias
RR (95% CI)
Excluding studies that did not pro-
vide complete
and clear reporting of dropout data
RR (95% CI)
Excluding trials with a total sample
size of
fewer than 50 randomised partici-
pants
RR (95% CI)
Alemtuzumab - 0.47 (0.35 to 0.63) 0.46 (0.39 to 0.56)
Natalizumab 0.66 (0.54 to 0.81) - 0.56 (0.47 to 0.66)
Fingolimod - 0.72 (0.65 to 0.80) 0.72 (0.64 to 0.81)
CI: confidence interval; NMA: network meta-analysis; RR: risk ratio.
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A P P E N D I C E S
Appendix 1. Keywords for searching the Cochrane Multiple Sclerosis Group Register
{interferon\*} OR {interferon beta} OR {beta-1 interferon} OR {beta 1 interferon} OR {interferon beta-1\*} OR {rebif } OR {avonex}
OR {Betaseron} OR {beta-seron} OR {betaferon} OR {beta-IFN-1\*} OR {interferon beta-1\*} OR {Interferon-beta\*} OR {interferon
beta\*} OR {recombinant interferon beta-1\*} OR {beta-1a interferon} OR {beta 1a interferon} OR {interferon beta-1a} OR {beta 1b
interferon} OR {interferon beta1b } OR {IFNb-1b} OR {IFNbeta-1b} OR {interferon beta-1b} OR {novantrone} OR {novantron}
OR {onkotrone} OR {pralifan} OR {mitozantrone} OR {mitoxantrone} OR {copolymer-1} OR {cop-1} OR {copaxone} OR {glati-
ramer acetate} OR {cpx} OR {cop1} OR {copolymer} OR {glatiramer} OR {immunomodulation\*} OR {immunomodulator\*} OR
{immunosuppression} OR {antegren} OR {natalizumab} OR {tysabri} OR {monoclonal antibody*} OR {Antibodies, Monoclonal} OR
{fingolimod} OR {FTY720} OR {FTY 720} OR {fingolimod hydrochloride} OR {FTY-720} OR {2-amino-2-(2-(4-octylphenyl)ethyl)-
1,3-propanediol hydrochloride} OR {Gilenya} OR {sphingosine-fosphate-receptor antagonist} OR {HMR1726} OR {A77 1726} OR
{Leflunomide} OR {Arava} OR {teriflunomide} OR {TFN} OR {teriflunomide-D4} OR {A771726} OR {Dihydroorotate dehydroge-
nase (DHODH) inhibitors} OR {(Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide} OR {dimethylfumarate} OR
{Fumaderm}OR {FAG201} OR {FAG201} OR {FAG-201} OR {BG 00012} OR {BG00012} OR {BG-00012} OR {BG 12 compound}
OR {BG12 compound} OR {BG-12 compound} OR {BG-12} OR {tecfidera} OR {Nrf2 activator} OR {oral fumarate} OR {fumaric
acid eaters} OR {alemtuzumab} OR {Campath 1G} OR {Campath-1G} OR {Campath-1-G} OR {Campath 1M} OR {Campath-1M}
OR {MabCampath} OR {Schering brand of alemtuzumab} OR {Campath} OR {Berlex brand of alemtuzumab} OR {Campath 1H} OR
{monoclonal antibody Campath-1H} OR {Campath-1H} OR {monoclonal antibody*} OR {Antibodies, Monoclonal} OR {lemtrada}
OR {daclizumab} OR {antigen} OR {zenapax} OR {dacliximab} OR {monoclonal antibody} OR {monoclonal antibodies} OR {anti-
gens} OR {Laquinimod} OR {azathioprine} OR {azathioprine} OR {immuran} OR {imuran} OR {imurel} OR {immunoglobulin\*}
OR {intravenous immunoglobulin\*} OR {iV immunoglobulin\*} {intravenous} OR {Intravenous IG} OR {Intravenous Antibodies}
{ivig} OR {igiv} OR {adrenal cortex hormones} OR {steroid\*} OR {methylprednisolone} OR {prednisolone} OR {dexamethasone} OR
{corticosteroid\*} OR {acth} OR {prednisone} OR {Adrenocorticotropic Hormone} OR {polyethylene glycol-interferon-beta-1a} OR
{PEG IFN-beta-1a} OR {Pegylated interferon beta-1a} OR {Ocrelizumab} OR {placebo\*}
AND
{relapsing remitting} OR {relapsing-remitting } OR {remitting-relapsing} OR {remitting relapsing} OR {relapses} OR {relapsing} OR
{relapse} OR {RR-MS}
C O N T R I B U T I O N S O F A U T H O R S
Concept: GF, GS
Title registration: GF
Protocol draft: GF, IT, CDG, GS
Protocol editing: GF, IT, CDG, GS, RD
Title and abstract review: GF, IT
Data abstraction: IT, IP
Data entry: IT, IP
Data analysis: CDG, IT
Drafting the review: GF, IT
Editing and revising the review: GF, IT, CDG, GS, RD
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D E C L A R A T I O N S O F I N T E R E S T
GF: none
GS: none
CDG: none
IT: none
RD: none
S O U R C E S O F S U P P O R T
Internal sources
• Fondazione Istituto Neurologico Carlo Besta - Milan, Italy.
External sources
• Ministero della Salute, Italy.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We excluded the route of administration of treatments (oral, subcutaneous, intravenous) from the effect modifiers that were possible
sources of inconsistency or heterogeneity, since it was not clinically expected.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Immunologic Factors [∗therapeutic use]; Immunosuppressive Agents [∗therapeutic use];Multiple Sclerosis, Relapsing-Remitting [∗drug
therapy]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Humans
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